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ABSTRACT
Until recently knowledge of oxalate metabolism has 
been hampered by problems in the measurement of 
oxalate in urine, plasma and other body fluids. The 
studies described in this thesis were directed towards 
the development of simple sensitive assays for 
oxalate, which could then be used to investigate 
oxalate metabolism in normal subjects and idiopathic 
calcium oxalate stone formers.
An evaluation was performed of several possible 
methods. The definitive method developed was a solvent 
generated ion exchange chromatographic system with 
electrochemical detection. Acidified urine was 
pretreated by dilution with neutral phosphate buffer 
and passage through a C^ g cartridge. Stabilised plasma 
was diluted with neutral acetate buffer and oxalate 
extracted using a strong anion exchange cartridge. 
Plasma samples were stabilised with the reducing agent 
dithiothreitol. There was no significant protein 
binding of oxalate at physiological pH.
Reference ranges were established for urine and plasma 
oxalate, and also for renal clearance and fractional 
excretion. Fasting lowered plasma and urine oxalate 
ranges and renal handling was modified by diet. 
Studies on normal subjects revealed no diurnal 
variation in urine oxalate but plasma oxalate
Ill
decreased overnight.
Oxalate loading in normal subjects demonstrated renal 
adaptation to the load, with net renal reabsorption of 
oxalate becoming net secretion. These studies suggest 
that the main site of oxalate absorption is the small 
intestine. It was found that increasing the load 
beyond a critical level did not increase the 
absorption, indicating a limited capacity.
Oxalate loading did not effect ketogenesis in normal 
subjects and loading with ascorbic acid (Ig), an 
oxalate precursor, did not alter urine or plasma
oxalate levels.
Idiopathic calcium oxalate stone formers showed a 
22.8% incidence of hyperoxaluria, although the 
frequency of hyperoxaluria within individuals varied. 
Hyperoxaluria was associated with hyperuricosuria, 
hypercalciuria and high urinary creatinine output in 
the fed state, but not on fasting.
Hyperoxalurics had a net tubular secretion of oxalate
in the fasting state, suggesting a renally mediated 
loss, delayed gut absorption or increased endogenous
production of oxalate.
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CHAPTER 1. INTRODUCTION
21.1. OXALATE - HISTORICAL BACKGROUND
Oxalic acid and its salts occur extensively in 
nature. Information on oxalate dates from the 17th 
Century when potassium oxalate was described as "salt 
of sorrel", coming from the plant Oxalis acetosella or 
wood sorrel. In 1776 Bergmann obtained oxalic acid by 
the chemical reaction of glucose with strong nitric 
acid. He called the product "acid of sugar" and 
discovered oxalate in renal calculi. Eight years later 
Carl Willhelm Scheele found this product to be the 
same as the acid obtained from sorrel. Scheele also 
produced evidence of the presence of calcium oxalate 
in rhubarb and other vegetables. Over the next twenty 
years Brugnatelli and William Hyde Wollaston made 
further investigation of renal stones and considered a 
connection between renal calculi and diet. In 1839 
Donne demonstrated the presence of calcium oxalate 
crystals in urine.
Towards the end of the 19th Century origins of oxalate 
other than diet were considered and it was shown that 
oxalate was derived from metabolic processes within 
the body. The twentieth century has seen the physical 
properties and molecular structure of oxalate 
described. There has also been extensive development 
of analytical methods for qualitative and quantitative 
identification of oxalate in body fluids.
31.2. PHYSICOCHEMICAL PROPERTIES OF OXALIC ACID.
Oxalic acid (CgO^ H^ ) is a dicarboxylic acid which 
crystallizes from aqueous solution as a white 
dihydrate. The hydrate loses its water at about 100° C 
and the anhydrous acid sublimes, with decomposition, 
above 150° C. Oxalic acid is a relatively strong acid 
(pKal = 1.23, pKa2 = 4.19) and is moderately soluble 
in water (8.7g/100ml of water at 20° C)
1.2.1 Structure.
Anhydrous oxalic acid has an alpha and a beta form 
that differ in intermolecular arrangement and in the 
distribution of hydrogen ions. The alpha crystal 
structure is an extended chain structure where the 
molecules are linked via the hydrogen bonds and the 
carboxyl groups form a puckered layer structure. The 
beta form is a cyclic type of carboxyl and hydrogen 
bond system arranged in chains. These structures are 
shown in f igure 1.1.
The dihydrate has a similar structure to the beta 
crystal formation but two water molecules are set 
asymmetrically between the hydroxyl and carboxyl 
groups.
The use of x-ray diffraction, electron diffraction and 
infrared spectroscopy has shown the oxalic acid 
molecule, both anhydrous or hydrated, to be accurately 
planar and the carboxyl groups have a trans-
y-anhydrous ox ilie acid
\  _  y - " - \
G -anhydrous oxalic acid
Figure 1.1 MOLECULAR STRUCTURES OF ANHYDROUS OXALIC ACID
5configuration. In aqueous solution the oxalic acid 
molecule has a broad range of configurations, the
dihedral angle between the two carboxyl groups varying
from 0 to 180 degrees.
1.2.2. Salts.
Oxalic acid forms neutral and acid salts with
monovalent metals and ammonia. Most divalent metals 
form only one salt, with the exception of barium and 
strontium. The salt that has the greatest significance 
so far as man is concerned is calcium oxalate. This is 
the main precipitating salt of oxalate. The forms of 
calcium oxalate occurring in nature are the
monohydrate (Whewellite) and the dihydrate 
(Weddelite). There is also thought to be an unstable 
trihydrate.
Most oxalates are sparingly soluble in water with the 
exception of the alkali metals, ammonium, and iron III 
salts. The oxalates of divalent metals do not differ 
greatly in their molar solubility. The most soluble is 
magnesium oxalate and the least soluble are calcium 
and lead. All are soluble in strong acid. Oxalate ions 
do have a weak attraction for protons and solutions of 
oxalates are slightly basic eg. the pH of O.lfr) sodium f/
oxalate is 8.5.
The factors that influence the solubility of calcium 
oxalate have attracted considerable attention due to
6the need to increase the solubility to a maximum in 
the treatment and prevention of urinary tract stones. 
Calcium oxalate is the salt of an acid and its 
solubility increases with increasing hydrogen ion 
concentration. The reason for this is the removal of 
oxalate ions to form weak bi- oxalate anions and 
oxalic acid. Solubility is changed very little in the 
physiological range but increases a great deal below 
pH 5.0. (Hodgkinson, 1977). Other relevant factors are 
that solubility can be decreased due to the presence 
of common ions such as calcium chloride or increased 
by the presence of chemically unrelated salt such as 
sodium chloride. This latter effect on solubility is 
called "salting in" and is due to increased ionic 
strength of the solution which promotes solubility due 
to changes in thermodynamic activity. Solubility is 
increased in the presence of substances that will form 
poorly dissociated complexes with either calcium or 
oxalate ions, eg. EDTA and citric acid, which complex 
with calcium. Magnesium will increase solubility by 
forming a soluble oxalate salt.
1.2.3. Calcium oxalate stone formation - 
physicochemical aspects.
Calcium oxalate is the main component of 66% of upper 
urinary tract stones in some industrialised nations 
(Hodgkinson 1970). The balance between supersaturation
7and the inhibitory activity of the urine determines 
whether crystal formation, aggregation and growth will 
occur.
It is essential for the formation of a stone that the 
urine be supersaturated for the precipitating 
crystalline phase. In urine the state of saturation 
for any potential crystal system is the product of 
several factors including solute concentration, pH, 
ionic strength and the formation of complexes. These 
factors can alter depending on such factors as diet 
and state of hydration.
Physicochemically, different levels of urine 
saturation occur. When urine is undersaturated with 
calcium oxalate there is an energy of dissolution and 
the crystals will dissolve if present. As saturation 
with calcium oxalate increases, the saturation product 
is reached. The ion activity at this stage has 
exceeded the solubility product; this is the 
metastable region. In this region if further 
saturation occurs there is the potential for crystal 
growth and heterogeneous nucléation but there may yet 
be no further crystallisation. Further addition of 
solute creates a state of supersaturation where 
spontaneous nucléation occurs. The lower limit of this 
supersaturated state is called the formation product. 
Once the supersaturated phase is reached crystal 
growth and aggregation proceed.
8Urine from healthy subjects as well as renal stone 
formers is supersaturated with calcium oxalate. 
Crystals can therefore be found in urine without 
subsequent stone formation. The amount of crystalluria 
and stone formation are related, and it has been shown 
by microscopy and crystal counting that there are 
qualitative and quantitative differences in the 
formation of calcium oxalate crystals between stone 
formers and non stone formers (Robertson, 1969 ; 
Robertson, Peacock and Nordin, 1969).
Calcium oxalate crystals found in normal subjects and 
stone formers are usually seen as octahedral crystals 
under the light microscope, often referred to as 
"envelope" oxalate crystals because of their 
appearance. A less common form of calcium oxalate 
crystal is the dumb-bell shape. The envelope crystal 
is thought of as the dihydrate and the dumb-bell as 
the monohydrate, though the dihydrate may appear in 
dumb-bell form. Dumb-bell crystals are frequently 
found in the urine of hyperoxaluric subjects and have 
the capacity to aggregate into rigid clusters.
The urinary concentration of calcium and oxalate are 
both important for crystallisation of calcium oxalate 
(Hallson, 1988). It has been suggested that oxalate 
exerts a greater influence on calcium oxalate 
crystallisation than calcium (Robertson and Peacock, 
1980). If oxalate concentration exceeds the normal
9range, the rate of calcium oxalate crystallisation 
increases rapidly until aggregates and crystals of the 
monohydrate become more frequent (Hallson, 1988). 
Excretion of oxalate and calcium are usually 
quantified using 24 hour urine samples, but it should 
be remembered that such measurement may disguise short 
periods of supersaturation during the 24 hour period. 
Crystal formation can be modified by inhibitors, 
complexors and promoters. Inhibitors of calcium 
oxalate crystal growth include citrate, pyrophosphate, 
glycosaminoglycans, RNA fragments and nephrocalcin. 
Citrate forms a soluble complex with calcium so 
reducing the state of saturation. Citrate can act as 
an inhibitor and a complexor (Meyer and Smith, 1975). 
As already mentioned, magnesium forms soluble 
complexes with oxalate. Promoters of crystal formation 
can at different stages in crystal formation also act 
as inhibitors, eg. glycosaminoglycans and Tamm- 
Horsfall proteins.
On analysis, most urinary stones are of mixed 
crystalline composition as a very high level of 
supersaturation would be necessary for homogeneous 
nucléation. Calcium oxalate crystals tend to have an 
homogeneous nucléation.
1.2.4. Oxalosis.
Crystalline deposits of calcium oxalate in tissue have
10
been reported, this is known as oxalosis. These 
deposits are due to excessive levels of plasma 
oxalate. The cause of this is either hereditary or 
acquired.
Crystals of calcium oxalate, due to disturbed oxalate 
metabolism, have been found in many different tissues. 
The primary site of deposition has been the kidney 
tubules. Other important sites include the bone, 
peripheral vessels and myocardium, with crystals 
occurring in both the myocardial and conducting 
fibres. Crystals have been found in the Haversian 
systems of younger patients and the marrow of patients 
of any age. Less common areas of involvement include 
the central nervous tissue, thymus, skeletal muscle, 
adipose tissue, synovial tissue, lymph nodes and skin. 
The histopathological occurrence and characterisation 
of calcium oxalate is described by Chaplin (1977). 
Systemic oxalosis in primary hyperoxaluria has been 
discussed by Mansell and Watts (1988).
There are instances of dystrophic oxalosis, which is 
oxalosis without disturbance of oxalate metabolism. 
There are numerous reports of oxalosis in ocular 
tissue and the local oxalosis that can be caused by 
aspergillosis. Deposition has also occurred in various 
granulomatous lesions. These dystrophic depositions 
are cited by Chaplin (1977).
11
1.3. ANALYSIS OF URINE OXALATE.
The problem of measuring oxalate in biological fluids, 
including urine, is highlighted by the large number of 
methods published and the number that have now been 
discarded for improved methodologies. Many of the
early methods used are now only of historical 
interest. These methods were prone to errors, time
consuming and required lengthy sample pretreatment. 
Methods of measurement for urine oxalate have
improved, but care still has to be taken with sample
collection, storage and analysis. Currently there is 
no one method which is clearly the best. All methods 
have certain advantages and disadvantages (Zerwekh et 
al. 1983).
Most of the methods used for the analysis of urinary 
oxalate require a preliminary extraction stage, to 
remove interfering substances. The following 
techniques have been used, precipitation, solvent 
extraction, ion exchange or adsorption chromatography. 
A recent enzymatic method has been developed that does 
not involve extraction of urine before analysis 
(Urdal, 1984) , but the majority of enzymatic methods 
have some form of sample pre-treatment (Inamdar, 
Raghavan and Pradhan, 1991).
1.3.1. Methods of Separation.
12
1.3.1.1. Precipitation
Historically precipitation has been the most commonly 
used method for extraction of oxalate from urine. 
Precipitation as the calcium salt has been used 
extensively (Archer et al. 1957, Fraser and Campbell, 
1972, Hodgkinson and Williams, 1972). The main problem 
with this approach is incomplete precipitation due to 
inhibitors, and losses during wash phases. To try and 
overcome this, modifications were introduced, with the 
aim of improving recovery. These modifications 
include, additions of known amounts of sodium oxalate 
(Fraser and Campbell, 1972), use of radioactive 
oxalate to check recovery (Koehl and Abecassis, 1976) 
and the precipitation of calcium sulphate in the 
presence of ethanol at pH 7.0 to co-precipitate 
calcium oxalate (Hodgkinson and Williams, 1972). Other 
authors have used lower solubility oxalates to try and 
achieve more complete precipitation, compounds such as 
thorium IV, cerium III, europium III and lead II have 
been tried with varying degrees of success (Koch and 
Strong 1969, Hodgkinson, 1977). The improved recovery 
in these methods required more complex analytical 
procedures.
1.3.1.2. Solvent extraction.
Solvent extraction has been tried using diethyl ether 
or tri-n-butyl phosphate (Zarembski and Hodgkinson,
13
1965). The diethyl ether gives an incomplete 
extraction and the tri-n-butyl phosphate is not very 
specific for oxalate.
1.3.1.3. Isotope dilution.
The technique of isotope dilution has been used to
overcome the problem of quantitative extraction and
SrvxCtln
precipitation (Hockaday, Fredrick and Clayton,1965) .
labeled oxalate is used to check the recovery of 
oxalate from precipitates or solvent extractions 
(Luque de Castro, 1988).
The basis of all the methods that use isotope dilution 
is the standard isotope dilution formula - stable
oxalate in urine equals total radioactivity added,
divided by the measured specific activity. Methods
involving isotope dilution do have improved accuracy, 
but are slow and laborious.
1.3.1.4. Ion exchange and adsorption chromatography.
Ion exchange and adsorption chromatography have been 
used to prepare samples. Anion exchange chromatography 
has been used to extract oxalate from urine (Chalmers 
and Watts, 1972) and adsorption onto alumina has been 
adopted by the Sigma chemical company in their 
commercial oxalate kit (1985) . The use of a basic 
silica to adsorb the oxalate has been criticised. This 
method required alkali to elute oxalate off the
14
alumina prior to analysis, which resulted in poor 
analytical recovery and interference from ascorbate 
due to oxalogenesis at high pH (Click, 1987).
The use of ion exchange or adsorption chromatography 
for extraction of oxalate does have disadvantages. The 
anions of other organic acids are often extracted 
simultaneously and these might interfere in some 
assays described in section 1.3.2.
Some workers have used sample preparation that 
involves the removal of interfering substances with 
resins or silica based packing material rather than 
extraction of oxalate. Laker, Hofmann and Meeuse 
(1980) used cation exchange resins to remove divalent 
metal ions and excess sodium chloride that interfered 
with the action of oxalate oxidase. These workers also 
used charcoal to remove ascorbate.
Larsson, Libert and Asperud (1982) used octadecyl- 
silane bonded phase packing to remove non polar and 
semi polar substances in a liquid chromatographic 
method for urine oxalate. A recent method devised by 
the Sigma company (Mingen and Madappally, 1989) to 
measure urine oxalate uses charcoal as an adsorbant to 
remove ascorbate, a known interfèrent in oxalate 
analysis. After the addition of charcoal the sample is 
mixed, then centrifuged and the supernatant analysed 
for oxalate.
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1.3.2. Measurement of oxalate.
The method of measurement of oxalate in urine can be 
divided into three main groups: Chemical, physical and 
enzymatic techniques.
1.3.2.1. Chemical methods.
Most of the chemical methods developed to measure 
oxalate would be regarded now as of historical 
interest only.
Archer et al (1957) oxidised oxalate after separation, 
using hot acidified potassium permanganate. This 
produced a pink colour at endpoint, but suffered from 
interferences and there were difficulties in 
standardising conditions. Cerium ions have also been 
used as an oxidising agent (Koch and Strong, 1969), 
but it has been reported (Hallson and Rose, 1974) that 
these methods underestimate urinary oxalate excretion. 
Fluorimetry and colorimetry have frequently been used 
to measure oxalate, some of the methods used have 
required the chemical reduction of oxalate to 
glyoxylate or glycolate before the final detection 
stage (Hodgkinson and Williams, 1972). Zarembski and 
Hodgkinson (1965) described a fluorimetric method in 
which oxalate is reduced to glyoxylate and then 
reacted with resorcinol to form a highly fluorescent 
complex. More recently Salinas, Martinez-Vidal and 
Gonzalez-Murcia (1989) have used an extraction
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spectophotometric method based on the formation of a 
mixed ligand vanadium (V) mandelohydroxamic acid 
oxalate complex. Detection was at 535 nm.
Many of these methods lack specificity or sensitivity 
along with the disadvantage of complex extraction 
procedures. This has made them unsuitable for routine 
use and often inaccurate.
1.3.2.2. Indirect determination of oxalate.
Oxalate has also been measured using atomic 
absorption, based on the measurement of calcium. 
Oxalate was precipitated in urine with a calcium salt 
and then the calcium was measured by atomic absorption 
(Fraser and Campbell, 1972) . This method suffered from 
incomplete precipitation of calcium oxalate.
1.3.2.3. Enzymatic methods
The majority of methods used at present are enzymatic. 
These methods, potentially offer specificity and ease 
of use on equipment avaliable in most clinical 
chemistry departments. Two enzymes are used in the 
analysis of urinary oxalate, oxalate oxidase (E.C.
1.2.3.4.) and oxalate decarboxylase (E.C 4.1.1.3). 
These enzymes have been used both in solution (Laker, 
Hofmann, Meeuse, 1980, Urdal, 1984) and immobilised 
onto suitable supports in continuous flow systems 
(Kasidas and Rose, 1985, Potezny et al. 1983).
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In the presence of oxalate oxidase, oxalic acid is 
oxidised by atmospheric oxygen, producing two 
molecules of carbon dioxide and one of hydrogen 
peroxide. These products have been monitored directly 
or after coupling with detection systems.
The carbon dioxide formed has been measured by various 
methods, including change in pH caused by the release 
of COg into a buffered alkaline solution (Kohlbecker, 
Richter and Butz, 1979, Hallson and Rose, 1974), 
colorimetry (Knowles and Hodgkinson, 1972) and 
conductivity measurement (Sallis, Lumley and Jordan, 
1977). These methods tended to underestimate oxalate, 
probably due to a combination of enzyme inhibition and 
losses of COgproduced.
Other methods have used the peroxide formed to 
determine oxalate levels, in a coupled reaction. The 
hydrogen peroxide can be measured photometrically 
using catalase/aldehyde dehydrogenase/NADP (Kohlbecker 
and Butz, 1981), horseradish peroxidase (E.C 
1.11.1.7.) with oxidative coupling of 3-methyT-2- 
benzothiazoline and N,N-dimethylalanine to produce an 
indamine dye (Potezny et al. 1983, Obzansky and 
Richardson, 1983, Madappally and Mingen, 1989) or with 
4-aminoantipyrine/phenol (Bias et al. 1980). Peroxide 
has also been detected using an amperometric hydrogen 
peroxide detector (Bradley and Rechnitz, 1986).
Oxalate oxidase can be inhibited by divalent cations
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and some anions such as fluoride (Luque De Castro,
1988). It can also be affected by the concentration of 
sodium chloride in some urines (Potezny et al. 1983). 
These interferences can be minimised by sample 
pretreatment with charcoal or a suitable sample 
dilution.
An interfèrent that has caused considerable problems 
in all oxalate methods, including those using oxalate 
oxidase, is ascorbic acid. Ascorbic acid has been 
shown to interfere with oxalate analysis in two ways, 
by in vitro conversion of ascorbate to oxalate 
(Chalmers, Cowley and McWhinney, 1985) and by 
interference in the chemical reaction of some methods. 
Interference in the reaction is due to ascorbic acid 
competing with the oxidative coupled indicator 
hydrogen peroxide. This causes spuriously low results 
(Crawford, Mahony and Gyory, 1985), and is a potential 
source of error in many of the methods using oxalate 
oxidase.
Various techniques and reagents have been used to 
prevent ascorbate interference; sodium nitrite 
(Kasidas and Rose, 1985), ferric chloride (Crider, 
1985), ascorbate oxidase (Crawford, Mahony and Gyory, 
1985) and charcoal (Madappally and Mingen, 1989). A 
recent study (Indamar, Raghavan and Pradhan, 1991) of 
these different approaches demonstrated that ascorbate 
oxidase and charcoal were effective at ascorbate
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concentrations of 3mmol/1 or less. Use of ascorbate 
oxidase makes a method more complex and expensive. 
Charcoal is simple and cheap, but recovery can vary 
between batches and types of charcoal.
Oxalate decarboxylase catalyses the decarboxylation of 
oxalate, producing one molecule of formate and one 
molecule of carbon dioxide. As with oxalate oxidase 
both products have been used to measure oxalate 
concentration.
Hallson and Rose (1974) measured oxalate by the pH
change in a buffer when COg was produced. Oxalate 
decarboxylase was inhibited by sulphate and phosphate, 
but this inhibition was overcome by using the correct 
enzyme concentration. The method was not practical for 
large numbers of samples.
Formate produced in the enzyme catalysed
decarboxylation has been measured after coupling with 
a second enzyme system, formate dehydrogenase/NAD"^ 
(Urdal, 1984, Yriberri, and Posen, 1980, Chalmers and 
Cowley, 1984). The reaction is monitored at 340nm, NAD* 
being converted to NADH. This can then be used to
estimate oxalate levels. The different pH optima of 
oxalate decarboxylase (pH 3.5) and formate 
dehydrogenase (pH 7.0), and the requirement for
further purification of commercially available NAD* to 
remove formate contamination have placed limitations 
on this approach (Costello, Hatch and Bourke, 1976).
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Despite this, a commercial kit based on this enzyme 
system has been produced by Boehringer Mannheim (1982) 
and some workers have automated the system (Urdal, 
1984/ Allen, Kadijevic and Romascnin, 1989).
Previous workers produced their own oxalate oxidase 
from various sources; moss (Laker, Hofmann and Meeuse, 
1980), beet stems (Obzansky and Richardson, 1983), 
banana peel (Raghavan and Devasagayam, 1985); this 
formed a necessary part of their methodology. Oxalate 
oxidase is now available commercially from the Sigma 
chemical company, the source is barley seedlings. 
Although the enzyme is relatively expensive, cost can 
be reduced by immobilising enzymes on a support or in 
electrodes. This does have disadvantages. 
Immobilisation of enzymes require some expertise and 
enzyme electrodes have a slow response time and tend 
to lack sensitivity. Immobilised enzyme systems have 
been used with continuous flow analysis, which has the 
advantage of high sample throughput.
Commercial enzyme kits have been produced by Sigma 
Diagnostics (1985) and Boehringer Mannheim (1982) but 
these are expensive and not without criticism 
(Parkinson et al. 1987, Click, 1987). The original 
Sigma kit was severely criticised for interference 
from ascorbic acid and for poor recovery. An updated 
version (Madappally and Mingen, 1989) appears to have 
solved these problems, though pH adjustment required
21
in the method has to be done with care to prevent 
oxalogenesis.
1.3.2.4. Physical methods.
Most of the physical techniques developed have been 
chromatographic. Three main techniques have been used; 
gas chromatography (GC), ion-chromatography and high 
performance liquid chromatography (HPLC). 
Chromatography offers the possibility of both 
selectivity and sensitivity, but the equipment can be 
expensive.
Gas chromatography has been used to measure urine 
oxalate (Chalmers and Watts, 1972' Moye et al. 1981), 
but conventional columns tend to lack resolution and 
sensitivity. The use of capillary-GC (Wolthers and 
Hayer 1982) has overcome these problems. A GC-mass 
spectrometry method has been described as a reference 
method for urine oxalate, the determination uses 
isotope dilution GC mass-spectrometry (Koolstra et al.
1987).
The main problem with GC measurement of urinary 
oxalate is that these methods require some form of 
sample separation followed by derivatisation, which 
makes the methods slow and laborious. The capital cost 
of the equipment can be high and techniques such as 
capillary-GC and GC mass spectrometry require a high 
degree of expertise.
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Ion chromatographic techniques have been developed 
(Robertson et al. 1982, Menon and Mahle, 1983). These 
methods use a system dedicated to the analysis of 
ionic species, the Dionex ion chromatographic system. 
(Dionex, Camberley, UK) . The column contains anion 
exchange material and the detector is conductimetric. 
These techniques use a high pH mobile phase, which 
promotes the conversion of ascorbate to oxalate on the 
column, causing overestimation of oxalate. A number of 
techniques were evaluated for the elimination of this 
interference (Petrarulo et al. 1990). Although none of 
the procedures completely solved the problem, two were 
able to minimise it. Urine buffered with boric acid 
overcame the alkaline oxidation of ascorbate at low 
ascorbate concentrations, less than 500umol/l. 
Ascorbate oxidase offered more efficient protection, 
being successful at ascorbate concentrations less than 
2 mmol/1. However, the use of ascorbate oxidase 
requires the sample to be incubated for 1 hour before 
analysis and is more expensive.
Unprocessed urine can be analysed on these ion- 
chromatographic systems, but the analysis time is 3 0 
minutes a sample, because an extended wash phase is 
required between specimens.
A number of methods have been published using HPLC to 
measure urine oxalate (McWhinney, Cowley and Chalmers, 
1986  ^ Hughes, Hagan and Sutton, 1982J Larsson, Libert
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and Asperud, 1982', Libert, 1981, Mayer, McCarthy and 
Greenberg, 1979', Jerez de la Piedra and Traba, 1986). 
These methods have used a range of different columns; 
normal phase, reverse phase and ion chromatographic, 
and differing forms of detection; ultra violet, 
amperometric, conductimetric and fluorimetric.
Some of these methods require sample derivatisation 
(McWhinney, Cowley and Chalmers, 1986; Hughes, Hagan 
and Sutton, 1982), which gives better selectivity but 
makes the method more time consuming. Larsson, Libert 
and Asperud, (1982) used an ion pair reagent in the 
mobile phase to try and improve selectivity. 
Unprocessed urine was injected and detection was at 
220nm in the ultra violet region. At this wavelength 
much interference can occur. Other methods require 
complex sample preparation, involving precipitation 
with calcium chloride and extraction with diethyl 
ether (Jerez, de la Piedra and Traba, 1986). This type 
of sample preparation is prone to poor recovery and is 
not suitable for large numbers of samples.
HPLC equipment is becoming more widely available in 
clinical chemistry departments and the use of 
chromatography does have the potential for the 
selective and sensitive analysis of oxalate. If sample 
preparation can be simplified whilst still giving a 
clean chromatogram, this offers an excellent way of 
assaying urine oxalate.
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Another physical method that has been used to measure 
urine oxalate is isotachophoresis. This involves the 
separation of oxalate from other ionic species by its 
net electrophoretic mobility in an electric field 
within polytetrafluoroethylene (PTFE) capillaries, 
followed by UV detection. Some of these procedures 
require preliminary sample separation (Schmidt, 
Hagmaier, Bruchelt and Rutishauer, 1980).
There are some miscellaneous methods such as non 
segm^ted flow analysis (Luque de Castro, 1988) and 
analysis of oxalate with disposable oxalate oxidase 
membrane strips (Inamdar, Tarachand and Raghavan,
1989). These methods use the enzymes described in 
section 1.3.2.3.
None of the urine methods, by whatever technique, are 
clearly better than any of the others. This has been 
highlighted by Zerwekh et al (1983) who have discussed 
all their advantages and disadvantages. Local 
laboratory resources often influence the decision 
concerning which methodology to use.
1.4. ANALYSIS OF PLASMA OXALATE.
The measurement of oxalate in plasma has presented a 
number of difficulties. This has been due to the low 
concentration of oxalate in the plasma of normal 
subjects and the problem of oxalogenesis during sample 
collection, preparation and analysis. More recently.
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protein binding has been highlighted as a potential 
analytical problem (Costello and Landwehr, 1988).
A lack of simple reliable methods for plasma oxalate 
analysis has hindered the investigation of oxalate 
metabolism. A range of methods have been developed for 
the analysis of plasma oxalate, but not until recently 
have they started to show satisfactory performance. 
PreI analytical factors are very important in obtaining 
precise and accurate results.
1.4.1. Sample preparation
Sample preparation for the measurement of plasma 
oxalate can involve the separation steps already 
discussed in the context of urine analysis. In 
addition, plasma contains proteins and other molecules 
which can interfere with plasma oxalate 
determinations. These have to be removed prior to 
analysis. This extraction is often in addition to some 
of those discussed in the urine section.
Various techniques have been used to prepare a protein 
free solution. The more recent ones include; 
acidification with 0.05m HCl followed by heat 
treatment at 100°C (Boer, van Leersum and Endeman, 
1984J Ackay and Rose, 1980), extraction into an 
organic phase followed by derivatisation (Wolthers and 
Hayer, 1982) and ultrafiltration (Kasidas and Rose, 
1986; Costello and Landwehr, 1988). Some of these
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techniques (Boer, van Leersum and Endeman, 1984; 
Kasidas, Nemat and Rose, 1990; Costello and Landwehr,
1988) had recoveries of oxalate greater than 95%, 
using ^^ C labelled oxalate to assess any losses.
The extent to which oxalate is protein bound, is
i?
effected by the pH of the environment and this has 
been shown to effect analytical recovery of oxalate 
(Costello and Landwehr, 1988, Schwille et al. 1989). 
As the pH falls below 7.4 there is increased protein 
binding. Acidification of samples in order to 
stabilise them should be avoided until after 
deproteinisation. Kasidas and Rose, (1986) 
ultrafiltered acidified plasma and did not find 
significant losses, but this could be due to 
offsetting errors.
In addition to the effect of pH on plasma oxalate 
recovery, the potential for oxalogenesis from 
ascorbate is present at pH 7.0 and above (Crawford, 
Mahony and Gyory, 1985) . This can be a significant 
problem in plasma, as ascorbate is present at a 
concentration some 20 to 30 times higher than oxalate. 
Schwille et al. (1989) used ion-chromatography with 
ultrafiltration to measure plasma oxalate and 
demonstrated problems with both analytical recovery 
due to pH and in vitro oxalogenesis. Oxalogenesis is 
discussed further in subsequent sections.
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1.4.2. Measurement of oxalate.
Plasma oxalate has been measured by a similar range of 
techniques as urine. The ability to measure plasma 
oxalate accurately has improved dramatically in the 
last 5 years, but it still presents a formidable 
analytical challenge.
1.4.2.1. Isotope dilution techniques.
This form of analysis is regarded as the gold standard 
for plasma measurement. The great variation in plasma 
oxalate reference ranges using direct forms of 
analysis have created the need for a reference method, 
so that accurate plasma levels can be defined. The use 
of isotope dilution methods do have certain 
disadvantages which are outlined below.
The principle of the technique is to infuse or inject 
intravenously labelled oxalate, which can then
distribute throughout the body compartments. Once the 
labelled oxalate is equilibrated in the body it is 
assumed that the specific radioactivities of plasma 
and urine oxalate are constant and equal. The 
radioactivity is measured in both the plasma and urine 
and the urine is also analysed for oxalate 
concentration by a direct method. Various methods for 
measuring the urine oxalate concentration have been 
used; isotope dilution (Williams, Johnson and Smith, 
1971), colorimetric (Prenen et al. 1982) and enzymatic
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(Constable et al. 1979). The plasma oxalate can then 
be calculated using the assumption stated above: 
plasma radioactivity divided by plasma oxalate will 
equal urine radioactivity divided by urine oxalate. 
There are disadvantages and problems with this type of 
analysis. The health hazards associated with the use 
of radioisotopes make this method limited in its 
application to human subjects. The procedure can be 
time consuming if constant infusion is used and can 
take more than 6 hours, the total volume of blood 
required can be large, up to 100ml (Prenen, Oei and 
Dorhout Mees, 1987).
A bolus injection of the isotope is rapid but a lack 
of constant activity in the blood will give some 
degree of error. The requirement for the direct 
measurement of urine oxalate with its inherent errors 
could introduce error into the plasma result. Despite 
these problems different workers have produced 
comparable results in normal subjects, plasma oxalate 
levels being less than 3.0 umol/1 (Costello and 
Landwehr, 1988).
This technique has been useful as a reference method 
for the development of direct assays ^which can 
be used routinely.
1.4.2.2. Chemical methods
These methods are of historical interest only. They
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were laborious, lacked specificity and often promoted 
oxalogenesis during the analysis due to the conditions 
used. An example is the method of Zarembski and 
Hodgkinson (1965), which used solvent extraction
followed by co-precipitation with a calcium salt. The 
precipitate was chemically reduced to glyoxylate which 
was then determined fluorimetrically after reacting 
with recorcinol.
1.4.2.3. Enzymatic techniques.
As with the chemical methods, many of the early enzyme 
methods are now obsolete. The enzymes and their
reactions have already been described in section
1.3.2.3. In many cases, the same or similar methods 
have been used to analyse plasma as urine, after 
adaptations. The ultimate aim, so far as plasma
measurement is concerned, has been to get normal 
ranges comparable with those obtained by isotope 
dilution.
Ackay and Rose (1980) used oxalate decarboxylase and 
measured the COg released into an alkaline buffer. The 
method used a large volume of blood (50 ml), was 
tedious and not suited for large numbers of samples. A 
Japanese group (Sugiura et al. 1980) used oxalate 
oxidase with colorimetric detection. The method was 
relatively simple but prone to interference by 
ascorbate. This resulted in a very high upper limit of
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normal, 46.0 umol/1. Hatch, Bourke and Costello (1977) 
used oxalate decarboxylase linked to formate 
dehydrogenase to measure plasma oxalate, but pH 
factors in their assay caused oxalogenesis resulting 
in overestimate of oxalate.
More recent methods using enzymes have proved more 
successful. Boer, van Leersum and Endeman (1984) used 
oxalate oxidase which, at the time, gave normal 
results which were among the lowest quoted in the 
literature (1.2-6.4 umol/1). The method did require a 
large blood sample (50ml), and was cumbersome. 
Parkinson, Kealey and Laker (1985) developed a multi 
enzyme bioluminescent method to measure plasma 
oxalate. This was a linked enzyme system using oxalate 
decarboxylase and formate dehydrogenase, which 
produced NADH. The NADH was detected by a 
bioluminescent reaction with bacterial luciferase. The 
reference range is one of the lowest published using a 
direct method (<0.8-1.5 umol/1), being similar to 
those from isotope dilution techniques. The 
bioluminescent reagents are expensive and it does 
require specialised equipment. It also suffers from 
the problem of a very high blank value, thought to be 
due to formate contamination in the reagents. The 
method was updated by Parkinson et al (1989), who 
immobilised the bioluminescent enzymes and used a 
continous flow system, helping to reduce cost.
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Another immobilised enzyme continuous flow method uses 
oxalate oxidase (Kasidas and Rose, 1986). The results 
on normal subjects from this method are similar to the 
isotope dilution methods but a relatively large sample 
volume (5ml of plasma), is required. The samples are 
also acidified before ultrafiltration, which 
potentially (Costello and Landwehr 1988) could lead to 
poor recovery due to protein binding. Although 
immobilised enzymes have to be prepared in house, this 
form of analysis does reduce cost because the enzyme 
is reusable.
Two recent enzyme methods, using oxalate decarboxylase 
or oxalate oxidase in solution (Costello and Landwehr, 
1988, Berckmans and Boer, 1988) have quoted reference 
ranges of the same order of magnitude as isotope 
dilution methods. The method of Berckmans can measure 
both plasma and urine but for plasma analysis uses 
4.75 ml of plasma and involves a 2 hour precipitation 
step. The method of Costello and Landwehr (1988) 
involves a precipitation and lyophylization step which 
make it cumbersome.
Enzyme methodologies can produce accurate results, but 
the methods are still specialised and in some cases 
cumbersome or use large sample volumes.
1.4.2.4. Physical methods.
The use of physical methods to measure plasma oxalate
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offers the potential advantage, as with urine, of 
specificity and sensitivity.
Early methods using gas chromatography were not 
successful. Derivatisation is usually required and the 
conditions for this were likely to cause oxalogenesis. 
They also had poor sensitivity and resolution. 
Wolthers and Hayers (1982) overcame these problems by 
using capillary gas chromatographic columns which gave 
better resolution and sensitivity. Derivatisation was 
performed in acidic conditions taking care to avoid 
oxalogenesis. As a result, an analytical recovery of 
nearly 100% was achieved with a mean normal plasma 
oxalate of 2.8 umol/1. The equipment is, expensive, 
not widely available and requires expertise to 
operate.
Very few methods have been published which use HPLC to 
measure plasma oxalate. Jerez in 1986 published a 
method but the sample preparation was rather complex 
and the reference range was higher than current 
methods, the upper limit of normal being 32 umol/1. 
Schwille et al (1989) used the ion chromatographic 
system produced by the Dionex Corporation (Camberley, 
UK) using conductimetric detection to measure plasma 
oxalate. The method used ultrafiltration as a 
deproteinisation step. The main disadvantages stated 
by the authors were the operational time 
(equilibration and standardisation took 3 hours), and
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the occasional poor chromatogram due to the presence 
of bubbles in the system. Oxalogenesis was also 
identified as a potential problem during 
ultrafiltration, this was guarded against, to some 
extent, by the addition of boric acid to the samples. 
HPLC equipment is more widely used in Clinical 
Chemistry laboratories than in the past and could 
offer the sensitivity and selectivity required for 
plasma oxalate analysis. The major disadvantage is the 
capital cost of the equipment.
Plasma oxalate analysis has improved dramatically in 
recent years but no one method has a clear advantage 
over the others. Oxalate therefore remains a difficult 
analyte to measure accurately.
1.5. SPECIMEN COLLECTION AND STORAGE AND THE PROBLEMS 
OF OXALOGENESIS.
Apart from the problem investigators have had in 
developing the methods to measure oxalate in urine and 
plasma, another major problem is sample stability. The 
source of this instability is not the breakdown of 
oxalate but in vitro oxalogenesis. Some of the 
problems associated with oxalogenesis have been 
mentioned in previous sections, in the context of 
sample preparation and analysis. Urine presents the 
additional problem of calcium oxalate precipitation, 
which has to be considered when samples are collected.
34
1.5.1. Collection, storage and oxalogenesis in urine.
In urine, ascorbate is considered to be the main
precursor in oxalogenesis (Mazzachi, Teubnerb and 
Ryall, 1984; Chalmers, Cowley and McWinney 1985; 
Conyers et al. 1985). These authors state that there 
is significant in vitro oxalogenesis from ascorbate at
pH 7 and above, so any analytical method or sample
preparation using neutral to alkali conditions may be
subject to error, as outlined in previous sections. 
The exact mechanism of the conversion of ascorbate to 
oxalate is not known but is thought to be non 
enzymatic.
In order to ensure the accurate measurement of urinary 
oxalate it is essential that any method be assessed 
with regard to interference for ascorbate. It is also 
essential that samples are stabilised from the time of 
collection to the completion of the analysis.
A range of techniques have been used to stabilise 
samples, some are more suitable than others for 
specific methods. If for example the stabiliser 
interferes in the method or the pH of the method 
inhibits the stabiliser, spurious results may be 
produced. Some of these techniques and their 
associated methods were referred to in previous 
sections. Many of these stabilisers are less than 100% 
efficient (Petrarulo et al. 1990; Inamdar, Raghavan 
and Pradhan, 1991).
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It has been stated, that to ensure the stability of 
urine oxalate before analysis, samples should be 
collected into acid and the final pH should be pH 1.5 
or less (Ng, Menon and Ladenson, 1984) . There are two 
factors to consider; one is the ascorbate 
interference, the other the solubility of oxalate with 
regard to its insoluble salt calcium oxalate. Ng,
Menon and Ladenson (1984) found that a pH of less than 
1.5 achieved a pH reversible dissolution of oxalate 
salts and stabilised the sample. Mazzachi, Teubner and 
Ryall (1984) also found that acidification of urine 
stabilised samples against oxalogenesis from 
ascorbate. This stability was further enhanced by 
freezing samples at -20 or -70 °C. These authors found 
samples collected into acid and stored at -20 °C were 
stable for 1 month, even in the presence of 15 mmol/1 
ascorbic acid. Mazzachi and his colleagues also
indicated that glyoxylate causes no significant 
increase in urinary oxalate.
Chalmers, Cowley and McWhinney (1985) have shown that 
disodium EDTA (10 mmol/1 final concentration) 
stabilises urine oxalate against ascorbate 
interference. They found that urine oxalate samples 
were most stable with regard to ascorbate between pH 
4.5-5.0. This approach will also improve the
solubility of oxalate by binding calcium with the 
disodium EDTA. Cannon, Eaton and Glen (1983)
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demonstrated improved recovery of oxalate by the 
addition of disodium EDTA to samples.
Whatever approach is taken to the collection and 
storage of samples the conditions and stability times 
must be clearly defined, to obtain accurate results.
1.5.2. Collection, storage and oxalogenesis in plasma
Sample handling, and causes of oxalogenesis in plasma 
must be considered before samples are analysed. It has 
been suggested that in vitro oxalogenesis in plasma 
can be due to the presence of glyoxylate (Akcay and 
Rose, 1980), ascorbate (Kasidas and Rose, 1986) and 
other precursors (France, Windleborn and Wallace, 
1985) when samples are collected and analysed. It is 
thought that the in vitro conversion of oxalate 
precursors may account for some of the discrepancy 
found between some of the early methods and isotope 
dilution techniques.
The role of glyoxylate as a precursor is debatable. 
Ackay and Rose (1980) showed that in the presence of 
enzyme inhibitors that block the enzymatic oxidation 
of glyoxylate, plasma results could be obtained 
similar to those by isotope dilution. This contention 
has not been supported by other workers who have tried 
to measure glyoxylate in blood and have been unable to 
find a detectable level (Zarembski and Hodgkinson, 
1965). Concentrations of glyoxylate below the limit of
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detection of their method would not result in 
significant oxalogenesis. France, Windleborn and 
Wallace (1985) demonstrated that the use of the 
inhibitors suggested by Ackay and Rose (1980) did not 
prevent oxalogenesis, suggesting that glyoxylate is 
not a significant oxalate precursor in vitro.
The first evidence of in vitro oxalogenesis from 
ascorbate was by Maguire et al (1981). Subsequent 
studies by France, Windleborn and Wallace (1985) and 
Kasidas and Rose (1986) confirmed such a process. The 
potential for conversion of ascorbate to oxalate in 
plasma is enhanced by two factors. The pH of plasma 
will favour the conversion, and as stated earlier, the 
relative concentrations of the two, ascorbate being 
present at a concentration some thirty times higher 
than oxalate.
The stability of the plasma oxalate level in a sample 
collected from a normal subject is not certain. 
Various times have been stated; 80 minutes (Schwille 
et al. 1989), 4 hours (Boer, van Leersum and Endeman, 
1984) and 6 hours (Parkinson et al. 1989) . These 
differences could be due to local conditions, such as 
the laboratory temperature, or could indicate 
different samples have differing potential for 
oxalogenesis. They will also depend on the performance 
characteristics of the assay. It has been suggested by 
one group that at high concentrations (>20 umol/1)
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plasma oxalate may inhibit its own production from 
ascorbate (Parkinson et al. 1989).
Collection of samples requires some form of 
stabilisation. The methods used include enzyme 
inhibitors as quoted above, but this is complex, 
expensive and of dubious value. The most widely used 
form of stabilisation is acidification. This has been 
achieved by the addition of acid to plasma (Kasidas 
and Rose, 1986) , by the use of a cation exchange 
column (Parkinson et al. 1989) and by dilution in 
boric acid (Schwille et al. 1989) . As indicated 
earlier, use of acidification to stabilise samples 
should be approached with caution as pH may effect the 
protein binding of oxalate. Protein free 
ultrafiltrates have been shown to be unstable after 1 
hour at room temperature (Schwille et al. 1989) if not 
acidified, this indicates a need to process samples 
with reasonable speed.
The length of time samples are stable during storage 
has not been extensively examined, because most 
methods process small numbers of samples when they are 
collected. A recent study showed plasma samples to be 
stable for 5 days at -20°C and 100 days at -70°C 
(Berckmans and Boer, 1988).
The collection and storage procedures for plasma 
oxalate are varied, and often method dependent. This 
problem must be assessed when developing a method.
39
1.6. Reference ranges.
The analytical problems outlined above for urine and 
plasma oxalate analysis have been reflected in the 
variation of reference ranges quoted over the years. 
In vivo isotope methods are regarded as the most 
accurate for plasma. By their nature they are unable 
to assess large populations. A typical mean and 
standard deviation for in vivo isotopic methods is 
1.29 +/- 0.37 umol/1 (Prenen, Oei and Dorhout Mees, 
1987). One method has been cited as a reference method 
for urine using GC mass spectroscopy Koolstra (1987), 
but again this could not be used in large population 
studies.
The concensus on urine and plasma reference ranges has 
moved closer in recent years, though there are still 
significant variations. Table 1.1 shows some of the 
reported reference ranges of recent years. The 
differences seen in normal ranges for more recent 
plasma methods are not clinically significant in 
relation to overt cases of primary or secondary 
hyperoxaluria. However, they may affect the
interpretation of renal handling studies and the more
subtle changes that may occur in renal stone formers. 
The effect of age, sex and dietary status on reference 
ranges is poorly documented and often contradictory
(Costello and Landwehr 1988). Lack of reliable
methodology has held this work back.
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Table 1.1 Recent reference ranges reported for urine 
and plasma oxalate.
Year (Authors) Range
(umol/24
N
hr)
Method
Urine
1983 (Menon & Mahle) 143-484 25 lon-
chromatography
1984 (Urdal) 160-670 17 Oxalate
decarboxylase
1985 (Kasidas & Rose) 60-420 61 Oxalate
oxidase
1986 (McWhinney et al) 170-420 11 Derivatisation
HPLC.
1988 (Berckmans & Boer) 100-560 27 Oxalate
oxidase
1989 (Allen et al) 150-450 35 Oxalate
decarboxylase
Plasma (umol/1)
1979 (Constable et al) 0.7-1.4 5 In vivo 
isotope 
dilution
1980 (Surgiura et al) 7.0-46.0 50 Oxalate
oxidase
1984 (Boer et al) 1.2-6.4 24 Oxalate
oxidase
1986 (Kasidas & Rose) 1.3-3.1 21 Immobilised
oxalate
oxidase
1989 (Schwille et al) 0.7-2.9 23 Ion
Chromatography
1989 (Parkinson et al) <0.8-2.0 14 Oxalate
decarboxylase
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1.7. NORMAL OXALATE METABOLISM.
Oxalate is thought to be a useless end product of 
metabolism in humans. The fact that it makes an 
insoluble salt with calcium has made it clinically 
significant. Approximately 75% of kidney stones 
contain oxalate and soft tissue deposition of oxalate 
is seen in primary hyperoxaluria and some cases of 
chronic renal failure.
Oxalate is eliminated from the body by the kidneys and 
the amount found in the urine and plasma is influenced 
by dietary intake, gut absorption, endogenous 
production and renal handling. Figure 1.2 quantifies 
these factors diagramatically, using current 
knowledge.
1.7.1. Dietary intake and gastrointestinal handling of 
oxalate.
Oxalate is a common component of food but its content 
is typically low, less than 0.01 mmol/lOOg (Kasidas 
and Rose, 1980). There are however certain exceptions. 
Oxalate is found in most plant tissue, but in much 
higher concentrations in rhubarb, spinach and 
beetroot. Generous amounts of oxalate are also found 
in tea, chocolate, peanuts and cocoa. Tea is regarded 
as the single most important source of oxalate in the 
average English diet. A typical western diet has been
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reported to contain between 800 umol/day to 1,900 
uitiol/day (Zarembski and Hodgkinson 1962, Anderson, 
Hollins and Bond, 1971). In India where the diet is 
vegetarian the daily intake can be as high as 15.9 
mmol/day (Singh et al. 1972.) Many of these studies 
were done when oxalate methods were not reliable and 
so may need re-evaluating.
The intake of oxalate rich foods is thought to produce 
seasonal and diurnal variation in urinary oxalate 
output (Kasidas, 1988). The seasonal variation can be 
related to the availability of certain produce, though 
calcium metabolism may play a role (Erickson et al. 
1984). The diurnal variation is thought to reflect 
dietary intake during the day, followed by restoration 
to basal levels by morning (Tiselius and Almgard, 
1977) , after sleep. Some studies found that stone 
formers had a different diurnal variation to normals 
(Tiselius and Almgard, 1977) others found no 
difference (Vahlensieck, Bach and Hesse^ 1982) . These 
studies used different sampling times and statistical 
analysis, this may have affected the conclusions 
drawn. Kasidas (1988) has suggested that plasma 
oxalate shows a similar diurnal variation to oxalate, 
but there is not much data available in this area.
The percentage of ingested oxalate which is actually 
absorbed from the gastrointestinal tract has been 
reported as less than 3% (Brinkley, Maguire and
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Gregory, 1981) and as high as 20% (Williams and 
Wandzilak, 1989). The variation in absorption can 
depend on how much oxalate the subject is given, 
whether they are fasting or given a test meal and the 
form in which the oxalate is taken. Despite the low 
levels of absorption a substantial decrease in urinary 
oxalate is possible during a low oxalate diet. 
Consequently the diet may play a more important role 
than has been previously assumed.
Part of the reason for the poor absorption of oxalate 
is the presence of oxalate degrading bacteria in the 
gut (Allison et al. 1986) which can degrade oxalate at 
the rate of 0.1 to 4.8 umol per gram per hour. Another 
major factor affecting absorption is the solubility of 
the oxalate in the gut. If the oxalate is soluble then 
it is available for absorption and more may be taken 
up. Dietary components that affect oxalate absorption 
include calcium, magnesium, iron, trace metals, fatty 
acids, bile salts and possibly fibre. Binding of 
oxalate to calcium in the gut, lowers the amount of 
free oxalate available for absorption. Therefore 
calcium restriction in the diet will increase oxalate 
absorption (Bataille et al. 1983). Magnesium has also 
been found to decrease oxalate absorption, possibly by 
the formation of a magnesium oxalate complex (Berg et 
al. 1986).
The site and mechanism of oxalate absorption in the
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intestinal lumen is not well understood. Peak
excretion of an oxalate load was found to be 2 to 4 
hours after loading (Barilla et al. 1978), which 
suggests the small bowel is the major site of 
absorption. This absorption study was based on urine 
results and not plasma analysis.
Early animal work suggested that the absorption of 
oxalate was a non-energy dependent nonsaturatable 
passive process (Binder, 1974J Saunders, Sillery and 
McDonald, 1975) that could occur along the whole
length of the gut. More recently Freel et al (1980) 
identified an energy dependent mechanism in rat colon. 
Freel stated that calcium was necessary to maintain 
the integrity of a conductive pathway for the 
absorption of oxalate. In 1986 Knickelbein and co­
workers demonstrated the presence of oxalate transport 
in the brush border of rabbit ileum. Oxalate could be 
transported in exchange for either hydroxyl or 
chloride ions, and their work suggested an active 
process.
Freel postulated a dual system under physiological 
conditions, where with a low concentration of soluble 
oxalate, active transport would be the main mode of 
oxalate absorption. When the soluble load of oxalate 
increased, passive diffusion would become more 
important. This has been supported by the work of 
Pinto and Paternain 1978. Using intestinal brush
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border from rabbits and humans, they found a specific 
protein in the cell cytosol that had a high affinity 
for oxalate. There is no evidence for a mechanism 
whereby oxalate is excreted into the gut.
Oxalate absorption depends on: the integrity of the 
whole gut, though it is not clear which part is 
primarily responsible for oxalate absorption or the 
exact mechanism of transport, the bioavailability or 
amount of oxalate in solution in the gut lumen and the 
presence of oxalate degrading bacteria in the gut.
1.7.2. Endogenous oxalate production
Oxalate at present is regarded as a non-essential 
metabolic end product in man. Under normal 
circumstances 80-90% of urinary oxalate is derived 
from endogenous production and 10-20% from exogenous 
sources in the diet. The endogenous production of 
oxalate is not fully understood, though it has 
recently been suggested that pathways can be 
formulated to link the endogenous production to 
dietary macronutrients (Conyers, Bais and Rofe, 1990). 
The major endogenous oxalate precursors normally 
quoted in the literature are ascorbic acid and 
glyoxylic acid (Menon and Mahle, 1982) . Each of these 
contributes 30-50% to the urinary oxalate output. Many 
of the investigations into the metabolic pathways have 
been conducted in experimental animals. Therefore
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there is some doubt as to the most important 
precursors in humans.
There are conflicting reports about ascorbate and its 
in vivo conversion to oxalate. It has been found by 
some investigators that an intake of 4g of ascorbate a 
day or more is required to produce an increase in 
urinary oxalate, though others have found no increase 
in oxalate output when lOg a day are taken (Levine, 
1986). However, there have been cases cited (Roth, 
1977, Tiselius and Almgard, 1977) of hyperoxaluria on 
an intake of Ig of ascorbate a day. The metabolic 
turnover of ascorbic acid is thought to be saturated 
at intakes of 200 mg per day (Williams and Wilson
1990).
Some of the contradictions may be due to the in vitro 
conversion of ascorbate to oxalate, in studies where 
little attention was paid to sample collection and 
assay conditions. Another possibility is that some 
individuals may have an abnormal ascorbate metabolism 
(Chalmers, Cowley and Brown 1986). Other variables in 
these studies are the length of time for which the 
ascorbate is taken and the type of preparation taken. 
Further investigations will be needed to resolve these 
problems.
Work on rats suggests that the conversion of ascorbate 
to oxalate is non enzymatic (Gibbs and Watts, 1973) . 
Other workers believe that the metabolic conversion is
48
enzymatic and the enzyme is saturated at low 
concentrations of ascorbic acid (Williams and 
Wandzilak, 1989).
The other major oxalate precursor, glyoxylate, is in 
fact an intermediary metabolite of oxalate. Glyoxylate 
can be enzymatically metabolised to oxalate. The 
enzymes involved are glycolic acid oxidase, xanthine 
oxidase and lactate dehydrogenase. Gibbs and Watts 
(1973) found lactate dehydrogenase to be the main 
enzyme responsible for the oxidation of glyoxylate to 
oxalate. The precursors of glyoxylate that contribute 
to oxalate production are numerous.
Glycine can be oxidised to glyoxylate by glycine 
oxidase. Glycine and glyoxylate share a reversible
I
reaction. The conversion of 3lVjOxylate to glycine is a 
transamination controlled by the peroxisomal enzyme, 
alanine glyoxylate aminotransferase, requiring 
pyridoxine as a cofactor. Deficiency of pyridoxine can 
lead to increased oxalate output (Faber et al. 1963). 
Minor pathways involve the amino acids tryptophan and 
serine that metabolise to oxalate via glycine and 
glyoxylate. Hydroxyproline can also be metabolised to 
oxalate via glyoxylate, but this is a very minor 
pathway. Glycolate is an immediate precursor of 
glyoxylate and oxalate, it can be converted to oxalate 
directly or via gloxylate. Tyrosine and phenyalanine 
can be metabolised to oxalate via glycolate.
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Hydroxypyruvate is an intermediate in the conversion 
of D and L- glycerate to oxalate. These metabolic 
pathways can be seen in figure 1.3.
The ideas of Conyers, Bais and Rofe (1990) about a 
link between 'dietary macronutrients, particularly 
carbohydrates, and urinary oxalate production is shown 
in figure 1.4. The range of amino acids that can be 
converted to oxalate suggest dietary protein may also 
contribute to urinary oxalate output.
Conyers, Bais and Rofe (1990) state that the role of 
glycine as an oxalate precursor is equivocal, and they 
are sceptical about the contribution of ascorbate to 
endogenous oxalate production. They postulate that 
carbohydrate metabolism in particular, and 
macronutrients in general may play an important part 
in endogenous oxalate production and that this area 
should be further investigated. Clearly a great deal 
more work needs to be done to elucidate the endogenous 
sources of oxalate.
1.7.3. Renal handling of oxalate.
Studies on the renal handling of oxalate have been 
hampered by a lack of reliable plasma oxalate methods. 
Much of the data on renal handling is based on animal 
work or human studies using indirect radioisotope 
determinations (Boer et al. 1985). Isotopes are 
limited in their use due to the associated health
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hazards. However a lot of important studies have been 
performed. Using radioisotopes it has been 
demonstrated that oxalate is excreted almost 
exclusively by the renal route (Osswald and Hautmann,
1979). Studies on oxalate assume it is freely 
ultrafilterable through the glomeruli and not 
catabolised in the body. Some workers state that 
oxalate in plasma is completely ultrafilterable 
(Kasidas, Nemat and Rose, 1990), whilst others have 
found that between 11-16% is protein bound (Schwille 
et al. 1988) . This obviously has implications for the 
measurement and interpretation of renal handling data. 
In most of the studies using radioisotopes the ratio 
between oxalate clearance and creatinine clearance has 
been found to exceed unity (Boer et al. 1985, Osswald, 
Hautmann, 1979). This implies, assuming that it is 
freely ultrafilterable, that there is net tubular 
secretion of oxalate. Micropuncture studies on animals 
have defined the early part of the proximal tubule as 
the site of the secretory process. In the mid portion 
of the proximal convoluted tubule there is thought to 
be bidirectional transport (Weinman et al. 1978). 
Micropuncture studies by one group have suggested two 
secretory processes in the proximal tubule. They have 
postulated the presence of a high affinity, low 
capacity oxalate transport system operating at low 
plasma oxalate concentrations and a low affinity, high
53
capacity transport system at high plasma oxalate 
concentrations (Knight et al. 1981). The transport of 
oxalate in the tubule was reduced by alpha 
ketoglutaric acid, suggesting a possible involvement 
of the dicarboxylate transporter. The distal tubule 
does not seem to be involved in oxalate transport, as 
it is thought to be impermeable to oxalate.
The net tubular secretion of oxalate in the kidney has 
not been a consistant finding. Micropuncture studies 
(Greger et al. 1978) and fractional excretion 
calculated from plasma and urine analysis, have shown 
net absorption of oxalate in the tubule (Wilson, Smith 
and Liedtke, 1988). Further to this, recent studies 
have shown oxalate creatinine clearance ratios above 
and below unity in the same study (Kasidas, Nemat and 
Rose, 1990). These findings would seem to support the 
existence of a bidirectional flux of oxalate. Further 
investigations are required to confirm these findings 
and to define more clearly the renal handling of 
oxalate.
Data on the renal clearance of oxalate has been 
difficult to obtain due to the lack of a reliable 
plasma oxalate method. Most of the data has been 
derived from infusion studies. Constable et al
(1979) found a mean clearance of 170 ml/min on 5 
normal subjects with a range of 105 to 227 ml/min. The 
use of reliable methods for oxalate analysis should
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allow accurate clearance data to be obtained.
1.7.4. Distribution volume of oxalate and biological 
half life.
Radioisotopes have been used to make estimates of the 
distribution volume of oxalate. Morgan et al (1987) 
estimated a distribution volume of 16.1-22.9 litres in 
normals. They also assessed metabolic pool size (10.0- 
33.2 umol/1), tissue oxalate accumulation rate (0-24 
umol/24 hour) and tissue oxalate clearance (0-26 
ml/min). the oxalate half life of elimination is 
thought to be approximately 92 minutes (Hodgkinson and 
Wilkinson 1974).
1.8. ABNORMAL OXALATE METABOLISM.
There are no known disease states associated with low 
levels of urine and plasma oxalate. It is the 
elevation of oxalate in urine and blood that is 
harmful.
High levels of oxalate in blood or urine or both, have 
been found in the primary hyperoxaluria (Watts et al.
1991), enteric hyperoxaluria (Bambach et al. 1981), 
idiopathic renal stone disease (Smith, 1990), 
pyridoxine deficiency (Yendt and Cohanim, 1985), the 
ingestion of substances metabolised to oxalate 
(Conyers Bais and Rofe, 1990) and in patients with end 
stage chronic renal failure (Morgan et al. 1987).
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1.8.1. Primary hyperoxalurias.
The primary hyperoxalurias consist of three inborn 
errors of metabolism which have an autosomal recessive 
form of inheritence. The urinary oxalate excretion is 
usually very high in these conditions (>lmmol/24 hr) , 
with all three types having the same clinical features 
This includes nephrocalcinosis, recurrent renal stones 
and progressive renal insufficiency, followed by 
systemic oxalosis. Oxalosis was described in section
1.2.4. .
Type I primary hyperoxaluria occurs most commonly and 
it has three clinical variants: infantile, juvenile
and adult. These variants are defined by the age of 
onset of urolithiasis and or renal failure. The 
juvenile group is the most common, occurring between 
the ages of 2 to 18 years.
The metabolic lesion associated with type I primary 
hyperoxaluria is due to a deficiency of the 
peroxisomal enzyme alanine:glyoxylate aminotransferase 
(AGT;EC 2.6.1.44.) (Danpure et al. 1987). This enzyme 
is required for the transamination of glyoxylate to 
glycine. The absence of the enzyme results in the 
movement of glyoxylate from the liver peroxisome to 
the cytosol where it is converted to oxalate and 
glycolate. This results in both hyperoxaluria and 
hyperglycolic aciduria (Danpure and Jennings, 1986).
The deficient enzyme can be assayed on percutaneous
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needle biopsies of the liver, which offers an 
enzymatic diagnosis for type I primary hyperoxaluria. 
Danpure et al (1987) found that the activity of AGT 
correlated inversely with urinary oxalate output.
Since primary hyperoxaluria type 1 seems to be a 
heterogeneous disease, clinically (Watts et al. 1985), 
enzymatically (Danpure, Jennings and Watts, 1987) and 
immunologically (Wise, Danpure and Jennings, 1987), it 
is conceivable that a mild enzyme deficiency could be 
related to mild hyperoxaluria. With this in mind, it 
is possible that some patients with calcium oxalate 
nephrolithiasis may have a mild enzyme defect, though 
no one has assayed hepatic enzymes in this context.
If endogenous over production of oxalate were 
responsible for some of the hyperoxaluria seen in 
calcium oxalate stone formers, one would expect the 
production of oxalate to be unaffected by fasting the 
patient. Not many studies have been performed on 
fasting urine samples, but those that have been done 
show no statistically significant difference between 
fasting and non-fasting results. However, some of 
these studies have been carried out on old 
(Hodgkinson, 1978) and unreliable methods (Schwille, 
Hanisch and Scholz, 1984), therefore they should be 
re-evaluated using more recent methodology.
A recent study (Schwille et al. 1989) on a small 
number of fasting individuals, suggested that the
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increased output of urinary oxalate seen in stone 
formers was mediated by the kidneys. This finding is 
not inconsistent with endogenous production. A recent 
publication by Kasidas, Nemat and Rose (1990) gave 
evidence of hyperoxaluria in some patients of 
endogenous origin originating from the kidney rather 
than the liver. Further investigations will be
required, analysing not only oxalate but also some of 
the metabolites involved in endogenous oxalate
production.
It has been found that some patients with type I 
primary hyperoxaluria respond to large doses of 
pyridoxine (Yendt and Cohanim 1985) with the lowering 
of urinary oxalate and glycolate excretion. Not all 
patients respond to this treatment, and those who do, 
show varying degrees of success. This variable
response again shows heterogeneity that is not 
completely explained on a molecular level. Pyridoxine 
is required as a co-factor in the transamination 
reaction of AGT. It is possible that the pyridoxine 
resistant and sensitive patients are explained by 
genetic heterogeneity with respect to mutations which 
change the affinity of the binding sites for the co­
factor. Alternatively the co-factor binding site may 
be deleted.
Type II primary hyperoxaluria is due to a deficiency 
of D-glycerate dehydrogenase (EC 1.1.1.29.). This
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enzyme normally catalyses the reduction of 
hydroxypyruvate to D-glycerate. The result of this 
metabolic lesion is the compensated lactate 
dehydrogenase conversion of hydroxypyruvate to L- 
glycerate. This results in L-glyceric aciduria. This 
is thought to be coupled to the lactate dehydrogenase 
catalysed oxidation of glyoxylate to oxalate, thereby 
causing hyperoxaluria.
Primary hyperoxaluria type III has no associated 
increase in the urinary output of glycolate or L- 
glyceric acid. Urinary oxalate output is similar to 
that for other primary hyperoxalurias; 1-2 mmol/24 hr. 
The abnormality appears to be the primary 
hyperabsorption of oxalate from the gut, without the 
presence of any intestinal disease.
The investigation and evaluation of patients with 
primary hyperoxaluria requires the measurement of 
blood and urine oxalate, glycolate and L-glycerate 
levels, ACT assay and the identification and
evaluation of organ damage due to oxalosis. Urine and 
plasma oxalate can help in the diagnosis and
management of this condition. Plasma oxalate is
particularly valuable to assess the imminence of the 
oxalotic phase of illness (Watts et al. 1991). 
Palliative treatment of primary hyperoxalurias may be 
possible with pyridoxine, if the patient responds. A 
more radical and definitive treatment now available in
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selected patients is a combined hepatic and renal 
transplant (Watts et al, 1991).
1.8.2. Secondary hyperoxalurias.
1.8.2.1. Enteric hyperoxaluria.
Enteric hyperoxaluria is a condition in which severe 
chronic bowel disease associated with fat and or bile 
acid malabsorption leads to the hyperabsorption of 
dietary oxalate, hyperoxaluria and recurrent calcium 
stone disease. In rare instances this can lead to 
renal tubular oxalosis and progressive renal failure. 
This is the commonest form of secondary hyperoxaluria. 
A wide variety of gastrointestinal disorders and 
surgical procedures have been shown to produce enteric 
hyperoxaluria (Williams, 1978). The risk of 
nephrolithiasis however appears to be confined to 
patients with steatorrhoea often associated with 
chronic inflammation of the small intestine, due to 
Crohn's disease, or following jejuno-ileal bypass 
operations for the treatment of obesity (Hofmann et al 
1983) . It can also be a consequence of small 
intestinal resection (Bambach et al. 1981).
In patients with these gastrointestinal disorders, the 
clinical consequences of enteric hyperoxaluria are 
less commonly found than the hyperoxaluria itself 
(Hylander, Jarnum and Frandsen 1978) . This suggests
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other risk factors, apart from hyperoxaluria, must be 
involved in the stone formation and renal oxalosis 
seen in enteric hyperoxaluria.
There are two mechanisms thought to be responsible for 
the hyperabsorption of oxalate in enteric 
hyperoxaluria. Firstly, as a consequence of fat 
malabsorption, fatty acids accumulate in the 
intestinal lumen. These fatty acids bind to 
intraluminal calcium and release oxalate, making it 
available for absorption. This is supported by the 
finding that oxalate excretion has a positive linear 
correlation with the degree of steatorrhoea (Anderson 
and Gillberg, 1977; Rampton, Kasidas and Rose, 1979). 
The second mechanism involves malabsorbed bile salts, 
which increase the permeability of the colon to 
oxalate. This was demonstrated by Dobbins and Binder 
(1976) in the rat. The colon seems to be the main site 
of oxalate absorption in enteric hyperoxaluria. The 
prolonged absorption of oxalate found in a group of 
such patients after they were given a test meal 
implies colonic absorption (Barilla et al. 1978). A 
third factor that may play a role in producing higher 
levels of oxalate in the gut of patients with 
steatorrhoea, is a reduced rate of oxalate degradation 
by gut bacteria (Allison et al. 1986).
Whilst oxalate absorption is the major factor in this 
type of secondary hyperoxaluria, it has been shown
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that oxalogenesis of dietary protein in jejuno-ileal 
bypass patients may also play a role (Hofmann et al. 
1983) .
Treatment, apart from that of the underlying gut 
disorder, includes diet restriction of oxalate and 
fat, and supplementation with calcium, magnesium or 
cholestyramine. Patients with jejuno-ileal bypass may 
require surgical reversal.
Andersson and Gillberg (1977) have used an oxalate 
loading test to identify patients with steatorrhoea. 
This test used spinach as the load, which contains
variable amounts of oxalate per unit weight. Rampton 
et al (1979) improved the test by administering a 
definitive load of sodium oxalate in the form of
capsules.
A limited appraisal of this test by Foster et al
(1984) concludes that this was not a useful 
alternative to faecal fat estimation, though 
methodology has now improved and a re-evaluation using 
current methods may be worthwhile.
1.8.2.2. Pyridoxine deficiency
Pyridoxal phosphate is the biologically active form of 
vitamin which functions as a cofactor for the
metabolism of many amino acids. The reactions that 
require pyridoxal phosphate are transaminations, 
decarboxylations and racémisation of amino acids.
62
The role of pyridoxine in primary hyperoxaluria has 
already been mentioned. Studies on human subjects who 
were vitamin deficient have shown they develop 
hyperoxaluria (Faber et al 1963). This relationship 
between oxalate production and pyridoxine led Rose 
(1988) to postulate a condition called mild metabolic 
hyperoxaluria characterised by raised urinary oxalate 
and glycolate, the urinary excretion of oxalate being 
between 500-800 umol/24 hours. There is also a raised 
plasma oxalate, indicating that the source of oxalate 
is not renal. Some of these patients have been shown 
to respond to pyridoxine with a reduced urinary 
oxalate output. Clinically, they have urolithiasis 
which can, in a proportion of cases, be improved by 
pyridoxine treatment.
1.8.2.3. Intake of oxalate precursors.
There are secondary hyperoxalurias caused by the 
metabolism of oxalate precursors. Many of these 
precursors have been identified as toxic to humans 
when taken in excess. A recent review by Conyers, Bais 
and Rofe (1990) talks of a dose related toxicity 
syndrome of renal, cerebral and liver dysfunction. 
There is metabolic acidosis and calcium oxalate 
crystal deposition.
The precursors mentioned by Conyers include ethylene 
glycol, methoxyflurane, glycerol, polysorbates.
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xylitol and the experimental hypoglycemic agent 
dichloroacetate.
All these substances which are able to produce this 
syndrome, they have also been shown to produce 
hyperoxaluria.
Ingestion of ethylene glycol can lead to 
hyperoxaluria, with fatal consequences. Ethylene 
glycol is converted to glycoaldehyde and to glycolate 
in the liver. A case of fatal ethylene glycol 
poisoning (Simpson, 1985) had a combined 
glycolate/oxalate level in urine of 5,750 umol/1. This 
resulted in oxalate deposition in the kidney and 
subsequent renal failure. Ethylene glycol has a sweet 
taste and is used in commercial products such as 
detergents, paints, pharmaceuticals, cosmetics and 
food preservation. The main source in toxic cases is 
anti freeze.
The anaesthetic agent methoxyflurane can be converted 
to oxalate and some cases of hyperoxaluria have been 
reported after the use of such an anaesthetic.
Studies suggested that oxalate produced by 
dichloroacetate metabolism interfered with 
carbohydrate metabolism at a cellular level (Yount and 
Harris, 1980). Dichloroacetate decreased blood 
glucose, lactate and pyruvate in diabetic and starved 
normal rats. Dichloroacetate is metabolised to 
glyoxylate and then to oxalate. It was found that
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oxalate inhibited pyruvate decarboxylase (EC 6.4.1.1.) 
and pyruvate kinases (EC 2.7.1.40.) in isolated 
hepatocytes (Buc, Demaugre and Leroux, 1978; Demaugre, 
Cepanec and Leroux, 1978).
Dichloroacetate was shown to inhibit ketogenesis in 
the ketotic state (Blackshear et al. 1975) but Buc et 
al in 1982 published work on isolated rat hepatocytes 
to show that oxalate enhanced ketogenesis and 
decreased fatty acid synthesis. A slight enhancement 
of ketogenesis by oxalate was also seen by another 
group using hepatocytes (Yount and Harris, 1980). This 
group also found that oxalate inhibited 
gluconeogenesis, possibly due to pyruvate carboxylase 
inhibition.
These studies were designed to investigate the toxic 
effects of oxalate at a cellular level. The results do 
suggest that oxalate may act on carbohydrate 
metabolism in a minor way.
Other precursors thought to promote hyperoxaluria 
include glycine, ascorbate and purines. Glycine rich 
fluids used for bladder irrigation after prostatectomy 
have been shown to produce hyperoxaluria (Fitzpatrick, 
Kasidas and Rose, 1981) but data on the role of 
glycine and increased oxalate production is equivocal 
(Conyers, Bias and Rofe, 1990).
The intake of ascorbate has been shown to cause 
hyperoxalemia in patients with end stage renal failure
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(Ono, 1986) and this can lead to renal oxalate 
deposition (Ono et al. 1989).
Generally the role of ascorbate as a cause of 
secondary hyperoxaluria is not so clear, as was 
outlined in section 1.7.2. on endogenous oxalate 
production. Individual cases of hyperoxaluria due to 
small intakes of ascorbate (Ig) have been reported 
(Roth, 1977) and more commonly hyperoxaluria as a 
result of large intakes, in excess of 4g per day 
(Schmidt et al 1981). These reports are often in 
contradiction. Fituri et al. (1983) showed that an 
intake of 8g a day in normal subjects did not increase 
oxalate output. These apparent discrepancies in the 
role of ascorbate with respect to secondary 
hyperoxaluria may be due to poor methodology, the 
effect of oxalogenesis post micturation, the fact that 
some studies use pure ascorbic acid (Fituri et al,
1983) whilst others use tablets containing other 
possible oxalate precursors. There is also the 
possibility that some individuals have abnormal 
ascorbate metabolism, as proposed by Cowley et al 
(1987). It was proposed by Cowley and his colleagues 
that some subjects had malabsorption of 
hydrocarboxylic acids. This interfered in ascorbate 
absorption from the gut, leading to increased 
conversion of ascorbate to oxalate in the gut with 
consequent hyperoxaluria. This area requires further
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study using reliable methods with with proper sample 
collection procedures.
The intake of purines has also been implicated as a 
cause of hyperoxaluria (Zarembski and Hodgkinson, 
1969). This observation, together with other studies, 
suggests macronutrients such as dietary animal protein 
(Yendt and Cohanim, 1989, Goldfarb, 1988) and 
carbohydrates (Conyers, Bias and Rofe, 1990, Rao, 
Davies and Blacklock, 1982, Ribaya-Mercado and 
Gershoff, 1984) may be a source of oxalate in 
hyperoxaluria. These suggestions of the effect of 
macronutrients on oxalate formation however await 
confirmation. For example, a recent report suggests no 
correlation of dietary animal protein intake to 
urinary oxalate output (Trinchieri et al. 1991) and 
Marangella et al (1989) find that animal protein has a 
minimal effect on oxalate excretion. Further studies 
are clearly needed.
1.9. RENAL STONE DISEASE AND OXALATE METABOLISM.
The commonest clinical manifestations of hyperoxaluria 
are the formation of renal stones, and in some 
severely affected individuals nephrocalcinosis.
Renal stone disease accounts for about seven to ten of 
every 1000 hospital admissions in the United States. 
The majority of patients are male, but in both sexes 
the peak age of onset is between 20 and 3 0 years.
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these are highly productive adult years. Despite the 
fact that nephrolithiasis is a common cause of 
morbidity rather than death or renal failure it should 
not be forgotten that the pain of renal colic is 
severe and often hospital admission is required.
Most of the renal stones produced are composed of or 
contain calcium oxalate. Conditions that increase the 
level of supersaturation raise the risk of stones. 
Infection can do this as microrganisms cause Struvite 
supersaturation. In these cases the infection is 
treated. The metabolic causes of stones in the kidney 
can result from many diseases, these are shown in 
table 1.2. In normal individuals urine is 
supersaturated with respect to calcium and oxalate so 
the potential for stone formation is always present. 
Any of the conditions in table 1.2 that raise the 
level of calcium and or oxalate in the urine increase 
the risk of calcium oxalate stone formation.
Calcium oxalate stone formation may be either 
idiopathic or the result of a specific metabolic 
abnormality. The specific abnormalities account for 
less than 10% of all calcium oxalate stones and these 
are treated by treating the underlying disease.
1.9.1. Idiopathic calcium oxalate stone disease.
Idiopathic calcium stone formation may be the result 
of a disorder or disorders of which the underlying
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Table 1.2 Classification of metabolic urolithiasis
Enzyme defects
Primary Hyperoxaluria 
Xanthinuria
2.8-dihydroxyadeninuria 
Tubular defects
Cystinuria
Renal tubular acidosis
Enteric urolithiasis
Enteric hyperoxaluria 
Uric acid lithiasis
Hypercalcémie states
Primary hyperparathyroidism
Milk-alkali syndrome
Immobilisation
Sarcoidosis
Hypervitaminosis D
Hyperthyroidism
Others
Uric acid lithiasis
Gout
Idiopathic
Low urine ouput states 
Myeloproliferative disorders
Idiopathic calcium oxalate urolithiasis
Hypercalciuria
Hyperoxaluria
Hyperuricosuria
Crystal modify^ defects
Citrate
Magnesium
Others
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pathology remains to be defined. The diagnosis is 
based on the exclusion of other primary causes of 
renal stone formation within the urinary tract. 
Despite the term idiopathic, groups of specific 
disorders have been defined.
Pak et al (1975, 1980) separated patients based on the 
presence or absence of hypercalciuria. This was done 
from the patients response to a calcium loading test. 
After the loading tests the hypercalciuric subjects 
were further divided into absorptive and renal
hypercalciuria. These terms defined gut or renal
origins. The hyperabsorptive group being further sub 
divided into, type I: hypercalciuria despite diet,
type II: hypercalciuria only during calcium load and 
type III: hypercalciuria with a phosphate leak.
Patients defined as renal hypercalciurics had a high 
urine calcium output even on fasting. Normocalciuric 
patients were then defined as hyperoxaluric, 
hyperuricosuric, hypocitric aciduria and inhibitor 
deficient.
This classification is frustrated by the observation 
that the abnormalities overlap. Two or more
abnormalities have been found in the same patient and 
the dividing lines are blurred (Smith, Werness and 
Erickson, 1984). A more practical approach is to 
identify specific risks in the urine of individuals 
with this syndrome. Robertson et al (1978) identified
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the risks as oxalate, inhibitors, pH, uric acid, 
calcium and urine volume. Without doubt urine volume 
is the most significant factor. At least 60% of stone 
formers in this group will stop forming stones if they 
have an adequate fluid intake (Smith, 1990).
All the factors that are measured to assess patients 
with idiopathic calcium oxalate stone formation
including volume and pH will depend on diet. Therefore 
initial observations are best made on urine collected 
while the patient is at home on their normal diet and 
fluid intake. Stress tests such as calcium loading 
should be deferred until baseline levels have been 
established.
The investigation of hyperoxaluria in idiopathic
calcium oxalate stone formation has tended to take 
second place to calcium. This is partly due to the 
difficulty in measuring oxalate and the doubt about 
the effectiveness of the standard treatment of
hyperoxaluria; reduced dietary intake. Oxalate 
concentration has been shown (Robertson and Peacock,
1980) to be one of the most important determinants of 
calcium oxalate solubility in urine. It has been 
demonstrated that urinary oxalate concentration has a 
greater effect on the formation of calcium oxalate 
crystalluria than comparable changes in calcium 
(Robertson, Peacock and Nordin, 1971), and that the 
incidence of stone episodes in patients with calcium
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oxalate stones is much more directly dependent on 
urinary oxalate levels than on urinary calcium 
(Robertson and Peacock, 1980). These studies indicate 
the importance of understanding the factors that 
control oxalate metabolism.
1.9.1.1. Possible causes of hyperoxaluria.
The cause of hyperoxaluria in idiopathic calcium 
oxalate stone formers is still not clear, although 
several suggestions have been advanced.
There is the possibility of an endogenous over 
production due to a mild metabolic defect as suggested 
in the section on primary hyperoxaluria. This requires 
further investigation as the evidence is contradictory 
(Williams and Wandzilak, 1989) .
The source of oxalate could be renally mediated as 
suggested by Schwille et al (1989) with his work on 
fasting urine. Here the plasma oxalate was low and the 
renal output raised implying a renal source. As has 
already been mentioned, in previous sections, workers 
have found net tubular secretion and reabsorption of 
oxalate (Kasidas, Nemat and Rose, 1990). Publications 
of clearance data have also differed, some studies 
showing no difference between stone formers and 
normals (Williams, Johnson and Smith, 1971) and others 
indicating a difference (Pinto et al. 1974). Many of 
these studies were performed on small numbers of
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subjects and before reliable plasma oxalate methods 
were available.
Hyperabsorption of dietary oxalate from the gut could 
explain the hyperoxaluria seen in stone formers, which 
tends to be mild (<800umol/24 hour).
Two mechanisms have been suggested: Oxalate
absorption from the diet is dependent on the 
availability of calcium within the intestinal lumen. 
If calcium concentration in the lumen falls oxalate 
absorption increases. The first possibility is that 
subjects on a low calcium diet (<500mg/day) will 
hyperabsorb oxalate (Bataille et al. 1983). This is 
the reason why patients on low calcium diet must also 
be on a low oxalate intake.
The second mechanism refers to patients with an 
abnormality in calcium absorption as defined by the 
calcium loading test of Pak et al (1975). These 
patients hyperabsorb calcium in the proximal 
intestine, which reduces the luminal calcium 
concentration in the distal part of the bowel allowing 
increased absorption of oxalate. Erickson et al (1984) 
were able to demonstrate this in an experimental human 
model of absorptive hypercalciuria.
However, recently L^ndsjo et al (1989) carried out 
studies that suggest a third possibility, a primary 
defect in oxalate absorption from the gut, causing 
increased oxalate uptake and excretion.
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Recent work by Baggio et al (1986) has produced an 
interesting explanation for hyperoxaluria in 
idiopathic renal stone formers. They observed an 
increased transmembrane oxalate flux in the red blood 
cells in a subset of patients with idiopathic calcium 
oxalate nephrolithiasis when compared to normals. In 
studies on five families the abnormality appears to be 
an autosomal monogenic dominant trait with complete 
penetrance and variable expressivity.
The same authors reported that the increased oxalate 
exchange rate in red cells was inhibited in vivo 
(Baggio et al. 1986) by thiazide treatment, and in 
vitro by anion transport inhibitors (Baggio et al.
1984). These facts suggest a true membrane defect, 
which may be an anion carrier problem. The studies 
indicated that this could be a generalised membrane 
abnormality seen in both gastrointestinal epithelial 
cells and renal epithelial cells. It was hypothesized 
that an inherited defect in the cellular transport of 
oxalate may be a common factor in idiopathic calcium 
oxalate stone disease.
Baggio et al (1990) subsequently produced evidence of 
a lower erythrocyte membrane content of 
glycosaminoglycans in idiopathic calcium oxalate stone 
formers. They hypothesized that this enhances
membrane protein phosphorylation, leading to an 
increased rate of transmembrane oxalate flux. More
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studies are needed in patients with and without the
red cell abnormality, but positive results may help to 
develop treatments for hyperoxaluria in idiopathic
renal stone formers.
1.10. CHRONIC RENAL FAILURE.
In patients with chronic renal failure it has been 
shown that there is a linear relationship between 
plasma oxalate and creatinine (Kasidas and Rose, 
1986). Some oxalate can be removed by haemodialysis 
(Boer, Van Leersum and Endeman, 1984) but levels soon 
rise again, with the possibility of oxalosis 
developing. Measurement of the plasrAo. oxalate;
creatinine ratio helps to give an indication of the 
oxalate production rate, and in cases of primary
hyperoxaluria with chronic renal failure, this ratio 
will be higher than with chronic renal failure alone 
(Kasidas, 1988). This information may help iiÂscriminate 
between the two conditions in an anuric patient. 
Oxalate retention increases rapidly when the
glomerular filtration rate of chronic renal failure 
patients falls below 20 ml/min (Morgan et al. 1987). 
This is well above the level at which renal 
replacement is needed for end stage renal failure. The 
measurement of plasma oxalate may be useful in the 
management of a patient if the danger of oxalosis is 
to be averted.
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1.11. THE AIMS OF THE PRESENT STUDY.
The study of oxalate metabolism has been limited by a
lack of simple and reliable methods for oxalate
analysis. Despite a large number of published methods, 
none are clearly superior. This is particularly true 
of plasma oxalate, where analysis, sample collection 
and sample storage still pose significant problems.
The major goal of the present study was to develop 
reliable methods for urine and plasma oxalate, which 
could be applied to metabolic studies. Thereafter they
were to be fully evaluated for performance and
potential interferents, particularly ascorbic acid.
The methods were to be used to define normal ranges 
for plasma oxalate, urine oxalate, oxalate clearance 
and fractional excretion of oxalate. It was intended 
to characterise these parameters in the fasting and 
fed state in order to learn more about the renal 
handling of oxalate and the effect of diet. Biological 
variation of oxalate was also to be investigated. 
Although there have been studies published on the 
gastrointestinal absorption and renal handling of 
oxalate only a few of these have used reliable methods 
for measuring plasma oxalate. To improve knowledge in 
this area a series of loading studies would be 
informative. These studies were to include oxalate 
loading with sodium oxalate and oxalate containing 
food stuffs. The sodium oxalate loading study was also
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to be used in an evaluation of the effect of oxalate 
on ketogenesis.
Using methods free from ascorbate interference, it was 
intended to investigate the effects of short and long 
term ascorbate intake on oxalate levels in blood and 
urine.
Finally, having fully characterised the methods 
developed and established normal ranges, they were to 
be used in the evaluation of a group of idiopathic 
calcium oxalate stone formers. Patients were also to 
be investigated with respect to their oxalate 
metabolism and renal handling of oxalate.
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CHAPTER 2.
DEVELOPMENT OF HIGH PRESSURE LIQUID 
CHROMATOGRAPHIC METHODS FOR THE 
MEASUREMENT OF OXALATE IN URINE AND 
PLASMA.
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INTRODUCTION
This chapter contains a series of experiments designed 
to produce a reliable method of oxalate analysis in 
biological fluids using HPLC. These include 
experiments to develop and evaluate the
chromatographic conditions to be used, and the 
extraction techniques for the analysis of oxalate in 
plasma and urine.
As stated in chapter one, the development of methods 
to measure oxalate in biological fluids has been a 
problem for many years. There has been, and still is, 
debate concerning the validity of oxalate measurement 
in biological fluids, particularly with reference to 
plasma methods. More than thirty plasma methods have 
been published, with suggested upper limit of normal 
for plasma levels ranging from 1.5 umol/1 to more than 
400 umol/1 (Costello and Landwehr, 1988).
The lack of a recognized reference method and the wide 
discrepancy in results and methodologies used, in many 
previous studies of oxalate metabolism, means that it 
is often difficult to be confident of the data 
generated and its interpretation. It was decided 
therefore to develop a method for both plasma and 
urine oxalate that could be used in metabolic studies. 
Initial attempts at method development included the 
use of oxalate decarboxylase/formate dehydrogenase 
enzyme with fHUOresence detection (Sodium
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Resazurin/Diaphbrase/NAD) to enhance sensitivity, 
immobilisation of oxalate oxidase in a coil that could 
be used with continuous flow technology and an 
oxalate oxidase enzyme system on a Cobas Bio 
centrifugal analyser. For a variety of reasons, some 
analytical, some logistical, these approaches did not 
work.
The use of high performance liquid chromatography 
(HPLC) offered the possibility of specificity and 
sensitivity that would allow both plasma and urine 
oxalate to be measured on the same system. The aim of 
this study was to develop a relatively simple and yet 
robust system for oxalate analysis, using HPLC with 
electrochemical detection.
HPLC is an analytical technique by which two or more 
compounds can be separated from one another by 
utilising differences in their interactions with the 
surface of a stationary phase, which is enclosed in a 
steel tube. To achieve this separation, a dynamic 
equilibrium distribution is set up between the 
compounds of interest, in a liquid mobile phase, and 
the stationary phase. The liquid mobile phase flows 
over the stationary phase, flow being maintained by 
the application of pressure.
There are many considerations in the development of 
such a separation system:
(1) the choice of stationary phase, which is dependant
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on the compound to be separated.
(2) column characteristics, such as size and surface 
groupings of packing materials, which will affect 
sample resolution.
(3) the choice of mobile phase, compounds of interest
must be soluble in the mobile phase
(4) the pH and molarity of the mobile phase must be 
optimised with respect to the chromatographic 
separation required.
Attempts made to separate the oxalate anion in
biological matrices using strong and weak anion 
exchange columns were not successful. These columns 
retained the oxalate anion too strongly. However, Kok 
et al (1984) and Larrson, Libert and Asperd (1982) 
attempted a new approach using HPLC with ion pair 
reagents in the mobile phase to measure urine oxalate. 
Ion pairs are charged detergent like compounds, 
soluble in the stationary phase, which are able to 
give retention and separation of ionised compounds on 
reverse phase stationary phases without greatly
altering the behaviour of neutral molecules. Based on 
the work of Kok et al (1984) it was decided to 
evaluate the ion pair cetrimide on a reverse phase 
column, for the separation of oxalate in urine and 
plasma.
Even when good separation has been achieved, the 
sensitivity of the method is limited by the detector.
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Electrochemical detection is very sensitive for 
measuring compounds that are electroactive (eg.
oxalate). The electrochemical detector contains a 
reference electrode, which acts as a stable, reliable 
half cell and can be used as a reference point for 
measurements. It also has a working electrode, which 
in this study is glassy carbon, at whose surface the 
electrochemical reaction occurs when an electroactive 
analyte is present.
The electrochemical detector produces a constant
voltage, which also has a constant current while the 
mobile phase is passing through it. If an 
electroactive compound enters the detector it will be 
oxidised or reduced, causing a change of current. The 
resultant current is amplified and presented to a 
recorder. The current change is proportional to the 
analyte concentration.
A voltammogram is used to identify the optimum 
potential to apply to an analyte. To produce a 
voltammogram, a standard solution containing the 
compound of interest is scanned by changing the 
voltage and measuring the current produced. If the 
sample is oxidised, as oxalate is, the current
response increases with voltage until a plateau is 
reached. The plateau is reached when any further 
increase in voltage does not change the current. The 
optimum voltage is just at the start of the plateau.
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It is here that the detector gives maximum sensitivity 
with maximum selectivity. If the voltage is increased 
beyond the plateau the current will start to increase 
again. This is the mobile phase oxidising. The 
voltammogram can characterise a compound by its half 
wave potential, which is the potential at half the 
final height of the plateau.
Previous workers had tried to use electrochemical 
detection to measure oxalate but they required complex 
sample preparation (Mayer, McCarthy and Greenberg, 
1979) or equipment that was not readily available and 
required frequent maintenance, causing large, day to 
day variation (between batch CV% 10-20%) in the 
results (Kok et al. 1984) . Also these methods were 
applicable only to urine. Electrochemical detection 
would give the required sensitivity, and careful 
sample preparation would give the necessary 
selectivity to measure oxalate in biological fluids. 
Sample preparation and extraction presented the 
greatest analytical challenge. This was solved in part 
by the use of bonded silica sorbents. Sorbent 
extraction is a physical extraction process involving 
a molecular equilibrium between a solid phase bonded 
sorbent and a liquid phase. This is a system which can 
be used in a variety of ways to purify a sample. The 
commonest approach is to apply a sample matrix to a 
sorbent bed. This results in selective absorption of
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certain compounds while others pass through the 
sorbent unretained. A wash phase follows which removes 
unwanted interferences, then the compound of interest 
is eluted from the sorbent with an appropriate 
solvent. An alternative way of using the solid phase 
sorbents for extraction, is to select a sorbent which 
adsorbs all interferences and allows the compound of 
interest to pass through unretained. Both of these 
approaches have been used in the method development 
described in this chapter. Table 2.1 shows the 
approach to developing a solid phase extraction 
technique.
In order to apply the experiments described in the 
earlier sections of the chapter to biological samples, 
it was necessary to perform further investigations. In 
the case of plasma analysis it was required to 
determine whether protein binding affected analyte 
recovery during sample preparation, a problem 
highlighted by Costello and Landwehr (1988) and 
Schwille et al (1989). Also plasma and urine had to be 
checked for stability during both collection and 
analysis.
A major problem relating to sample stability is the 
presence of ascorbic acid, which can be converted to 
oxalate in biological samples in vitro (Mazzachi, 
Teubner and Ryall, 1984, Crawford, Mahony and Gyory,
1985). To ensure an accurate analysis, this potential
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Table 2.1 Development of Sorbent Extraction Methods.
1.SELECTION OF SORBENT
(a) analyte properties
eg. ionic,polar, non polar
(b) matrix properties
eg. aqueous, organic,pH,ionic strength
(c) matrix components
eg. proteins, fats,salts,solids
2.TESTING SELECTED SORBENT
(a) optimize retention of standards
(b) optimize elution of standards
(identify wash solvents)
(c) test blank matrix
(use wash solvent)
(d) test spiked matrix
(trouble shoot if required)
3.TROUBLESHOOTING METHOD
(a) inadequate retention of standards.
* alter matrix * change sorbent
(b) inadequate elution of standards
* stronger elution solvent
* less retentive sorbent
(c) insufficient matrix clean up
* wash solvents
* more selective sorbent
(d) variable isolate recovery
* sample pretreatment * selectivity
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interfèrent was investigated.
The approach to this problem in plasma was based on 
the work of Okamura (1980). Okamura developed a method 
to measure ascorbic acid and dehydroascorbic acid. In 
his method, he converted dehydroascorbic to ascorbic 
acid using the reducing agents dithiothreitol and dl 
homocysteine. These reducing agents were investigated 
as potential stabilisers of plasma oxalate samples.
The methods presented here, combine the specificity of 
HPLC with the sensitivity of electrochemical detection 
and require minimal sample preparation and no 
derivatisation. The methods described in this chapter 
will be used throughout the thesis to measure plasma 
and urine oxalate.
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SECTION:! OPTIMISATION OF THE CHROMATOGRAPHIC AND 
DETECTOR CONDITIONS FOR THE ANALYSIS OF OXALATE.
2.1. MATERIALS.
All reagents, unless otherwise stated, were of Analar 
grade and were supplied by B.D.H. Chemicals Limited, 
(Poole, Dorset, U.K). All aqueous solutions were made 
up in double deionized water.
2.1.1. Equipment and Reagents.
Equipment comprised a single piston HPLC pump, (Gilson 
model 302; Anachem Ltd. Luton, Beds. U.K.) an 
autosampler (WISP 71GB, Millipore U.K. Ltd., Watford, 
Herts, U.K.), an electrochemical detector with a 
glassy carbon working electrode (EG and G; PARC Model 
400, Jones Chromatography, Cardif, U.K.), and a strip 
chart recorder (Gould Scientific Ltd., Harrow Middx. 
U.K.). Analytical columns (Spherisorb 0DS2 5u 250x4mm, 
Spherisorb CDS 5 and 3u 100x4mm and Spherisorb 0DS2 5u 
100x4mm) and preparative columns, (1ml) Bond Elut C18 
and strong anion exchange (SAX), were supplied by 
Jones Chromatography Ltd Cardiff U.K. ^
-  TA.XfM £THVCA‘'^2^»0(®<t.0PYLCCHU»ff.XÎ>t ,
Reagents; hexadecyltrimethylammonium bromide
(cetrimide) from Fisons Ltd., (Loughborough U.K.); 
HPLC grade methanol (Rathburn Chemicals Ltd. 
Peebleshire U.K.); and helium (BOC, Crawley, Sussex,
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UK) . Phosphate buffers were made from potassium 
dihydrogen phosphate and disodium hydrogen phosphate 
in methanol;water 10:90 v/v. Column conditioning 
solutions tested were methanol water mixes, containing 
cetrimide.
Standards were prepared from a 10 mmol/1 stock 
solution made up in deionised water. Oxalic acid was 
Aristar grade. (BDH Ltd. Poole Dorset UK.). Working 
standards were diluted in deionised water or a low 
oxalate urine or plasma.
2.2. METHODS AND RESULTS.
2.2.1. Voltammogram to establish operating potential.
A voltammogram was made using the electrochemical 
detector on scanning mode. This was to identify the 
optimum voltage for the measurement of oxalate by 
oxidation. An aqueous standard solution was circulated 
through the detector but no column was attached. 
Conditions on the electrochemical detector:
El scan start voltage; OmV 
E2 scan end voltage; +150OmV
Current range 0.5 - 20uA full scale deflection 
Scan cycle half: El to E2 
Scan rate 10 mV/sec.
Offset: auto.
DC mode
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Time constant 5 seconds.
The sample concentration was lOOug/ml (lmmol/1 
approx). Pump flow rate 1.2 ml/min, chart speed 60 
mm/min. Assessment was made at ambient temperature. 
Results of the voltammogram are shown in figure 2.1. 
The optimum applied potential for oxalate is 1.25 
volts, this is the voltage at which the voltammogram 
plateaus.
Routine operating conditions for the detector always 
included the above voltage but the sensitivity setting 
on the detector was dependant upon the condition of 
the working electrode at the time of the analysis, but 
was typically between 0.5 - 1.0 uA full scale
deflection.
2.2.2. Optimisation of Chromatographic conditions
Optimum conditions for the chromatography were 
established after the assessment of variables in the 
chromatographic system.
Various analytical columns were tried to see if a 
short retention time with complete resolution of 
oxalate from other moieties was possible. This 
assessment was performed on aqueous standards 
initially, then on samples with a low oxalate 
concentration augmented with standards. The following 
columns were tried: 100 x 4 mm. ODS 5u column, 100 x 4 
mm. 0DS2 5u column and a 100 x 4 mm. ODS 3u column.
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Anion exchange columns were also tried, both weak and 
strong, but neither proved acceptable due to 
prohibitive retention times. The best resolution and 
the greatest flexibility was achieved with a 
Spherisorb 0DS2 5u 250 x 4mm analytical column.
A Spherisorb 0DS2 5u 250 x 4 mm analytical column 
could be preconditioned by pumping 500 ml of cetrimide 
preconditioning solution through it at a flow rate of 
Iml/minute, followed by 500 ml of mobile phase at the 
same rate to act as a wash solution. This process was 
performed with the electrochemical detector 
disconnected. The mobile phase selected was a 
phosphate buffer made up in a methanol/water mixture. 
The cetrimide, methanol concentration and volume of 
the conditioning solution were varied independently of 
each other to establish if these factors effect 
oxalate retention. The significance of changing the pH 
and molarity of the mobile phase was also assessed.
The results of varying the methanol and cetrimide 
concentration and the volume of the conditioning 
solution used are shown in figures 2.2 - 2.4. The
effect of variation in the pH and molarity of the 
mobile phase are shown in figures 2.5 and 2.6. Each 
data point shown in these figures is the mean of three 
injections, an aqueous oxalate sample (100 umol/1) was 
injected. Oxalate retention on the column is expressed 
as retention volume, which is the volume of mobile
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FIGURE 2^ THE EFFECT OF CHANGING THE % 
OF METHANOL IN THE CONDITIONING SOLUTION 
ON THE RETENTION VOLUME OF OXALATE.
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FIGURE 23  EFFECT OF VARYING THE 
CETRIMIDE CONCENTRATION ON THE RETENTION 
VOLUME OF OXALATE.
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FIGURE 2.4 THE EFFECT OF VARYING THE 
VOLUME OF THE CONDITIONING SOLUTION 
ON THE RETENTION VOLUME OF OXALATE.
ê -X- Mean of 3 sample»
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Conditions: Flow rate Iml/min: 
Conditioning solution 75:25(v/v) aqueous 
\methanol: Cetrimide Cone. 2 nunol/1
FIGURE 2.5 THE EFFECT OF THE MOBILE 
PHASE pH ON THE RETENTION VOLUME OF 
OXALATE.
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Conditions: Flow rate Iml/min: Mobile 
phase 0.1M phosphate buffer pH 7.0,10% 
methanol: Cetrimide cone. 2 mmol/1
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FIGURE 2.6 THE EFFECT OF THE MOLARITY 
OF THE MOBILE PHASE ON THE RETENTION 
VOLUME OF OXALATE.
ê -X- Mean of 3 sampleg8 -
I 7 -
8
015 -4 -
I 0.200.05
Molarity of the mobile phase ^olar)
0.00 0.10 0.15
Condhioiis: Flow rate Iml/min: Mobile 
phase, phosphate buffer pH 7.010% 
methanol: Certrimide Cone. 2 mmol/1
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phase required to elute oxalate from the chromatic 
column. Knowledge of the flow rate allows retention 
time to be calculated.
2.2.3. Final conditions for the chromatography.
The chromatographic conditions which gave the most 
rapid analysis with good resolution' from other peaks 
were selected for use in the assay being developed. 
Column: Spherisorb ODS or 0DS2 250 X 4 mm. Mobile 
phase: 0.1 M pH 7.0 Phosphate buffer 10% methanol v/v, 
degassed with helium and filtered before use. Column 
preparation: Pass 500 ml 2mmol/1 Cetrimide 75:25 (v/v) 
deionized water:methanol through the column without 
the detector attached. The column is then washed with 
mobile phase for 2 hours before use. The detector is 
then reconnected and the system is ready for analysis.
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SECTION 2. DEVELOPMENT OF OPTIMUM CONDITIONS FOR THE 
EXTRACTION OF OXALIC ACID FROM URINE AND BLOOD.
2.3. MATERIALS
All reagents unless otherwise stated, were of Analar 
grade and were supplied by B.D.H. Chemicals 
limited,(Poole Dorset UK) . All aqueous solutions were 
made up in double deionized water.
2.3.1. Equipment and Reagents.
Equipment and reagents are as stated in section 1 of 
this chapter. Additional reagents include: dl
homocysteine and dithiothreitol (Sigma Ltd. Poole 
Dorset U.K.), acetonitrile HPLC grade (Rathburn 
Chemicals Ltd. Peebleshire U.K.). Working standards 
were diluted from a 10 mmol/1 stock solution of 
Aristar oxalic acid.
2.4 METHODS AND RESULTS.
2.4.1 Development of the Urine extraction technique.
Optimum conditions for sample extraction were 
identified by assessing recovery and the ability to 
resolve oxalate from other peaks on the chromatogram. 
Direct injection of urine samples onto the column 
whether the urine was diluted or not resulted in a 
chromatogram that could not resolve the oxalate peak
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from interfering substances.
Extraction using solid phase sorbent systems was
evaluated. Packing materials examined included C 18
bonded silica octadecyl primed with the ion pair
cetrimide in a scaled down version of the main column 
chromatography and weak anion exchange sorbents. Use 
of these materials resulted in the extracted sample 
being injected onto the column in matrices containing 
interférants from which the oxalate peak was not
resolved and in which variable recoveries were 
produced.
CIS bond elut cartridges, used as supplied by the 
manufacturer, proved most successful in removing 
interférants whilst giving 100% recovery of oxalate.
The CIS cartridges were prepared before sample 
application by the passage of 1ml of HPLC grade 
methanol followed by 1ml of a selected buffer, this 
same buffer being used to dilute the urine sample 
prior to application to the cartridge. The diluted 
sample was then passed through the cartridge under 
gravity, collected, mixed, and 20 ul injected for 
chromatography.
Sample dilution was -necessary for three reasons; to / 
counter the high sensitivity of the detection system, 
to create a reproducible environrtienb from urines which 
vary greatly in composition, and to ensure the 
exchange capacity of the cartridge is not exceeded.
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Phosphate, glycine and acetate buffers at various 
pH's and molarities were assessed as potential 
diluents. The chromatograms these produced highlighted 
the need to make the enviroment of the sample as near 
to that of the mobile phase used in the chromatography 
as possible. This meant the use of a phosphate buffer, 
ideally 0.1 M pH 7.0. Phosphate buffer was evaluated 
with respect to initial dilution of the sample, pH and 
molarity. Initial sample dilutions ranging from 1 in 3 
to 1 in 20 with phosphate buffer, O.IM pH 7.0 were 
examined. Results showed dilution in this range had no 
effect on recovery, all results were greater than 90%. 
A dilution of 1 in 5 was selected as optimum, ensuring 
sufficient sensitivity and a clean chromatogram. It 
was noted that a dilution less than 1 in 3 made the 
recovery and chromatography unreliable. Independently 
varying the pH from 4.0 to 7.0 and the molarity from 
0.05M to 0.2M did not alter the recovery data.
Urine samples augmented with 200 umol/1 and 500 umol/1 
of oxalate had recoveries of 96.2% +/- 2.6% (+/-SD)
and 95.8% +/- 2.9% (+/-SD) respectively, using data
from 10 individual urine samples.
In order to assess whether the C18 cartridges could be 
reused, the urines augmented with 200umol/l and 500 
umol/1 of oxalate were analysed five times using the 
same cartridges, cleaned between assays with methanol 
(2ml). Endogenous oxalate levels ranged between 92 and
98
602 umol/1 (mean 294). These results are shown in 
table 2 .2 , demonstrating that the cartridges could be 
used at least three times.
2.4.1.1. The final urine extraction conditions.
800 ul O.IM phosphate buffer pH 7.0 is added to 200 ul
urine. This solution is passed through a Bond Elut C
18 cartridge preconditioned with methanol (1ml) and 
O.IM phosphate buffer pH 7.0 (1ml). A sample (20 ul)
of eluent is taken for chromatography. The resultant 
chromatography is shown in figure 2.7.
2.4.2. Development of the Plasma extraction technique.
The plasma extraction presented different problems to
the urine extraction due to the greater sensitivity
required and the different matrix involved. The use of 
C18 cartridges for plasma resulted in uninterpretable 
chromatograms. Preliminary studies showed that direct 
injection of plasma onto the column produced a mass 
of peaks that could not be differentiated and the high 
protein content of the sample reduced the life of the 
column.
2.4.2.1 Selection of extraction cartridge.
A range of anion exchange cartridges were selected for 
assessment. They were prepared by the passage of 1ml
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Table 2.2 Assessment of the reuse of C 18 cartridges 
for the extraction of urine oxalate.
Mean
urine
oxalate
umol/1
Range 
of urine 
oxalate 
umol/1
^Recovery
(%)
Augmented 
Urine Oxalate 
Extracts
1st extract 486
773
283-802
580-1072
96.2
95.8
(2 .6)
(2.9) -
2nd extract 484 286-784 95.1 (3.1) NS
763 561-1095 94.5 (2.9) NS
3rd extract 482 279-793 94.0 (3.2) NS
770 587-1062 95.4 (2.5) NS
4 th extract 477 256-783 91.5 (3.9) <0.05
741 548-1014 89.5 (4.1) <0.05
5th extract 463 254-755 84.5 (7.6) <0.001
694 474-959 80.0 (9.5) <0.001
“Mean (+/-SD) of ten estimations, ^Students paired t test was 
applied between the first extracts and each of the subsequent 
extracts. Significance of t is denoted by p. MS = no 
significance.
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Figure 2.7 Typical chromatogram of urine oxalate; (1) 
denotes oxalate peak. Urine oxalate concentration 220 
umol/1. Adjusted retention time (t^ ) 2 minutes 36
seconds. Retention time (t^ ) 5 minutes 52 seconds.
Phase capacity ratio 1.25. Flow rate of Iml/minute. 
Peak width at half height 3 mm.
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methanol followed by 1ml of selected buffer, this 
buffer was also used to dilute the sample before 
application to the cartridge.
The ability of sorbents to retain oxalate was 
investigated using an aqueous oxalate standard, 
20umol/l, diluted in 0.05M acetate buffer pH 7.0. The 
pH of 7.0 ensures that all the oxalate present is in 
the ionized form, (pKal= 1.3; pKa2=4.3 ) this allows
maximum interaction with the anion exchange column. 
After sample application eluent was collected from the 
cartridge and 100 ul injected for analysis. Results 
are shown in table 2.3. Similar results were achieved 
if the standard was diluted in 0.05M pH 7.0 
phosphate buffer. The strong anion exchange (SAX) 
cartridge showed the greatest affinity for oxalate. 
This cartridge was selected for further assessment.
2.4.2.2. Elution of oxalate from the SAX cartridge.
Elution may be achieved with a stronger counter ion 
than oxalate, or a low pH which makes oxalate less 
ionized. Use of inorganic acids to produce low pH 
resulted in chromatograms with no resolution of the 
oxalate peak from interfering substances. Counter ions 
(citrate, acetate and phosphate) at the appropriate pH 
and molarity were employed to release oxalate. Citrate 
and acetate produced low recovery and at high 
concentrations they interfered with peak resolution on
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Table 2.3 An assessment of the retention of oxalate 
on different anion exchange cartridges.
Cartridge type ® Retention 
(%)
® Elution 
(%)
Strong anion 98.3
exchange (functional (96-101)
group, quaternary amine)
not
significant
Weak anion exchange 
(functional group 
aminopropyl)
44.3
(39-48)
53.0
(48-56)
Weak anion exchange 
(functional group 
ethylenediamine-N- 
propyl)
34.0
(28-38)
66.3
(62-70)
C 18 primed with 
cetrimide.
83.3
(80-84)
16.0
(12-19)
C 18 not
significant
98.0
(95-101)
20 umol/1 oxalate in 0,05M acetate buffer pH 7,0 was applied to 
the cartridges, "Mean (Range) of three estimations.
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the chromatogram. The use of phosphate (potassium 
dihydrogen orthophosphate pH with orthophosphoric 
acid to produce a buffer) did recover oxalate from the 
cartridge. Initial studies indicated that a pH of 3.0 
and molarity in excess of 0.5M would give 100 %
recovery. Results of pH and molarity profiles are 
shown in tables 2.4 and 2.5.
From these studies it was shown that 0.6 M potassium 
dihydrogen phosphate adjusted to pH 3.0 with 
orthophosphoric acid gave maximum recovery.
2.4.2.3. Identification of suitable wash solutions.
Between sample application and elution it is necessary 
to wash the SAX column. This must be with a solution 
that does not elute the oxalate. Normally the solution 
would be similar to the elution solvent but weaker in 
composition. The purpose of the wash is to remove some 
interfering substances before sample recovery. 
Potential wash solutions were assessed by analysis for 
oxalate after their passage through the cartridge. 
Phosphate buffer 0.02M pH 7.Ormethanol(1:1 v/v) and 
0.05M acetate buffer pH 7.0 both gave 0% recovery of 
oxalate when tested, this was independent of the 
volume applied up to 3ml.
104
Table 2.4 An assessment of the recovery of oxalate
from an anion exchange cartridge after elution with
potassium dihydrogen orthophosphate (pH 3.0) at
different molarities.
Molarity % Recovery +/-SD
0.12 0 -
0.24 47 2.5
0.36 57 1.9
0.48 85 2.1
0.50 97 1.5
0.60 101 1.9
0.80 98 2.1
n = 5 for each data block. 20 umol/1 of oxalate in 0.05M acetate
buffer pH 7.0 was applied to cartridges.
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Table 2.5 An assessment of the recovery of oxalate 
from an anion exchange cartridge after elution with 
potassium dihydrogen orthophosphate (0.6M) at 
different pH values.
pH % recovery +/-SD
2.5 92 1.9
3.0 99 1.8
3.5 90 2.0
4.0 85 2.1
pH was adjusted using orthophosphor ic acid, n = 5 for each data 
block. 20 umol/1 of oxalate in 0.05M acetate buffer pH 7.0 was 
applied to the cartridge.
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2.4.2.4. Preparation of samples before loading onto 
SAX cartridges.
Sample preparation was assessed by the recovery of 
added oxalate in aqueous standards and plasma samples 
subjected to different extraction procedures. The 
presence of protein in the sample matrix can cause 
poor recovery due to protein binding or interference 
in the chromatography. A change in sample pH, use of 
protein dénaturation or precipitation may be necessary 
to overcome this.
The use of perchloric acid and trichloroacetic acid to 
precipitate proteins resulted in a lack of resolution 
of the oxalate peak on the chromatogram. However, 
three extraction techniques did prove Successful; two 
using protein precipitation and one pH adjustment. 
After comparison of these a primary method was 
selected. In the evaluation of these extractions, 
samples were stabilised before and during analysis by 
either dl homocysteine or dithiothreitol, using lOOul 
of 2.5 mmol/1 stabiliser per 1ml of plasma. Further 
details on the stabilisers are given in section 3 of 
this chapter.
Conditions were optimised with respect to pH and 
molarity of the diluent buffer in which the samples 
were applied to the cartridge. The object of this 
optimisation was to ensure maximum retention of 
oxalate on the SAX cartridge.
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The following extractions were compared;
(a) 1.1 ml of stabilised plasma or standard was added 
to an equal volume of 0.05M Hydrochloric acid and 
heated to 100 C for 5 minutes (Akcay and Rose, 1980: 
Boer, van Leersum and Enderman, 1984), after vortex 
mixing and centrifugation (4000 rpm for 10 minutes) 
the supernatant (1ml) was added to 0.02M phosphate 
buffer pH 7.0. The solution (final pH 7.0) was then 
passed through a BondElut SAX column preconditioned 
with methanol (1ml) and 0.02 M phosphate buffer pH
7.0.(1ml). A wash solution of 0.02M phosphate buffer 
pH7.0/methanol (1:1 v/v) 1ml was then passed.
(b) 2.5 ml of acidified acetonitrile ( conc. HCl: 
acetonitrile, 1:99 v/v) was added to 1.1 ml of 
stabilised plasma or standard. After vortex mixing and 
centrifugation (4000 rpm, 5 min), supernatant (2ml) 
was added to O.IM disodium hydrogen orthophosphate (pH 
9.1) to produce a final pH of 7.0 in the sample. The 
solution was mixed and passed through a Bond Elute SAX 
cartridge preconditioned and washed as in (a).
(c) 2 ml of 0.05 M acetate buffer pH 7.0 was added to
1.1 ml of stabilised plasma or standard, the solution 
was mixed (final pH 7.8) and passed through a Bond 
Elute SAX cartridge preconditioned with methanol 
(1ml) and 0.05 M acetate buffer pH 7.0 (1ml). 1ml of 
0.05M Acetate buffer pH 7.0 was applied as a wash 
solution.
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Elution of oxalate from the SAX columns was in all 
methods by the use of 0.6M phosphate buffer pH 3.0. 
100 ul of the eluent was collected and injected for 
analysis.
Results of oxalate recovery using the three different 
techniques are shown in table 2.6. Each of the stages 
of the three methods was checked for losses of oxalate 
by analysis of eluent. No significant losses were 
found in any of the stages checked. Aqueous samples 
gave the same recovery data as the plasma samples, 
even in method (b) which only had 80 % recovery. The 
additional 20% appears to have remained on the 
cartridge as no oxalate was detected in the waste 
eluate.
Conditions were chosen to give maximum recovery and 
optimum resolution of oxalate on the chromatographic 
system, with simplicity of preparation. As a result 
method (c) was selected.
Method (c) was further evaluated with respect to 
dilution pH and molarity of the sample diluent. Using 
0.05M acetate buffer pH 7.0 recovery of greater than 
95% was achieved with dilutions ranging from 1:1 to 
1:5, though passage through the cartridge is more 
rapid the higher the dilution. Using a 1:1 dilution 
the pH of the acetate diluent was varied; pH 4.0, pH
5.0, pH 6.0 and pH 7.0, resulted in final pH's in the 
diluted sample of pH 5.5, pH 6.7, pH 7.5 and pH 7.8
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Table 2.6 The recovery of oxalate from different 
sample preparations for plasma oxalate analysis.
Added Treatment a Treatment b Treatment c 
oxalate Recovery % Recovery % Recovery %
umol/1 (SD) (SD) (SD)
PLASMA
10 99.2 (4.6) 81.5 (3.8) 98.7 (4.1)
20 96.4 (3.6) 79.3 (4.2) 97.7 (3.2)
AQUEOUS
10 98.2 (3.7) 80.7 (3.0) 98.0 (2.3)
20 95.8 (4.5) 80.0 (2.3) 98.2 (2.2)
The endogenous plasma oxalate concentrations for each of the 
different extractions were; (a) 12 umol/1 (b) 9umol/l (c) 10.1
umol/1. Samples were treated with the following; (a) HCl 0.05M 
and heat to 100°C (b) Concentrated HClzAcetonitrile, 1:99 v/v. (c) 
0.05M Acetate buffer pH 7.0. For full details see text. The 
number of estimations in each data block is 10. Paired student t 
test showed no significant difference between plasma and aqueous 
recovery for each of the preparations.
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respectively. Recovery was greater than 95% using 
initial buffer diluents from pH 5.0-7.0. There was
visible turbidity and recovery was less than 50%, when
acetate 0.05M pH 4.0 was used, this could indicate
some pH dependant protein binding or precipitation. 
Acetate buffer diluent 0.0 5M pH 7.0 gave the same
final pH in both aqueous standards and plasma samples. 
Molarity changes in the diluent between 0.02M and O.IM 
had no effect on recovery data.
2.4.2.5 The Final plasma extraction conditions.
1ml of 0.05M acetate buffer pH 7.0 is added to 1.1ml 
of stabilised plasma or aqueous standard. Sample is 
vortexed and passed through a Bond Elute SAX column 
preconditioned with methanol (1ml) and 0.05M acetate 
buffer pH 7.0 (1ml). The column is washed with 0.05M
acetate buffer pH 7.0 (1.0 ml), and oxalic acid eluted 
with two 500 ul aliquots of 0.6M potassium dihydrogen 
orthophosphate pH 3.0 (adjusted with 0.6M 
orthophosphoric acid). Eluants are mixed and 100 ul 
taken for chromatography. Chromatography is shown in 
f igure 2 .8 .
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Figure 2.8 Typical chromatogram of plasma oxalate.
(1) denotes oxalate peak ; plasma oxalate 
concentration 12 umol/1. Adjusted retention time t^  2 
minutes 48 seconds. Retention time t^  6 minutes 16 
seconds. Phase capacity ratio 1.23. Peak width at half 
height 2mm.
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SECTION 3. ASSESSMENT OF THE INTERFERENCE OF
ASCORBATE IN THE ANALYSIS OF OXALATE AND THE 
STABILISATION OF SAMPLES
2.5. MATERIALS
All reagents unless otherwise stated, were of Analar 
grade and were supplied by B.D.H. Chemicals Limited, 
(Poole Dorset U.K.). All aqueous solutions were made 
up in deionized water.
2.5.1. Equipment and Reagents
Equipment and reagents were as stated in section 1 of 
this chapter, with the exception of the following : 
ascorbic acid, dithiothreitol and dl homocysteine 
(Sigma Ltd. Poole Dorset U.K.). Aqueous ascorbate 
solutions were made up from a 10 mmol/1 stock 
solution. This solution was kept in the dark at 4°C and 
made up fresh each day. Dithiothreitol and dl 
homocysteine solutions were made up with deionised 
water.
2.6. METHOD AND RESULTS
Samples were analysed using the chromatography and 
extraction techniques described in sections 1 and 2 . 
Ascorbate interference was assessed with respect to 
the chromatography and the in vitro conversion of 
ascorbate to oxalate. Conditions for the successful
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storage of samples for oxalate analysis were then 
established.
2.6.1. Investigation of oxalogenesis from ascorbate.
This investigation was performed in an aqueous 
environment, 0.05 M phosphate buffer pH 7.0.
Three tubes were prepared containing the following :-
(1) 0.05 M phosphate buffer pH 7.0
(2) 1 mmol/1 ascorbate made up in 0.05M phosphate 
buffer pH 7.0.
(3) 400 umpl/1 oxalate made up in 0.05 M phosphate 
buffer pH 7.0.
All three samples were analysed immediately. The 
chromatograms showed no peaks in (1) at the retention 
volumes of oxalate or ascorbate, an ascorbate peak in 
sample (2) and an oxalate peak in sample (3).
The 3 samples were then incubated for 24 hours at 25°C 
and reanalysed : (1) and (3) remained unchanged but
(2) had the original peak at the retention volume of 
ascorbate, though reduced in height, and a new peak at 
the retention volume of oxalate. The oxalate 
concentration of this peak was 127 umol/1. This 
indicates an in vitro conversion of ascorbate to 
oxalate. This study confirms that ascorbate is 
converted to oxalate at 25°C and pH 7.0.
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2.6.2 Stability and ascorbate interference of the 
urine method.
2.6.2.1. Chromatography and extraction of ascorbate.
A solution containing ascorbate (100 umol/1) and 
oxalate (200 umol/1) was prepared in 0.1 M phosphate 
buffer, pH 7.0. Potential interference of ascorbate in 
the chromatography was assessed by injecting 20 ul of 
this solution onto the column.
The retention volume for oxalate was 6.2 mis and for 
ascorbate 2.8 mis. Resolution of these peaks (R^ ) , 
defined as the separation of two peaks divided by the 
average peak width, gave an R^  value of 1 1.1. 
Separation is regarded as complete if the R^  value 
exceeds 1.5. There is therefore no interference from 
ascorbate in the chromatography.
The same solution was then put through the extraction 
procedure for urine oxalate, to establish if ascorbate 
was eluted from the cartridges. The resultant 
chromatography gave both ascorbate and oxalate peaks 
demonstrating that ascorbate is also recovered from 
this procedure.
2.6.2.2 Urine oxalate stability during sample 
preparation and analysis.
Three 20 ml aliquots of a urine sample were taken, two 
were augmented with ascorbic acid at concentrations of
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2 mmol/1 and 5 mmol/1, the third acted as a blank. The 
blank urine had an ascorbate concentration of 204 
umol/1. These samples were diluted in O.IM phosphate 
buffer pH 7.0 as described in section 2. The diluted 
samples were then stored at room temperature, 4°C 
and -20°C for up to 20 hours. Samples were analysed 
for oxalate hourly for the first 4 hours, then a final 
measurement was made at 20 hours. No significant 
change in oxalate concentration occurred under any of 
the storage conditions used for at least 4 hours after 
dilution. This included samples to which ascorbate had 
been added. At 20 hours however the oxalate 
concentrations had increased in all samples except the 
blank urine stored at -20°C. Results are shown in Table
2.7. These results demonstrate that samples for urine 
oxalate measurement will be stable during sample 
preparation and analysis for at least 4 hours, even in 
the presence of 5 mmol/1 ascorbic acid.
To establish if ascorbate at very high concentrations 
would interfere in oxalate analysis, a urine with an 
oxalate concentration of 312 umol/1 was divided into 
eight aliquots. The eight aliquots consisted of a 
blank urine and seven urines augmented with ascorbate 
at concentration of 2 mmol/1, 4 mmol/1, 6.0 mmo/1, 8.0 
mmol/1, 10 mmol/1 15 mmol/1 and 20 mmol/1. All samples 
were analysed for oxalate. No significant difference 
was found between the blank and any of the
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Table 2.7 The stability of urine oxalate diluted in a
O.IM phosphate buffer pH 7.0 and stored for up to 20
hours at different temperatures and with different
amounts of ascorbate added.
Time (hour) after addition 
of ascorbic acid
0 4 20
Urine oxalate 
(umol/1)
(Temperature -20°C)
Ul (umol/1) 162 162 160
U2 (umol/1) 158 165 550
U3 (umol/1) 166 164 850
(Temperature 4°C)
Ul (umol/1) 162 164 190
U2 (umol/1) 158 166 585
U3 (umol/1) 166 164 985
(Room Temperature)
Ul (umol/1) 162 159 195
U2 (umol/1) 158 165 555
U3 (umol/1) 166 162 965
Ul: Blank urine endogenous ascorbate concentration 204 umol/1,
U2: Urine augmented with 2 mmol/1 ascorbate, U3 : Urine augmented 
with 5 mmol/1 ascorbate.
117
augmented samples, mean oxalate 310 umol/1, SD +/-4.2.
2.6.2.3. Stability of urine oxalate during storage.
A similar experiment to that described in the first 
paragraph of section 2 .6 .2.2 was performed using the 
same urine sample, aliquoted and augmented as before. 
Samples were not diluted before storage and the pH of 
the urine was adjusted to less than 1.5 by the 
addition of 6 N hydrochloric acid. Storage was at the 
same temperatures as before but samples were analysed 
for oxalate after 20 hours and 65 hours storage. 
Results are shown in table 2.8.
The results in table 2.B indicate that samples 
collected and stored at a pH of less than 1.5 are 
stable for up to 65 hours even in the presence of 5 
mmol/1 ascorbate.
A stability study over a month was performed based on 
the results above: Six different urines were used and 
a range of oxalate concentrations was obtained by 
augmenting some samples with oxalate. One of the 
urines had ascorbate added at a concentration of 10 
mmol/1. Initial oxalate concentrations were as 
follows: 176 umol/1, 1079 umol/1, 220 umol/1, 556
umol/1, 798 umol/1 and 558 umol/1, the last sample 
contained the ascorbate. All the samples were analysed 
at zero time, then each urine was divided into five 
aliquots. These aliquots were stored at -20°C, pH <1.5
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Table 2.8 The stability of urine oxalate samples 
stored at pH <1.5 for up to 65 hours at different 
temperatures and with different concentrations of 
ascorbate.
Time (hour) after addition 
of ascorbic acid
0 20 65
Urine oxalate 
(umol/1)
(Temperature -20°C)
Ul (umol/1) 162 161 156
U2 (umol/1) 158 160 158
U3 (umol/1) 166 159 161
(Temperature 4°C)
Ul (umol/1) 162 163 151
U2 (umol/1) 158 160 155
U3 (umol/1) 166 158 158
Room Temperature
Ul (umol/1) 162 159 151
U2 (umol/1) 158 155 160
U3 (umol/1) 166 159 159
Ul : Blank, urine endogenous ascorbate concentration 204 umol/1;
U2,U3: urine augmented with 2 mmol/I and 5 mmol/I ascorbate
respectively.
119
and assayed at days 1, 14, 21 and 28 after storage.
Students paired t test showed no significant
difference between the zero time result and the 28 
days result.
These results indicate that urine samples stored at 
-20°C, pH <1.5 are stable for at least 1 month even in 
the presence of lOmmol/1 ascorbate.
2.6.2.4. Final recommendations for the collection and 
storage of urine samples.
24 hour urine samples should be collected into a 4 
litre bottle containing 6N hydrochloric acid (25ml). 
After collection the final pH should be less than 1.5. 
The pH should be adjusted if necessary. Such samples
can be stored at room temperature for a minimum of 65
hours. Stability can be maintained for 1 month if
samples are stored at -20°C.
2.6.3 Stability and ascorbate interference of the 
plasma oxalate method.
2.6.3.1 Chromatography and extraction of ascorbate.
A solution containing ascorbate (20 umol/1) and 
oxalate (30 umol/1) was prepared in 0.6 M phosphate
buffer pH 3.0. Potential interference of ascorbate in
the chromatography was assessed by injecting 100 ul of
this solution onto the column.
120
The retention volume for oxalate was 6.2 mis and for 
ascorbate 2.9 mis. Resolution of these peaks, as 
defined in section 2.6.2.1, gave an R^  value of 9.9. 
There is therefore no interference from ascorbate in
the chromatography.
The same solution was then put through the extraction 
procedure for plasma oxalate, to establish if
ascorbate was eluted from the cartridges. The
resultant chromatography demonstrated that ascorbate 
is recovered from this procedure.
2.6.3.2. Assessment of plasma oxalate stability
during preparation and analysis.
Based on the work of Okumara in 1980 on ascorbate
analysis dithiothreitol and dl homocysteine were 
selected as potential sample stabilisers. An 
evaluation of these reducing agents and the
optimisation of conditions for their use was
performed. Triplicate samples were analysed, mean 
values are reported with ranges.
Phosphate buffers (O.IM) pH's 5.0, 6.0 and 7.0 were
prepared. Each buffer had dehydroascorbic acid added 
to a final concentration of lOOumol/1, and 
dithiothreitol or dl homocysteine to a final
concentration of lOmmol/1. The buffer solutions were 
mixed and incubated for one hour at room temperature.
The solutions were then analysed for ascorbate by the
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method of Foote, Fry and Starkey (1986). The 
assumption was made that one umol of dehydrascorbate 
will go to one umol of ascorbate. Recovery was 14.7% 
(13-16%) at pH 5.0 and 99% (98-102%) and 99.7% (98-
104%) respective/y for pH 7.0 and 8.0, using dl 
homocysteine. Recovery using dithiothreitol was: pH
5.0, 15.3% (12-18%); pH 7.0, 96.7% (95-98%); pH 8.0,
99.3% (98-101%). The pH selected was 7.0, as the
column eluent runs at this pH. The same experiment was 
repeated at pH 7.0 but varying the concentration of 
the stabiliser to give values of 0.1, 0.2, 0.5, 1.0,
2.5, 5.0, 10.0 mmol/1. Recovery of >95% was achieved
at 1.0 mmol/1 and above with both stabilisers. The 
concentration selected was 2.5 mmol/1 as this allowed 
a margin of error from sample to sample. 
Dithiothreitol at 2.5 mmol/1 gave recovery of 98% (96- 
100%). Dl homocysteine at 2.5 mmol/1 gave recovery of 
98.7% (96-101%). The experiment was repeated for a
third time using pH 7.0 buffer, 2.5 mmol/1 stabiliser 
and varying the time of incubation at 5,10,15,30 and 
60 minutes. Recovery was >94% from 15 minutes, dl 
homocysteine at 15 minutes, 95.3% (94-97%);
dithiothreitol 97% (94.2-101.1%). Final conditions
were pH 7.0, 2.5 mmol/1 stabiliser incubate at room
temperature for 15 minutes. Using these conditions 
five aliquots of a plasma pool spiked as for the 
buffers were evaluated. The endogenous ascorbate was
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40 umol/1 and recovery ranged from 103 to 110%, with a 
mean of 105.8%. The recovery in excess of 100% 
presumably reflects endogenous dehydrascorbate levels. 
Investigations were then carried out into the effect 
on oxalate results, of sample stabilisation during 
preparation and analysis.
Five subjects had 20 mis of heparinised blood 
collected by venesection. The plasma was separated 
from cells by centrifugation within 15 minutes of 
collection. Each sample was then divided into three 
1ml aliquots; (a) untreated, (b) preserved with 
dithiothreitol (lOOul of 2.5 mmol/1), (c) preserved 
with dl homocysteine (lOOul of 2.5 mmol/1/). All
samples were then analysed for oxalate. The results 
are shown in figure 2.9. There is a significant 
difference between group (a) and groups (b) and (c) , p 
<0.05 for both comparisons, demonstrating that 
oxalogenesis does occur during sample preparation if 
no preservative is used. There was no significant 
difference in results between group (b) and (c), 
Students paired t test was applied. Dithiothreitol was 
the preservative of choice for the reasons stated by 
Okamura (1980). Dithiothreitol acts as a reducing 
agent over a slightly wider pH range than dl 
homocysteine and it is more stable in an aqueous 
environment.
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2.6.3.3 In vitro oxalogenesis before sample 
preparation.
Section 2.6.1 has shown that oxalogenesis from 
ascorbate can, in the right environment, readily 
occur. The ability of plasma to generate oxalate in 
vitro over 24 hours was tested.
Four normal subjects were bled. Three gave 25 mis of 
blood into sodium heparin, the fourth 10 mis. The 25 
ml samples were centrifuged and the plasma separated 
from cells within 15 minutes of venesection. The 10 ml 
collection was divided into 5 ml aliquots of whole 
blood, one aliquot was separated immediately and 
analysed with aliquots from each of the other three 
specimens. The remainder of the specimens were left at 
room temperature. Aliquots were taken at timed 
intervals and stabilised with dithiothreitol (lOOul of
2.5 mmol/1 dithiothreitol per 1ml of plasma.) 
immediately before analysis. The results are shown in 
figure 2.10. These subjects had total plasma 
ascorbates of 58, 46, 42 and 60 umol/1.
It can be seen from figure 2.10 that very significant 
oxalogenesis can occur rapidly after sample 
collection. Between 1 and 4 hours after collection 
there was a significant difference (p < 0.01) from the 
basal reading. The whole blood sample showed 
oxalogenesis similar to plasma, initial reading 2.3 
umol/1, 24 hour result 14.8 umol/1.
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FIGURE 2.10 OXALOGENESIS IN THREE PLASMA 
SAMPLES LEFT AT ROOM TEMPERATURE AFTER 
COLLECTION WITHOUT PRESERVATIVE.
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FIGURE 2.11 THE STABILITY OF A PLASMA 
OXALATE SAMPLE AUGMENTED WITH 300 UMOL/L 
ASCORBATE AT ROOM TEMPERATURE.
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The ability of dithiothreitol to prevent oxalogenesis 
at very high concentrations of ascorbate was examined. 
A plasma sample was divided into three aliquots, (a) 
1ml plasma containing 300 umol/1 ascorbate (b) 1 ml
plasma containing 100 ul of 2.5 mmol/1 dithiothreitol
(c) 1 ml plasma with both 100 ul of 2.5 mmol/1
dithiothreitol and 300 umol/1 ascorbate. The samples 
were kept at room temperature and analysed for plasma 
oxalate at time intervals of; 0, 1 4, 6 and 24
hours. Results are shown in figure 2.11. This confirms 
dithiothreitol as a potent stabiliser of plasma 
oxalate.
2.6.3.4. Stability of plasma oxalate during storage.
Plasma oxalate stability was examined over a period of 
1 month with respect to the preservative used, the 
storage temperature and the presence of ascorbate. 
Plasma was obtained from normal subjects to produce a 
low oxalate pool, samples were kept at - 70°C while 
sufficient plasma was collected.
The pool was dispensed in 1ml aliquots. The aliquots 
were then placed into six groups of eight as follows: 
(a) no addition, (b) 300 umol/1 ascorbate (c) 100 ul
2.5 mmol/1 dithiothreitol (d) 100 ul 2.5 mmol/1 dl
homocysteine (e) 100 ul 2.5 mmol/1 dithiothreitol with 
300 umol/1 ascorbate (f) 100 ul 2.5 mmol/ldl
homocysteine with 300 umol/1 ascorbate. An extra
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aliquot was prepared for each group, these were 
analysed for basal levels. Each group was divided into 
two and samples were stored at -20°C and -70°C.
Aliquots from each group were measured at 1, 7, 14
and 28 days. Results are shown in figures 2.12 to 
2.15. Results show that storage at - 70°C for 1 month, 
or -20°C for 1 week, with either of the preservatives 
was acceptable.
To confirm the above findings aliquots of five 
different samples that covered a range of oxalate 
concentrations, 2.7, 3.5, 10.1, 21.9 and 39.7 umol/1,
were analysed on 0, 7, 14, 21 and 28 days after
storage. Storage conditions were - 70°C with 100 ul of
2.5 mmol/1 dithiothreitol per 1ml of plasma. Students 
paired t test was applied to the data and no 
significant difference was found between day 0 and 
days 7, 14 and 28. Results on day 21 had a p value
<0.01, this was due to one result at the 10.1 umol/1 
level that gave a result of 8.0 umol/1. Recalculation 
of the day 21 data without the 10.1 umol/1 level 
showed no significant difference from zero time.
2.6.3.5. Final recommendations for sample collection 
and storage.
Plasma is separated from cells within 30 minutes of 
venesection. lOOul of 2.5 mmol/1 dithiothreitol or dl 
homocysteine is added per ml of plasma, and samples
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FIGURE 2.13 STABILITY OF PLASMA OXALATE 
POOL AT -70 C USING DL-HOMOCYSTEINE AND 
DITHIOTHREITOL AS PRESERVATIVES.
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FIGURE 2.14 STABILITY OF PLASMA OXALATE 
AT -20 C WHEN AUGMENTED WITH 300 UMOL/L 
ASCORBATE WITH AND WITHOUT PRESERVATIVE.
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FIGURE 2.15 STABILITY OF PLASMA OXALATE 
AT -70 C WHEN AUGMENTED WITH 300 UMOL/L 
ASCORBATE WITH AND WITHOUT PRESRVATIVE.
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are stored at -70°C if required. Samples are then 
stable for 1 month.
If -70°C storage is not available, - 20°C for 1 week is 
acceptable.
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DISCUSSION
The developed method facilitates analysis of oxalate 
both in plasma and in urine by the same 
chromatographic system. Inclusion of the ion pair 
reagent cetrimide in the mobile phase is not possible 
since the bromide counter ion attached to the 
cetrimide molecule oxidises at l.lv, a voltage less 
than the optimum oxidation potential (1.25v) of 
oxalate. Conditioning the column with cetrimide has 
proved successful. It is only necessary to repeat the 
procedure after several hundred injections, when the 
retention time of oxalate decreases, or when 
unacceptable peak broadening occurs. Advantages of 
using the ion pair reagent on the column are the 
flexibility that it allows to the oxalate retention 
time and the fact that the column is reusable. Once 
peak broadening occurs, the ion pair reagent can be 
removed with 100% methanol and the column regenerated 
with conditioning solution.
Derivitisation of oxalate, essential in some HPLC 
methods (Murray et al 1982; Hughes, Hagen and Sutton, 
1982; McWhinney, Cowley and Chalmers, 1986), is 
unnecessary and makes this method simple and easy to 
perform. In contrast to a recently reported ion 
chromatographic method (Schwille et al. 1989) only a 
short equilibration time is necessary, sample 
throughput is relatively rapid and dedicated
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instrumentation of a complex nature is not required. 
Sample pretreatment differs for plasma and urine 
specimens. Dilution of stabilised acidified urine with 
neutral phosphate buffers results in a pH between 6.2 
to 6.6, a pH at which oxalogenesis from ascorbate can 
occur. Investigation showed that samples were stable 
with respect to oxalate concentration, even when urine 
was augmented with 20 mmol/1 ascorbate, provided the 
assay was completed within four hours of sample 
dilution.
Plasma samples were shown to be stable with respect to 
oxalogenesis from ascorbate provided, dithiothreitol 
was added at the time of collection. Close attention 
to detail in sample collection and storage to avoid 
spurious elevation of oxalate concentration is vital. 
Poorly designed sample collection protocols may have 
contributed to the large variation in reference ranges 
for plasma (Costello and Landwehr, 1988) and urine 
(Luque de Castro, 1988) oxalate in the past.
Recent publications (Schwille et al. 1989 and Costello 
and Landwehr, 1988) have suggested that oxalate in 
plasma may be protein bound and that this process is 
enhanced at low pH. This is of great importance in 
recent methods (Schwille et al. 1989, Costello and 
Landwehr, 1988, Rose and Kasidas, 1986) as acidity has 
been used to stabilise samples. This makes 
ultrafiltration at neutral pH, prior to further sample
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preparation, as suggested by some authors, (Schwille 
et al. 1989, Costello and Landwehr, 1988) essential 
for accurate analysis.
Using the method described in this thesis, the 
recovery of oxalate from plasma is comparable to that 
from aqueous standards subjected to the same 
procedure. This suggests that no protein binding 
occurs using the conditions selected. Also the chosen 
sample stabiliser is effective at neutral pH, thereby 
avoiding any enhancement of protein binding. During 
the extraction on the SAX cartridge protein is eluted 
whilst oxalate is retained. Subsequent elution of 
oxalate at low pH (phosphate buffer pH 3.0) then
ensures stability of the extract, as suggested by 
previous authors (Parkinson et al, 1987, and Costello 
and Landwehr, 1988).
Pretreatment with acidified acetonitrile and heat 
treatment of acidified plasma appeared not to affect 
protein binding despite the low pH used, in contrast 
to findings by Costello and Landwher (1988). This may 
be due to the destruction of potential protein binding 
sites by the severe conditions used. Pretreatment by 
dilution with acetate buffer was found to be a more
precise and convenient procedure. When coupled to
isolation of oxalate using a strong anion exchange 
column it produced a cleaner extract for
chromatography.
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Since no suitable internal standard could be 
identified for the assay, reproducable extraction 
efficiency, as demonstrated in the method described, 
is essential.
Significant oxalogenesis was observed between 1 and 4 
hours when samples were stored at room temperature 
without stabilisation. This was much earlier than had 
been suggested by previous authors (Parkinson et al. 
1989, Boer, van Leersum and Enderman, 1984, Berckmanns 
and Boer, 1988) who indicated no change until 4 to 6 
hours, though Schwille et al (1989) found oxalogenesis 
occurring between 1 and 2 hours at room temperature. 
These differences may be due to the method employed or 
the concentration of oxalate precursors in the samples 
tested. Those authors who showed oxalogenesis starting 
later, used samples prepared at low pH in the presence 
of protein which may have lead to losses of oxalate. 
In normal samples this loss could be a significant 
part of the total concentration produced during early 
oxalogenesis, despite good recovery from samples 
augmented with higher levels of oxalate by these 
methods. The mechanism that causes oxalogenesis from 
ascorbate is not clear, but the work here suggests a 
pH dependant non-enzymatic conversion.
Pretreatment of urine samples by C18 Bond Elut 
cartridges has been used by other authors (Larrson, 
Libert and Aspered 1982, Berckmans and Boer, 1988)
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under various conditions. Using the method described 
here, these cartridges can be reused up to three times 
provided they are pretreated with methanol and 
phosphate buffer, and close attention is paid to 
oxalate recovery. The method described for urine is 
unsuitable for plasma samples since the clean up 
achieved is insufficient and the dilution required 
results in unacceptably low sensitivity at the oxalate 
concentrations found in plasma.
In summary, the method described is simple enough for 
routine use and takes advantage of the excellent 
sensitivity and selectivity obtained from HPLC with 
amperometric detection. A strict sample collection and 
storage procedure prevents oxalogenesis, and oxalate 
loss during sample pretreatment is minimised.
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CHAPTER 3.
EVALUATION OF THE URINE AND PLASMA OXALATE 
METHODS AND THE ESTIMATION OF REFERENCE 
RANGES AND BIOLOGICAL VARIATION.
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INTRODUCTION.
The methods described in chapter 2 for urine and 
plasma oxalate were developed so that oxalate 
measurement would be accurate, reproducible and 
sensitive enough for use in metabolic studies.
In this chapter a full evaluation of the precision, 
accuracy, sensitivity and selectivity of the methods 
developed, is undertaken. During method development, 
linearity, recovery and stability were examined to 
ensure the methods were viable. These areas now have 
to be further evaluated to ensure the assays are 
robust enough for routine use.
The potential interference of ascorbate was discussed 
in the previous chapter and further assessment of this 
has been made here, but other potential interfering 
substances are also considered. There has been 
evidence, by Ackay and Rose (1980), to suggest that in 
vitro production of oxalate in plasma can occur from 
glyoxylate. These authors used inhibitors to prevent 
this. The sample stability results of chapter 2 
suggest that this in vitro effect of glyoxylate at 
physiological levels is either controlled by the 
reducing agents used to stabilise ascorbate or that 
little if any conversion occurs. Further stability
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studies will help confirm this.
Calcium is a potential interfèrent in the urine
method. High concentrations of calcium may result in 
precipitation of calcium oxalate and loss of recovery. 
This risk is assessed.
Published reference ranges for urine and plasma 
oxalate have varied greatly depending on the methods 
used (Laker, 1983) . In more recent methods of urine 
oxalate analysis, variation in reference ranges have 
been reduced. Despite this, there is still method 
dependent variation and upper limits of normal can 
vary from 349umol/l (Crider, 1984) to over 670 umol/1 
(Urdal, 1984). Plasma oxalate reference ranges 
published, have shown more dramatic variation than 
those of urine. Upper limits of normal have ranged
from 1.5 umol/1 to 444 umol/1, depending on the method
used (Costello and Landwehr, 1988). This reflects the 
great difficulty encountered in handling and measuring 
this analyte in plasma. The most recent methods for 
the measurement of plasma oxalate (Costello and 
Landwehr, 1988? Parkinson et al. 1989* Schwille et al. 
1989) have shown some concensus with respect to 
reference ranges reflecting better methodology and 
sample collection, though data using large populations 
is still scarce, and some discrepancy in ranges still 
exists.
The differences in reference ranges between methods
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may be due to some or all of the following: sample
collection and storage, whether the subjects were fed 
or fasted, the population studied, gender, biological 
variation, time of collection or the methodology 
itself. Therefore having fully evaluated the 
methodology and storage and collection conditions in 
the earlier part of this chapter, the final sections 
are devoted to producing reliable reference ranges, 
investigating biological variation and examining the 
effect of fasting on oxalate output.
Some of the factors that affect population studies 
have been examined by other workers but sample 
handling and analytical problems may have produced 
unreliable results. The effect of gender on oxalate 
reference ranges in both urine and plasma has produced 
contradictory results (Costello and Landwher, 1988), 
and Schwille et al (1989) have discussed the need to 
further evaluate fasting urine oxalate levels in renal 
stone patients. This can only be done with reliable 
data on normal subjects. Biological variation has been 
investigated, though this has been almost exclusively 
using urine oxalate. A diurnal variation has been 
documented for both plasma (Kasidas, 1988) and urine 
oxalate (Tiselius amd Almgard, 1977, Touitou et al. 
1983) in normal subjects, but some of the earlier 
studies have used methods that are not as accurate and 
precise as the methods described here. Different
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authors have used different statistical evaluations of 
the data and in some cases the significance of
variance has not been assessed (Tiselius and Almgard, 
1977; Kasidas, 1988). One report on the seasonal
variation of oxalate showed no significant variation 
in oxalate production in normals (Touitou et al.
1983). Biological variation could influence 
interpretation of data, reference values and the
timing of sample collections. For this reason it has 
been investigated.
The analytical, storage and collection difficulties 
that exist in urine and plasma oxalate measurement, 
have prevented the reliable investigation of the renal 
handling of oxalate (Williams and Wandzilak, 1989). 
Investigation of renal handling has produced 
contradictory data, particularly with respect to the 
fractional excretion of oxalate. Williams and Wilson 
(1990) , suggest that recent data (Wilson et al. 1988) 
on the fractional excretion of oxalate needs further 
investigation and confirmation.
If oxalate metabolism is to be fully understood, 
calculated parameters like oxalate clearance and 
fractional excretion, need to be well defined and 
documented in normal subjects. For this it is 
essential that the method used and the collection and 
storage of samples are reliable in plasma and urine. 
Reference ranges for these derived parameters are
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defined in this chapter and their biological variation 
over different time periods is investigated. These 
will help to form the basis for further studies in 
patient groups.
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SECTION 1: EVALUATION OF PLASMA AND URINE OXALATE
METHODS
3.1. MATERIALS
Reagents and materials were as stated in previous 
sections . All reagents unless otherwise stated , were 
of Analar grade and were supplied by B.D.H. Chemicals 
Limited (Poole Dorset U.K.). All aqueous solutions 
were made up in deionized water.
3.1.1. Equipment and reagents.
Equipment, reagents, chromatography and the extraction 
used for both plasma and urine is as stated in chapter 
2 .
Working standards were prepared from a 10 mmol/1 stock 
solution made up in deionised water. Oxalic acid was 
Aristar grade.
3.2. METHODS AND RESULTS
3.2.1. Linearity.
The linearity of the urine and plasma assays was
assessed by the use of both aqueous samples and
biological samples. All samples analysed were 
extracted. A stock standard of oxalic acid (10 mmol/1) 
was prepared in deionised water. Aqueous samples, with
a range of concentrations, were then prepared by
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diluting the stock standard in deionised water. 
Samples were analysed in duplicate, first in ascending 
then decending order. The results can be seen in 
figures 3.1a and 3.1b.
It was found that some supplies of water or reagents 
had small amounts of oxalate present (2-6 umol/1) that 
could interfere with the plasma method. A reagent 
blank using deionised water as a sample, was run with 
all assays to confirm no interference.
Linearity assessment using biological samples was 
performed on specimens of urine and plasma oxalate 
which were augmented with oxalate to cover the working 
range of the assay. Endogenous level for urine was 84 
umol/1 and for plasma 2.8 umol/1. Samples were 
augmented with oxalate from the lOmmol/1 stock 
solution, possible error due to dilution was 
corrected. Results are shown in figures 3.2a and 3.2b. 
Any sample exceeding the limit of linearity as defined 
by the relevant graphs (urine 1000 umol/1; plasma 50 
umol/1) should be diluted. Urine is diluted in 
phosphate buffer (0.1 M, pH 7.0) diluent and plasma in 
acetate buffer diluent (0.05 M, pH 7.0). An 
alternative to the dilution of plasma is to alter the 
sensitivity settings on the detector, in order to 
measure over the urine range.
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FIGURE 3.1a LINEARITY OF THE URINE 
OXALATE METHOD ASSESSED USING AQUEOUS 
STANDARDS.
y ■ 0.00166X + 0.013
0 200 400 600
Oxalate concentration (nmol/1)
Coefficient of correlation 0.998 
Full scale deflection on the detector 
2.0 uA
800 1000
FIGURE 3.1b LINEARITY OF THE PLASMA 
OXALATE METHOD ASSESSED USING AQUEOUS 
STANDARDS.
0.6
y -  0.0121 + 0.00099I
0.3-
0.0
15 5010 20 25 450 5 30 35 40
Oxalate concentration (umol/1)
Coefficient of correlation 0.995 
Fall scale deflection on the detector 
0.5 a A
145
FIGURE 3.2a LINEARITY OF URINE OXALATE 
ASSESSED USING A URINE SAMPLE AUGMENTED 
WITH OXALATE.
—  y “ 0.0017% + 0.16
200 400 600
Oxalate added to urine (umol/1) 
Coefficient of correlation 0.99 
Full scale deflection on the detector 
2 oA
800
FIGURE 3.2b LINEARITY OF PLASMA OXALATE 
ASSESSED USING A PLASMA SAMPLE AUGMENTED 
WITH OXALATE.
y -  0.0109 + 0.0386
10 15 20
Oxalate added to plasma (umol/Q
Coefficient of correlation 0.98 
Full scale deflection on the detector 
0.5 hA
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3.2.2. Precision studies.
Within and between assay precision was determined at 
different concentration levels in both urine and 
plasma. Pooled urine and plasma were used for the 
assessment. Between assay precision was performed over 
a period of 30 working days. Results of the precision 
studies can be seen in Table 3.1.
3.2.3. Recovery studies
Assessment of analytical recovery was performed on 
pooled plasma and urine augmented with known amounts 
of oxalate at three different concentrations.
In addition, ten plasma and urine samples with 
various endogenous levels of oxalate, were augmented 
with two different concentrations of oxalate and the 
recovery calculated. Results of the recovery studies 
are shown in table 3.2 and 3.3.
3.2.4. Limit of detection
This was defined as the smallest amount of analyte 
that can be distinguished from zero with 95% 
confidence. This value can be found by repeatedly 
assaying a sample with an analyte concentration at or 
near zero level. Twice the standard deviation of this 
value is the limit of detection.
The limit of detection for the urine assay was based 
on 20 repeat measurements of a sample that gave a mean
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Table 3.1 Within and between assay precision for the 
determination of oxalate in plasma and urine
Urine Plasma
n Mean
umol/1
SD CV(%) n Mean
umol/1
SD CV(%)
Within Assay
15 76.6 2.5 3.2 12 3.9 0.12 3.0
15 271 11.1 4.1 12 21.2 0.74 3.5
15 467.3 12.1 2.6 12 37.8 1.5 3.9
15 685 13.2 1.9
Between Assay
15 79.2 6.6 8.4 18 3.8 0.75 5.2
15 276.5 8.8 3.2 18 20.3 0.85 4.2
15 481.4 13.5 2.8 18 39.3 1.8 4.7
15 580 18.7 3.2
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Table 3.2 Recovery of oxalate from urine and plasma 
pools augmented with different amount of oxalate.
Urine
oxalate
Addition
umol/1
Recovery % (SD)
200
400
600
97.0 (4.1) 
101.4 (3.4) 
101.0 (2.3)
Plasma
oxalate
Addition
umol/1
5
10
30
Recovery % (SD)
99.1 (5.5)
98.5 (4.0)
98.1 (4.5)
Endogenous concentration of pooled urine was 170 umol/1 
Endogenous concentration of pooled plasma was 3,9 umol/1.
In each data block n=10.
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Table 3.3 Recovery of oxalate from augmented patient 
samples.
Mean
oxalate
umol/1
Range 
of oxalate 
umol/1
Recovery % (SD)
Urine Oxalate
Addition
umol/1
Endogenous 310 92-602 - -
200 486 283-802 96.2 2.6
500 773 580-1072 95.8 2.9
Plasma Oxalate
Addition
umol/1
Endogenous 7.4 2.1-19.0 - -
10 16.8 11.8-28.1 96.7 4.4
20 27.1 22.6-37.6 98.9 4.7
In each data block n = 10.
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value of 41 umol/1, a standard deviation +/- 17.5 and 
coefficient of variation of 42.6%. Therefore the limit 
of detection was 35.0 umol/1.
The limit of detection for the plasma assay was 
assessed on twenty repeat measurements of a sample 
that gave a mean value of 1.1 umol/1 , a standard 
deviation of 0.2 6 umol/1 and a coefficient of 
variation of 23.6 %. Therefore the limit of detection 
was 0.5 umol/1.
3.2.5. Sample stability during storage
Stability was determined by using the storage con­
ditions defined in chapter 2 for plasma and urine. 
Twenty samples of plasma and twenty samples of urine 
were collected as described in chapter 2, then each 
sample was divided into two aliquots. One aliquot was 
untreated the other had ascorbate added (urine 2 
mmol/1 ; plasma 200 umol/1; final concentration), all 
samples were then analysed and stored for a period of 
1 month before being reassayed.
Urines were stored at -20°C. The mean value for urine 
samples analysed on day 1 was 224.0 umol/1, range 64 
to 515 umol/1. After 1 month the mean was 223.7 umol/1 
with a range of 56 to 53 6 umol/1. Students paired t 
test was applied to the data; no significant 
difference was found at a significance level of 5%. 
Plasma samples were stored at -70°C and -20°C. The
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original twenty samples in two aliquots were stored at 
-70°C and an additional twelve samples were kept at - 
20°C. Mean sample values on day 1 for the samples 
stored at -70°C were 11.6 umol/1, range 1.9 to 38.3, at 
1 month the mean was unchanged but the range was 2.1 
to 40.0.
Samples stored at -20°C on day 1 had a mean of 17.6 
umol/1 and a range of 4.4 to 39.7 and at 1 week a mean 
of 17.7 umol/1 and a range of 4.5 to 41.2 umol/1. 
Students paired t test was applied to the storage data 
and no significant difference at the 5% confidence 
level was found after storage of samples at either 
temperature under the conditions defined.
3.2.6. Interference studies
These studies were performed on aqueous samples using 
primarily the electrochemical instrument settings for 
urine analysis. This study was only to identify 
analytical separation of components.
Samples were prepared in the buffers that would be 
used to inject extracted samples onto the column. 
Oxalate was present at a concentration of 200 umol/1 
for the urine settings and 20 umo/1 for the plasma 
settings.
Results of the interference studies are shown in table
3.4. No analytical interference was found with any of 
the substances tested. Glucose and glycolate were not
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Table 3.4 Assessment of potential interférants on the 
chromatography.
COMPOUND ^RETENTION ‘RELATIVE
VOLUME (MLS) RETENTION
CONCENTRATION
OF COMPOUND 
(mmol/1)
Ascorbate 2.3
Urate 3.2
Citrate 15.8
Glycolate ND
Glyoxylate 2.7
Glucose ND
Lactate 2.7
Succinate ND
Pyruvate 5.8
Fumarate ND
Malate ND
0.32
0.44
2.20
ND
0.38
ND
0.38
ND
0.81
ND
ND
5.0
1.0
4.0
4.0 
0.4
20.0
5.0 
0.2 
0.2 
0.1 
0.1
Retention volume for oxalate is 7.2 mis. ^Retention volume, is 
retention time multiplied by flow rate. ‘^Relative retention, is 
retention time divided by the retention time of oxalate. Revalue 
defines resolution. It is the retention of the interférant minus 
the retention of oxalate divided by the average peak width of the 
two peaks. ND indicates not detected.
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detected on the instrument settings for urine 
analysis. Using the more sensitive instrument settings 
of the plasma method, glycolate could be detected but 
not glucose. In all cases where detection occured, 
values (definition in table were greater than
1.5, indicating complete resolution of oxalate from 
the component under investigation.
The urine oxalate method was assessed for the effect 
of calcium on the analysis of oxalate. Two urine 
samples, at levels of 157 umol/1 and 947 umol/1 of 
oxalate, were analysed after being augmented with 
calcium chloride. Calcium concentrations of 5 mmol/1, 
10 mmol/1 and 20 mmol/1 were added. Samples were all 
analysed with and without added Sodium EDTA (lOmmol/1 
final concentration in the urine), to identify if 
chelation of calcium by the EDTA would release any 
bound oxalate.
Application of Students t test to the data showed no 
significant difference between samples at the 5% 
confidence level, with or without EDTA. Results can be 
seen in Table 3.5. There was no decrease in oxalate 
concentration in the urine as the calcium 
concentration increased.
3.2.7. Method comparison
The urine method was compared to an enzymatic method 
using oxalate oxidase (Mingen and Madappally 1989),
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Table 3.5 The effect of different calcium
concentrations in the urine on the oxalate results, 
with and without EDTA
Calcium 
added to 
urine 
(mmol/1)
Final Calcium 
Concentration 
in urine 
(mmol/1)
Oxalate Concentration 
in urine (umol/1)
With ®EDTA Without
EDTA
SI S2 SI S2
Endogenous 4.36 152 940 149 949
5 9.36 150 955 152 968
10 14.86 160 1019 152 968
20 24.36 158 1006 155 987
“Tetrasodium EDTA (10 mmol/1) final concentration in urine. SI low 
oxalate sample; 32 high oxalate sample.
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which is available as a commercial kit from the Sigma 
Chemical Company, catalogue No. 591. Results are shown 
in figure 3.3. This method is free of interference 
from ascorbate. An earlier version (catalogue No. 590) 
of this method was interfered with by ascorbate and 
also gave variable recovery; comparison with this 
earlier version is shown in figure 3.4.
Analysis by the improved enzyme method of Mingen and 
Madappally (1989) analysed oxalate in buffered urine 
which was mixed with activated charcoal to remove 
interferents. Samples were then centrifuged and the 
supernatant assayed on a centrifugal analyser (Cobas 
Bio) spectrophotometrically at 590 nm.
The plasma method was compared to the immobilised 
enzyme method of Kasidas and Rose (1986). The results 
of this comparison are shown in figure 3.5.
Sample stabilisation for the plasma comparison was 
dependent on the method used to measure the oxalate. 
The samples used for the comparison with the 
immobilised enzyme method were collected, then the 
plasma was divided into two aliquots. One aliquot was 
stored as described in chapter 2, for HPLC, the other 
had tetrasodium EDTA added (lOmmol/1 final 
concentration in plasma) and was measured by the 
enzyme method. Samples were stored at -70°C until 
analysis. Two of the samples used in this comparison 
were augmented with 200 umol/1 ascorbate. There was a
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FIGURE 3.3 COMPARISON OF URINE OXALATE 
ANALYSIS BY HPLC WITH AN OXALATE OXIDASE 
METHOD (SIGMA 591).
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y " + 14
!
1
i
200 400 600 800
Oxalate oxidase method (umol/1)
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interference from ascorbic acid, 
n -  78 Coefficient of correlation r-0.97
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FIGURE 3.4 COMPARISON OF URINE OXALATE 
ANALYSIS BY HPLC WITH AN OXALATE OXIDASE 
METHOD (SIGMA 590).
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FIGURE 3.5 COMPARISON OF PLASMA OXALATE 
ANALYSIS BY HPLC WITH AN OXALATE OXIDASE 
METHOD WHICH USES IMMOBILISED ENZYME
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Oxalate oxidase method (umol/1) 
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n -  20. Coefficient of correlation 
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modification to the method of Kasidas and Rose (1986) . 
The plasma sample was not acidified until after 
ultrafiltration.
3.2.8. Quality control
Analytical runs were quality controlled using pooled 
urine and plasma samples. Samples were collected and 
stored as recommended in sections 2.6.2.4 and 2.6.3.5 
Means and standard deviations for the pools were 
derived by analysing the pool fifteen times on 
separately calibrated runs. In order to have a low and 
a high control, it was necessary to augment a low 
control pool with oxalate. An additional control check 
was to assess recovery in the augmented sample. Some 
of the precision data in section 3.2.2 is derived 
from control values. Analytical runs were regarded as 
acceptable if the control values were within +/- two 
standard deviations of the pool mean. External quality 
control samples from Mr. C.T. Samuell of University 
College and Middlesex School of Medicine were also 
analysed on the urine method.
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SECTION 2. REFERENCE RANGES FOR URINE AND PLASMA 
OXALATE AND PARAMETERS DERIVED FROM THESE 
MEASUREMENTS.
3.3. MATERIALS
Reagents and materials were as used in the previous 
sections . All reagents unless otherwise stated , were 
of Analar grade and were supplied by B.D.H. Chemicals 
limited (Poole Dorset U.K.). All aqueous solutions 
were made up in deionized water.
3.3.1. Equipment.
Equipment was as stated in previous sections.
3.4 METHODS AND RESULTS 
3.4.1 Statistical methods.
Means values for data are generally given as mean +/- 
standard deviation (SD). Means for normally
distributed data were compared by Students unpaired or 
paired t test, when the sample number (n) was less 
than 30. If n is greater than 30 then standard error 
of the difference between two means is used. Data that 
is not normally distributed was compared by non- 
parametric statistics. Means were compared by the U 
test or the signed rank test. Standard deviations or 
variance were assessed by the F statistic, or the
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Kruskal-Wallis test if non parametric.
The Chi square goodness of fit test was used to assess 
normal distribution and to compare frequencies where 
appropriate. To identify skew in a distribution, the 
Pearsonian coefficient of skewness is used. Zero 
coefficient indicates complete symmetry. If reference 
range data is skewed, it is transformed to °^logarithms 
so that it can be expressed as SD or is expressed as a 
range.
Any other statistical methods used will be quoted in 
the text; all are described in Modern Elementary 
Statistics (Freund, 1988).
During data analysis the significance level used is 5% 
unless otherwise stated.
3.4.2. Analytical methods.
The chromatography, extraction, collection and storage 
techniques used in this section were described in 
chapter 2. The methods developed were used to 
establish normal ranges.
Creatinine was measured by the Jaffe method; urea 
using o-phthalaldehyde colour reagent, and calcium by 
a cresopthalein complexone method. All were measured 
on the Perspective analyser (American Monitor UK).
3.4.3. General details of normal subjects.
Subjects used to establish the normal ranges were
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assessed before samples were collected. Males and 
females; age range 21 to 58; (mean 33.2; median 39 ; 
mode 25 ); height range 166.5 cm to 194 cm.; weight 
range 51.5 to 110.5 kg. All subjects had normal blood 
pressure. There was no history of renal stone disease 
and all had normal renal function. Plasma creatinine, 
urea and creatinine clearance were measured. In all 
subjects plasma calcium was normal and 24 hour urinary 
calcium output was less than 7.5mmol/l.
Unless otherwise stated, collections were made whilst 
the individuals were ambulant and on their normal 
diet. Blood samples were taken with minimal stasis and 
if possible without use of a cuff.
A full biochemical profile was performed on the blood 
and urine collected for normal ranges. All parameters 
were found to be normal.
3.4.4. Urinary 24 hour oxalate output.
To establish a reference range, ninety one normal 
subjects (52 male, 39 female) collected 24 hour urine 
samples for oxalate analysis. The distribution of the 
results is displayed in figures 3.6 to 3.8.
The data was analysed in three groups; total results, 
male and female. Results are shown in table 3.6. The 
Pearsonian coefficient of skewness was calculated for 
all groups, this showed no significant skewness of the 
data, results being very close to zero. On inspection
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FIGURE 3.7 DISTRIBUTION OF 24 HOUR 
URINARY OXALATE OUTPUT IN NORMAL ADULT
MALES
H" 52
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FIGURE 3.8 DISTRIBUTION OF 24 HOUR 
URINARY OXALATE OUTPUT IN NORMAL ADULT 
FEMALES
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Table 3.6 Results of the data analysis on 24 hour 
urinary oxalate output (umol/24 hour) in normal 
subj ects.
Males and Males Females
Females
n 91 52 39
mean (umol/24hr) 303 303 304
median (umol/24hr) 312 314 312
SD (umol/24hr) 97 100 91
2SD range 109-497 102-506 121-486
(umol/24hr)
Range (umol/24hr) 80-574 80-574 92-488
Pearsonian -0.27 - 0.33 -0.09
coefficient
of skewness
Chi square NS NS NS
goodness of fit
test
NS means no significant difference from normal distribution by 
the Chi square test at the 5% level of significance. n - number 
of subjects.
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of figure 3.7 however, the male distribution did 
appear to have a slight negative skew. To establish if 
each group had an approximation to a normal 
distribution, the Chi square goodness of fit test was 
applied. In each group the result indicated no 
significant difference from a normal distribution.
There was no statistically significant difference 
between the male and female groups in either their 
means or standard deviations. Results are shown in 
table 3.6.
The oxalate concentration (umol/1) of the samples were 
statistically evaluated. All the groups demonstrated 
a normal distribution and no statistically significant 
difference was found between the means and standard 
deviations of the male and female groups. Table 3.7 
shows the results of the data analysis.
3.4.5. Fasting urinary oxalate output.
Samples were analysed to investigate the effects of 
fasting on urinary oxalate output in timed 
collections. Two groups of subjects, fasting (n = 59 ) 
and non fasting (n = 78), collected 2 hour urine
samples. Fasting samples were collected between 9am 
and 10am in the morning following the fast. The 
majority of non fasting samples were collected during 
the morning, though some were collected at other times 
of the day. The fasted group had not eaten for 14
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Table 3.7 Urinary oxalate concentrations (umol/1) in 
normal subjects.
Male and 
Female
Male Female
n 91 52 39
mean (umol/1) 228. 6 226.9 231.0
median (umol/1) 206.0 204.0 210.0
SD (umol/1) 105. 6 113.0 96.2
This data was used to calculate 
reference ranges. No significant
the 24 hour urinary oxalate 
difference was seen between
males and females.
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hours before collection, but could drink water freely. 
Samples were analysed for oxalate and creatinine, 
urine flow rate was recorded, then data analysis was 
performed. The data was examined in three forms: 
concentration (umol/1), oxalate:creatinine ratio and 
oxalate output per unit time.
According to the chi square goodness of fit test, the 
data collected was not all normally distributed. It 
was therefore necessary to use some non parametric 
data analysis. The distribution of oxalate 
concentration, oxalate:creatinine ratio and oxalate 
output in umol/min is shown in figures 3.9a and b to 
3.11a and b. Comparison of the fasting and nonfasting 
data is shown in table 3.8.
The data in this study was examined for correlation 
to, urine flow rate, body weight and body surface 
area. It was noted that urine oxalate concentration 
correlated weakly with body weight and body surface 
area ( r <0.32), but gave a negative correlation with 
urine flow rate (r = -0.64). The correlation with
urine flow rate was significant (p <0.001) , this was
assessed by Spearman's rank correlation coefficient, 
to ensure it was not a spurious correlation. The 
relationship is demonstrated in figure 3.12, this fits 
an exponential distribution.
The urine flow rate and creatinine concentration 
(mmol/1) of the fasting and non-fasting groups were
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FIGURE 3.9a DISTRIBUTION OF FASTING 
URINE OXALATE CONCENTRATION 
(UMOL/L) IN NORMAL ADULT SUBJECTS
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FIGURE 3.9b DISTRIBUTION OF NON-FASTING 
URINE OXALATE CONCENTRATION (UMOL/L) 
IN NORMAL ADULT SUBJECTS
14-
t 
15*
*o
1 4 -
2 -
32525 125 225 425 525 625 725 1025825 925
Urinary oxalate (umol/1)
Urine collections were 2 hours
169
FIGURE 3.10a DISTRIBUTION OF FASTING 
OXALATE:CREATININE RATIO 
IN NORMAL ADULT SUBJECTS
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FIGURE 3,10b DISTRIBUTION OF NON-FASTING 
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ADULT SUBJECTS
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FIGURE 3.11a DISTRIBUTION OF FASTING 
URINARY OXALATE OUTPUT 
(UMOL/MIN) IN NORMAL SUBJECTS
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FIGURE 3.11b DISTRIBUTION OF NON-FASTING 
URINARY OXALATE OUTPUT (UMOL/MIN)
IN NORMAL SUBJECTS
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Table 3.8 Results of fasting and non fasting urinary 
oxalate output in normal subjects.
FASTING SAMPLES ( n = 58 )
Ox/Great 
Ratio
umol/1
oxalate
umol/min
oxalate
umol/120
oxalate
Mean 0.014 133.6 0.12 14.4
Median 0.011 115.0 0.12 14.4
SD 0.014 82.1 0.054 6.5
Range 0.003-
0.039
1 0.0-
337.0
0.019- 
0.244
2.3 — 
28.8
Chi NS p<0.005 NS NS
square 
goodness 
of fit
NON - FASTING SAMPLES ( n = 78 )
Mean 0.024 246.5 0.22 26.4
Median 0.022 208.0 0.21 25.2
SD 0.010 157.2 0.083 10.0
Range 0.005— 
0.055
57.0-
734.0
0.060— 
0.430
7.2
51.6
Chi NS p<0.005 NS NS
square 
goodness 
of fit
Comparison of the fasting and non fasting data shows a 
significant difference in oxalate concentration (p<0.001)f 
oxalate:creatinine ratio (p<0.001) and oxalate output in umol/min
(p<0,001).
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compared. No significant difference was found in flow 
rate or creatinine concentration between the groups.
3.4.6. Plasma oxalate.
The plasma oxalate references range were determined 
from samples collected by venesection of 50 
individuals (29 male and 21 female) over a period of 
several months. Samples were taken at various times 
during the day on a random basis.
The distribution of these results can be seen in 
figures 3.13 to 3.15. The chi square goodness of fit 
analysis could not be easily applied to the separate 
male and female groups, due to the relatively small 
numbers of samples. Chi square fit of the male and 
female results combined showed that there was a 
significant difference from a normal distribution 
(p<0.005). The separate male and female data was 
assessed by visual inspection of the frequency 
distribution in figures 3.14 and 3.15. The data on 
females demonstrated positive skewness, while the male 
distribution appeared normal. Analysis of the data can 
be seen in table 3.9.
3.4.7. Fasting plasma oxalate.
The effect of fasting on the plasma oxalate reference 
range was examined. Samples were collected after 
subjects (n = 32) had fasted for 14 hours. The fasting
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FIGURE 3.14 DISTRIBUTION OF NON-FASTING 
PLASMA OXALATE LEVELS IN NORMAL ADULT 
MALE SUBJECTS
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FIGURE 3.15 DISTRIBUTION OF NON-FASTING 
PLASMA OXALATE LEVELS IN NORMAL ADULT 
FEMALES
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Table 3.9. The results of the data analysis on 
plasma oxalate reference ranges.
Non Fasting plasma oxalate Fasting
plasma
oxalate
n
mean
(umol/1)
median
(umol/1)
SD
(umol/1)
Male Female
Range
(umol/1)
29
2.2
2.0
0.86
21
1.7
1.4
0.83
Pearsonian 0.26 
coefficient 
of skew
Chi square 
Goodness of 
fit
0.90
Male
and
Female
50
2.0
1.8
0.89
2SD range 0.5-3.9 0.0-3.3 0.1-3.9
(umol/1)
0.7-3.9 0.7-3.5 0.7-3.9
0.61
p<0.005
Male
and
Female
32
1.5
1.4
0.67
0.1-2.8
0.6—2 .9
0.30
NS
There was a significant difference between the male and female 
groups (p<0.05) and the fasting and non fasting groups (p<0.05).
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group consisted of equal numbers of males and females. 
The results were compared to the non fasting data from 
section 3.4.6. See figure 3.16 and table 3.9.
The fasting data was assessed for normal distribution 
using the Chi square goodness of fit test. The result 
showed no significant difference from a normal 
distribution. However, the chi square value was close 
to the critical value. Inspection of figure 3.16 
does show a slight positive skewness, but this is not 
statistically significant.
The fasting and non fasting plasma data showed a 
significant difference between the groups (p<0.05).
3.4.8. Oxalate clearance and fractional excretion of 
oxalate.
Timed urine collections, with mid point blood samples, 
were used to study oxalate clearance and the 
fractional excretion of oxalate. The study involved 
two separate collection periods, a 2 hour collection 
(9am - lOp after a 14 hour overnight fast and a 24 
hour collection with no dietary restrictions. During 
the 2 hour collection subjects were allowed to drink 
water freely.
Forty five samples were collected in the 2 hour study 
and thirty five in the 24 hour study. Thirty nine 
different individuals took part, of which only six 
were female. The minimum number of samples from
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different individuals in each of the collection 
periods was twenty seven. Oxalate and creatinine were 
measured in all blood and urine samples collected. 
These measurements were used to calculate oxalate 
clearance, creatinine clearance and fractional 
excretion of oxalate (oxalate clearance / creatinine 
clearance x 100). All calculated parameters were 
derived using standard formulae. The urine flow rates 
of subjects were also calculated.
The distribution of oxalate clearance and the 
fractional excretion of oxalate in the study can be 
seen in figures 3.17a and b and 3.18a and b. 
Fractional excretion during the 2 hour collection, 
demonstrated a normal distribution, whereas the other 
distributions examined were significantly different 
from normal (p<0.05). There was no significant 
difference between the 2 hour and the 24 hour 
collections with respect to urine flow rate, 
creatinine clearance or plasma creatinine. Significant 
differences did occur in plasma oxalate umol/1 
(p<0.05), urine oxalate umol/1 (p<0.01), and oxalate 
clearance ml/min (p<0.05). Results of the study can be 
seen in table 3.10.
No correlation was found in either of the collection 
periods between oxalate clearance or fractional 
excretion and the following:- body surface area, 
creatinine clearance and flow rate. Oxalate clearance
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FIGURE 3.17a DISTRIBUTION OF OXALATE 
CLEARANCE IN FASTING NORMAL SUBJECTS
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FIGURE 3.17b DISTRIBUTION OF OXALATE 
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FIGURE 3.18a DISTRIBUTION OF THE 
FRACTIONAL EXCRETION OF OXALATE IN 
FASTING NORMAL SUBJECTS
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FIGURE 3.18b DISTRIBUTION OF THE 
FRACTIONAL EXCRETION OF OXALATE IN 
NON-FASTING NORMAL SUBJECTS
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Table 3.10 Oxalate clearance and fractional excretion 
data on normal subjects during a 2 hour fasting urine
collection and a 24 hour 
Oxalate
urine collection 
Clearance
2 Hour urine 
collection (Fasting)
24 Hour urine 
collection
n 45 35
mean (ml/min) 88.8 132.4
median (ml/min) 76.7 116.7
SD (ml/min) 36.2 60.7
Range (ml/min) 31-166 47-267
Pearsonian 
coefficient 
of skewness
1.0 0.78
Fractional excretion of oxalate
2 Hour urine : 
collection (Fasting)
24 Hour urine 
collection
n 45 35
mean (%) 81.1 126.7
median (%) 83.0 135.3
SD (%) 41.2 68.5
Range (%) 28-201 29-226
Pearsonian -0.14 -0.38
coefficient 
of skewness
Plasma oxalate 2 hour period; mean 1.6 +/- 0.8 (umol/1); 24 hour 
¥
period; mean 2.0 +/- 0.8 (umol/1). Urine oxalate 2 hour period;
y ¥ **
mean 131 +/- 91 (umol/1); 24 hour period; mean 198 umol/1,
SD +/- 102. ^ o > o ^  \ a  o  .o\
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and fractional excretion of oxalate did not correlate 
in the 2 hour collection period, but during the 24 
hour collection, a correlation coefficient of 0.79 was 
found between the fractional excretion of oxalate and 
the oxalate clearance. This indicates a strong 
correlation, ___
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SECTION 3. BIOLOGICAL VARIATION OF OXALATE IN PLASMA 
AND URINE.
3.5. MATERIALS
Reagents and materials were as used in the previous 
sections . All reagents, unless otherwise stated, were 
of Analar grade and were supplied by B.D.H. Chemicals 
limited (Poole Dorset U.K.). All aqueous solutions 
were made up in deionized water.
3.5.1 Equipment.
Equipment was as stated in previous sections.
3.6 METHODS AND RESULTS
3.6.1 Sampling protocol.
Biological variation of oxalate within individuals was 
studied over 24 hours. Samples were collected and
stored as described in chapter 2 .
The study over 24 hours involved seven subjects, three 
male and four female. They collected 6 hourly urine 
samples over a 24 hour period, starting at 07.00
hours. During the course of these collections, blood
samples were taken by venesection at 1 0.00, 16.00,
20.00, and 07.00 hours. The final blood sample was 
taken at the conclusion of the last urine collection. 
All subjects were on their normal diets. Some of the
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volunteers were performing emergency on call duties 
during the collection period so their sleep patterns 
were not normal.
3.6.2. Parameters measured and analysis of the data.
The urine volumes were measured, and all blood and 
urine samples were analysed for oxalate and 
creatinine. From these analyses, the following 
parameters were derived by calculation:- urine flow 
rate, creatinine clearance, oxalate clearance and 
fractional excretion of oxalate.
All results are displayed graphically, data points on 
the graphs are displayed as means + or - the standard 
error of the estimate (SEM).
Students paired t test, F statistic and Kruskal-Wallis 
test were applied, where appropriate, to assess any 
statistically significant variation in the parameters 
measured.
Intra-individual and inter-individual biological 
variation of urine and plasma oxalate were assessed by 
the calculation of variance (SD^ ) . The variance of the 
results for each subject was used to calculate the 
average intra-individual variation by subtraction of 
the analytical variation from the observed dispersion. 
Inter-individual variance was calculated by 
subtracting analytical variance and intra-individual
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variance from the overall variance of all subjects 
(Howey, Browning and Fraser, 1987).
3.6.3. Biological variation of urinary oxalate.
All urine collections are plotted as outputs of 
oxalate in umols per collection period. Results can be 
seen in figure 3.19. No statistically significant 
biological variation was found.
The urine flow rate of subjects was calculated for 
each collection period. Statistical analysis, using 
the paired t test, revealed no significant variation 
between collections. There was no significant 
correlation (r<0.2) between urine oxalate output per 
collection period and urine flow rate.
Intra and inter-individual variance was dependent on 
urine collection times. Variance is expressed as SD^  
but these results are given as SD. Results were as 
follows:- 6 hour urine collections over a 24 hour 
period, intra-individual variation 15.1 umol, inter­
individual variation 4.0 umol.
3.6.4. Biological variation of plasma oxalate.
Results of the plasma oxalate studies can be seen in 
figure 3.20. There was a significant variation in 
plasma oxalate over the twenty four hour period. 
Plasma oxalate levels increased significantly (p<0.05) 
between 07.00 hours and 10.00 hours, decreasing again
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FIGURE 3.19 MEAN INDIVIDUAL VARIATION 
OF URINARY OXALATE OVER 24 HOURS IN 
SEVEN NON-FASTING SUBJECTS
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between 20.00 hours and 07.00 hours the following day. 
These results can be seen in figure 3.20. The sampling 
times were selected, where possible, to coincide with 
the mid point of the appropriate urine collection.
Intra and inter-individual variance was dependent upon 
urine collection times. Variance is expressed as SD^  
but these results are given as SD. Results were as 
follows:- 6 hourly collections over a 24 hour period, 
intra-individual variation 0.49 umol/1, inter­
individual variation, none detected.
3.6.5. Biological variation of oxalate clearance and 
the fractional excretion of oxalate.
Using the data from the urine and plasma studies, 
oxalate clearance and fractional excretion of oxalate 
were examined for variation. It has already been 
stated that blood samples were taken, when possible, 
at the mid point of urine collections. In cases where 
this could not be achieved, the sample was taken as 
near the mid point as was practical. All calculations 
were performed using standard formulae. Results on 
urine flow rates were described in section 3.6.3. 
Creatinine clearance was calculated for all of the 
studies performed. Significant differences were found 
between the 07.00-13.00 hour and the 01.00-07.00 hour 
collections (p<0.005), also between the 1^.00-01.00 
hour and the 01.00-07.00 hour collections (p<0.05).
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The variation of oxalate clearance and the fractional 
excretion of oxalate showed no statistically 
significant difference. Results are displayed 
graphically in figures 3.21 and 3.22. Large intra­
individual variation of oxalate clearance (69- 
295ml/min) and fractional excretion (45-295%) was 
found in certain individuals within a 24 hour period.
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FIGURE 3.21 MEAN INDIVIDUAL 
VARIATION OF OXALATE CLEARANCE IN SEVEN 
NON FASTING SUBJECTS OVER 24 HOURS
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FIGURE 3.22 MEAN INDIVIDUAL VARIATION 
OF FRACTIONAL EXCRETION OF OXALATE IN 
SEVEN NON-FASTING SUBJECTS OVER 24 HOURS
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DISCUSSION.
The first section of this chapter contains the full 
validation of the urine and plasma oxalate methods. 
The results show the methods described to be precise, 
accurate and simple.
The between batch precision of the plasma method near 
the reference range was better than those recently 
published physical and enzymatic methods (Schwille et 
al. 1989, Boer, van Leersum and Enderman, 1984). The 
methods developed were free from interferences and 
samples were found to be stable under the conditions 
described. The in vitro production of oxalate from 
glyoxylate, as described by Ackay and Rose (1980) has 
therefore either been controlled by the collection and 
storage conditions used or was negligible in these 
studies.
The plasma method described, uses a sample volume of 1 
ml, though it is possible to perform the assay on 500 
ul of plasma. This is an improvement over some recent 
methods (Berckmans and Boer, 1988 and Kasidas and 
Rose, 1986) which require more than 4 mis of plasma.
The sensitivity and linearity limits defined in this 
chapter are based on the normal operating conditions 
described. These give levels of sensitivity comparable 
to other methods (Schwille et al. 1989J Berckmans and 
Boer, 1988 and Costello and Landwehr, 1988), but it is 
possible to adjust the electrochemical detector to
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extend these limits. Adjustment of conditions means 
that the instrument requires about 1 hour to produce a 
steady baseline. Then, provided that the column is in 
good condition, low nmol/1 levels can be detected. The 
quality of peaks can be enhanced using a 15 cm. 3u ODS 
column. The method does require a good quality 
electrochemical detector. The EG and G; Parc Model 400 
from Jones Chromatography (Mid Glamorgan, UK) is 
excellent, but two other manufacturer's models proved 
inadequate for plasma measurement. In both cases this 
was due to excessive baseline noise.
Comparative studies demonstrated excellent agreement 
between plasma oxalate results from this method and 
those from the previously reported procedure of 
Kasidas and Rose (1986). The excellent correlation 
between the two methods probably results in part from 
the fact that the samples for comparison were 
collected and stored simultaneously prior to analysis, 
thereby reducing pre analytical variables to a 
minimum.
Comparison of the urine method with values from a 
commercially available kit (Sigma procedure 591), 
based on work by Mingen and Madappally (1989), showed 
acceptable correlation, as shown in figure 3.3. This 
Sigma method was an improvement over a previous kit 
method (Sigma procedure 590) which had reported 
interference from ascorbate (Kasidas and Rose, 1987) .
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A comparison of Sigma procedure 590 with HPLC (figure 
3.4) gave an inferior correlation.
The possibility of oxalate binding to protein was 
discussed in chapter 2. The recovery data in this 
chapter suggest that under the conditions defined, no 
significant protein binding occurred. When plasma, 
diluted in acetate buffer is loaded onto the SAX 
cartridge, plasma proteins pass unretained. Unless 
there is some interaction at the resin surface, 
protein bound materials would also be lost. The 
recovery results were not less than 95%, suggesting 
only negligible amounts of oxalate were protein bound. 
As the method is free from interference by 
oxalogenesis, a compensatory effect is unlikely to 
account for the recovery data.
These findings appear contrary to a recent report by 
Schwille et al (1989), who, when using ultrafiltration 
(MW cut off 10,000) at pH 7.4 to extract samples, 
suggested that 11-16 % of oxalate is protein bound. If 
Schwille's conclusions are correct, the present method 
either suffers from interference, which seems unlikely 
as interference was investigated thoroughly, or that 
the oxalate measured really represents total oxalate. 
In order to measure total oxalate by this method any 
protein binding would have to be disrupted. This may 
be possible if for example, an interaction on the SAX 
cartridge stripped the oxalate from protein, or the
194
use of dithiothreitol as a preservative affected the 
binding sites on the protein and released the oxalate. 
There is however, evidence not only from the present 
work, but from other authors, in support of negligible 
in vivo protein binding. The excellent comparison of 
this method with the Kasidas method, which used 
ultrafiltration (MW cutoff 10,000) as an initial step, 
tends to support negligible in vivo protein binding. 
The samples for this comparison were not acidified 
until after ultrafiltration, to ensure no protein 
binding of oxalate due to a low pH (Costello and 
Landwher, 1988). The methods of Costello and Landwehr 
(1988) and Berckmans and Boer (1988) use 
ultrafiltration and achieve complete recovery of 
oxalate, also suggesting negligible protein binding. 
Further investigations using ultrafiltrates on the 
HPLC method may further clarify this debate though it 
would appear that oxalate is freely filtratable.
The present method has demonstrated that it is 
acceptable for routine use even though some expertise 
is required to use the equipment. Correct sample 
storage and collection help maintain quality of 
results if all precautions are observed. The accuracy 
and precision of the method and the fact that it is 
applicable to plasma and urine make this system ideal 
for metabolic studies.
Establishing a reliable method and defining the
195
correct storage and collection conditions for an 
analyte are the first stages in making a measurement 
clinically useful. It is the definition of reference 
ranges that makes the analysis of clinical value. To 
interpret patient data, normal metabolism must be 
defined.
This chapter contains reference ranges for the 
methods. In agreement with a previous report (Menon 
and Mahle, 1983) no sex related difference were found 
in the reference ranges for 24 hour urinary oxalate 
output. The reference range found for 24 hour urinary 
oxalate is in close agreement with other recent 
reports (table 1.1) although lower than that used for 
some enzymatic procedures (Urdal 1984), possibly 
reflecting the higher selectivity of the method 
currently described.
There has been a suggestion that some 24 hour urinary 
oxalate populations are positively skewed (Larking 
1983) . The urinary oxalate data reported here were 
normally distributed for both males and females.
The contribution dietary oxalate makes to urinary 
oxalate output is thought to approximate to between 
10-20% (Williams and Wandzilka, 1989). If a patient 
has hyperoxalauria it is important to try and 
establish the source of the oxalate and the cause of 
its increased excretion. Reference ranges for 2 hour 
urine collections in fasting and non fasting normals
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were derived to establish levels of output in normal 
metabolism.
The investigation of fasting and non fasting 2 hour 
collections revealed that almost twice as much oxalate 
was excreted in the non fasting state. The urinary 
oxalate output did not correlate to urine 
concentration or flow rate. It appears to be a 
response to diet.
The non fasting samples were collected between 2-4 
hours after breakfast. Most subjects had consumed 
coffee or tea for breakfast, which indicates that 
during a short collection period, diet can contribute 
more than 10-20% of the urinary oxalate output. All 
these subjects, fasting and non fasting, had normal 24 
hour urine outputs as defined in section 3.4.4. A 
renal stone can form when the concentration of a stone 
forming salt exceeds its solubility in urine. Periods 
of high concentration may occur during a 24 hour 
period which are not apparent from measuring a 24 hour 
urine alone.
The mean fasting 2 hour oxalate: creatinine ratio 
(0.014) was lower than that found by Hodgkinson in 
1978 (0.020) and Schwille, Hanisch and Scholz in 1984
(0.029). This may reflect improved methodology and 
indicates the need to re-evaluate the contribution of 
diet to urine oxalate output. These lower fasting 
urine oxalate levels may also have implications for
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the interpretation of fasting oxalate levels found in 
renal stone formers. This is further investigated in 
chapter 5.
The plasma reference ranges for this method were 
affected by both sex and diet. Females had a lower 
reference range than males and the fasted subjects had 
a lower range than the non fasted.
The non fasting reference range derived for plasma 
oxalate agrees with that of some recently reported 
methods (Costello and Landwehr, 1989, Berckmans and 
Boer, 1988, Kasidas and Rose, 1986), though it is 
slightly higher than in vivo isotopic methods and the 
bioluminescent method of Parkinson et al (1989). The 
fasting reference range agrees with that of Schwille 
et al (1989) , who used only fasting subjects. This 
helps support the contention that there is a 
difference in fasting and non fasting plasma oxalate 
levels.
The information in the literature is conflicting with 
regards to male and female reference ranges and 
whether significant differences between the two exsist 
(Berckmans and Boer, 1988, Rose and Kasidas, 1986, 
Costello and Landwehr, 1988). This apparent confusion 
may reflect poor definition of the populations studied 
with respect to such things as sampling time, diet, 
menstural cycle , the oral contraceptive and storage 
and collection of samples.
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The non fasting plasma oxalate and the female plasma 
oxalate distributions were positively skewed. This 
could be due to analytical error or poor sample 
collection, but this is extremely unlikely as these 
areas have been fully evaluated. Other factors that 
deserve consideration are hormonal influence, diet or 
the fact that there may have been insufficient numbers 
in the populations studied (female n=21; male n=29: 
non fasting n=50; fasting n=32) Greater numbers may 
have shown a normal distribution.
Fasting plasma samples gave a normal distribution so 
diet may be a contributory factor to the skewed 
distributions seen in the fed state. This could be due 
to the content of the diet or the sampling time in 
relation to food intake. This is investigated further 
in chapter 4.
The female subjects were all less than forty years of 
age and menstruating normally. No information on 
contraception was documented. Four of the female 
subjects were vegetarian, but the five females that 
contributed to the positive skew had no obvious 
differences from the rest of the group. The female 
subjects with higher oxalate output may be a small 
group of subjects where dietary factors and sample 
collection times overcame other factors which gave 
the female group a lower mean plasma oxalate level 
from the male group. The skewed distribution of the
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non fasting group in this study is due largely to the 
inclusion of the female population.
The lower reference range in females compared to males 
may be due to an hormonal effect. The investigation of 
oxalate levels in pre and post menopausal subjects or
pre and post hormone replacement (HRT) would be of
interest. Further studies on larger numbers of 
subjects will be required to distinguish the effects 
of diet from those of sex. The present method has 
identified population differences due to sex and diet. 
These factors require careful thought when results are 
interpreted.
Studies on the clearance and fractional excretion of 
oxalate showed marked variation in the population as
well as within individuals. Oxalate clearance was less
variable in the fasting state (31-166 ml/min) than the 
non fasting state (47-267 ml/min). Results indicate a 
lower clearance rate than some earlier studies, 
(Williams, Johnson and Smith, 1971, and Pinto et al. 
1974) which have quoted oxalate clearances in normals 
ranging from 101 to 358 ml/min. This probably reflects 
better methodology, particularly with reference to the 
assessment of plasma levels.
Recent studies on the fractional excretion of oxalate 
by Kasidas, Nemet and Rose (1990) suggest that 
fractional excretion in most normal subjects is less 
than 100%. This indicates net tubular reabsorption of
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oxalate in the majority of people. The results of the 
present study are similar to those of Kasidas for 
samples collected in the fasting state, the majority 
being less than 100%, indicating net tubular 
reabsorption. The results of the fractional excretion 
of the 24 hour urines, when subjects were on an 
unrestricted diet, gives a bimodal distribution. There 
are two distinct populations, one giving a fractional 
excretion between 20-120% the other between 120-220%. 
This suggests that both tubular reabsorption and 
secretion can occur in the normal population on an 
unrestricted diet. The renal handling data in the fed 
state may be subject to error due to variation in 
plasma oxalate throughout the twenty four hour period 
and the effect of diet on the urine creatinine output. 
Further studies, using shorter collection times, are 
described in the following chapter in order to try and 
reduce these errors.
Many of the same subjects had fractional excretion 
measured in both fasting and non-fasting samples. 
Individuals were able to demonstrate net reabsorption 
or net secretion of oxalate on different occasions. 
These results indicate the possibility of 
bidirectional tubular handling of oxalate or the 
presence of two populations of nephrons that handle 
oxalate differently. The handling of oxalate may 
depend on the oxalate load presented to the kidney.
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The ability of the kidney for net secretion may not 
become apparent until a large enough load is present. 
There was however proven correlation between
oxalate clearance and fractional excretion. A 
correlation (0.79) was found as previously reported 
(Kasidas, Nemet and Rose, 1990) tkU wo.s. checked by 
the Spearman rank correlation coefficient, 
significant correlation occurred.
The results found, may account for differences in the 
literature on the fractional excretion of oxalate 
found in normal subjects (Kasidas, Nemet and Rose, 
1988; Williams and Wilson, 1990). For a substance that 
is an end product of metabolism it would make sense 
that there is limited reabsorptive capacity. This 
interpretation may become more complex if tubular 
cells can produce oxalate metabolically as suggested 
by Kasidas, Nemet and Rose (1990). Micropuncture 
studies have indicated a bidirectional flux of oxalate 
with secretion playing a major role in oxalate 
excretion (Williams and Wilson, 1989) and that the 
proximal tubule is the major site of secretion. It has 
been postulated that there is present in the proximal 
tubule a high affinity, low capacity transport system 
operating at low plasma oxalate concentration and a 
low affinity high capacity oxalate transport system 
operating at high plasma concentration (Knight et al. 
1981). This could explain the results presented here.
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Biological variation was studied, as it has been 
suggested that plasma and urine oxalate have a 
circadian rhythym in healthy subjects and an ultradian 
and circannual variation in stone forming subjects 
(Touitou et al. 1983, Hodgkinson, 1970, Kasidas, 
1988). Results of the urine oxalate variation study in 
healthy subjects produced trends that other workers 
had seen (Touitou et al. 1983, Kasidas, 1988), with 
similar outputs of oxalate per unit time; but 
statistical analysis of the data indicated no 
significant variation.
No significant variation was seen in plasma oxalate, 
with the exception of levels in early morning which 
were significantly lower than samples from the rest of 
the day. This was not in accordance with steady rise 
throughout the day in plasma oxalate that had been 
suggested by Kasidas (1988). The early morning result 
probably shows the difference between a fasting and 
non fasting result (This sample was taken before 
breakfast).
Changes in oxalate clearance and fractional excretion 
also showed no significant changes. The 
intraindividual variation of these parameters however 
was large. Within a 24 hour period, fractional 
excretion in an individual could vary from 150% to 
60%. This required variance to be assessed by two way 
analysis to see if the wide intra-individual variation
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influenced the analysis of the biological variation. 
Despite this, no significant variation could be found. 
The reason for the discrepancies between this study 
and previous studies require some discussion. This 
could be due to the data analysis used. This study 
identified large intra-individual variation but 
analysis of variance by the F statistic or paired t 
test showed no significant variation between data 
points.
A previous author (Kasidas 1988) stated that circadian 
rhythm is lost on a low oxalate diet. This is a 
possible explanation as no attempt was made to modify 
the volunteer's diets. The calcium content of the 
water may also be relevant to the lack of significant 
variation. As the study took place in a hard water 
area, it is possible that less oxalate was absorbed 
due to the higher calcium content of the diet 
(Erickson et al 1984) and so diurnal variation was not 
seen. This effect is further investigated in chapter 
4. During these studies, the collection times for 
urines were not as frequent as some other authors have 
described, 4 hour (Touitou et al. 1983) and in some 
cases 1 hour collections (Tiselius and Almgard, 1977). 
Collections over longer time periods may mask peaks of 
oxalate output. Finally, earlier methodologies 
suffered from analytical interferences. This may also 
help to explain the differences observed between the
204
results of this study and earlier ones (Touitou et al. 
1983, Tiselius and Almgard, 1977).
Some of the questions posed in this chapter are 
investigated further in chapter 4.
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CHAPTER 4. STUDIES ON ORAL OXALATE AND ASCORBATE 
LOADING.
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INTRODUCTION.
As stated in chapter 1, it is thought that entire gut 
integrity is required for oxalate absorption but it is 
still not known which section of the normal gut is
primarily responsible for oxalate absorption or indeed 
what the exact mechanism of oxalate transport is in 
normals.
The daily intake of oxalate in the diet is about 1200 
umol/day, but only a small percentage of this is
absorbed. The actual percentage absorbtion has varied 
in different studies, results ranging from less than 
3% to 20% (Williams and Wandzilak, 1989; Williams and 
Wilson, 1990). The variation in results seen in 
oxalate loading studies reflects the different 
experimental conditions and methods used to estimate 
oxalate. One of the factors influencing this 
variation, is that oxalate has been given orally in 
different forms. Some workers have used a oxalate 
tracer, which is measured in the urine after being 
absorbed (Prenen et al. 1984; Schwille et al. 1984; 
Lindsjo et al. 1989), others have given salts of 
oxalate (Barilla et el. 1978; Rampton et al. 1984) or
oxalate rich food (Balcke et al. 1985) . Other
differences in previous loading studies are the 
methods used to measure oxalate and the diet of 
subjects. With regard to methods, many studies of 
oxalate absorption have relied upon measurement of
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urine oxalate to assess the percentage absorption. A 
variety of methodologies have been used to measure 
oxalate, some less reliable than others. This has 
contributed to variation of results. Dietary regimes 
of volunteers before and during loading have also 
varied. Subjects have been on normal diet, fasted or 
given a test meal. These dietary factors will 
certainly affect the bioavailability of oxalate 
(Bataille et al. 1983) .
None of the studies mentioned above have measured 
plasma oxalate or investigated the effect of an 
oxalate load on the renal clearance or fractional 
excretion of oxalate. The measurement of plasma 
oxalate in this study allows the effect of an oxalate 
load on renal handling to be assessed.
Results from the previous chapter suggest renal 
handling may be modified by diet. This is investigated 
by loading volunteers with both sodium oxalate 
capsules and foodstuffs. The oral sodium oxalate study 
was a two legged double blind study using seven 
fasting subjects. This allowed comparison of the 
fasting output of oxalate to that after an oxalate 
load. Oxalate loading studies were also performed by 
administration of chocolate and coffee. Chocolate has 
been cited as a common source of oxalate in the diet 
(Williams and Wilson, 1990) and the chocolate study 
was a re-evaluation of the work of Balcke et al (1985)
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using the present method. Balcke investigated the 
urinary output of oxalate after a chocolate load, but 
this study also measures plasma oxalate and the renal 
handling of the load.
The variation seen in blood and urine oxalate during 
fasting and after loading may be taken together with 
the information already presented in chapter 3 on
biological variation. Important variations in urinary 
oxalate excretion may have been missed in the 
collections used in the previous chapter. This study 
measures samples over shorter time periods to try and 
identify the effect of an oxalate load on plasma and 
urine oxalate variation.
The sodium oxalate loading study was also used to
assess the effect of oxalate on ketogenesis. 
Dichloroacetate has been used for the treatment of
diabetes mellitus, hyperlipidaemia and lactic 
acidosis. Reports have shown (Demaugre, Cepanec and 
Leroux, 1978; Buc et al. 1982) that oxalate, a 
catabolite of dichloracetate, can inhibit 
gluconeogenesis and pyruvate decarboxylation and 
enhance ketogenesis in isolated rat hepatocytes. On
this basis, normal fasting subjects, who were 
ketogenic, had their blood ketones measured with and 
without oxalate loading.
A recent paper by Trinchieri et al. (1991) correlated 
urinary oxalate output with dietary ascorbate intake.
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The estimated intake per day in their study was less 
than Ig. There have been suggestions that 0.5-lg a day 
may be enough to enhance urinary oxalate output (JAMA, 
1988). Other authors have said that more than 4g a day 
of ascorbate must be taken before urinary oxalate 
output starts to increase (Levine, 1986). To 
investigate the effect of a moderate intake Ig loads 
of ascorbate were given to volunteers over different 
time periods. The effect of ascorbate intake on 
oxalate metabolism is assessed over two time periods, 
8 hours and 3 months. As the methods used were free 
from in vitro interference of oxalate, the results 
should reflect the true in vivo changes.
The final section of this chapter looks at the 
bioavailability of oxalate in water samples, obtained 
from different geographical locations, with varying 
calcium content. The effect of calcium in the water 
was cited in the last chapter as a possible reason for 
the lack of observed diurnal variation.
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SECTION 1. ORAL SODIUM OXALATE LOADING IN NORMAL 
SUBJECTS.
4.1. MATERIALS AND METHODS.
4.1.1. Subjects.
All the subjects were males, the age range was 26 to 
50 years. None of the volunteers had any history of 
renal disorder and had normal renal function as 
defined by creatinine clearance, plasma creatinine and 
plasma urea. They were all normocalcaemic and 
normocalciuric. The volunteers had been on their 
normal diets prior to the investigation and none of 
them were on any drug treatment.
4.1.2 Study Protocol.
The gastrointestinal absorption and renal handling of 
oxalate was examined in a two legged double blind 
study. Data was also collected on the effect of 
oxalate on ketones in the blood. Seven subjects took 
part in the study.
Subjects fasted from 19.00 hours on day 1 of the 
study. They were allowed to drink distilled water 
during this fasting period. Subjects also exercised by 
running or cycling on the evening of day 1. At 07.00 
hours on day 2 the volunteers emptied their bladders 
then collected all subsequent urine until 09.00 hours.
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They drank between 200-400 ml of distilled water 
during this collection period. At 08.45 hours a 
cannula was inserted into a vein in the forearm and a 
minus 15 minute blood sample taken immediately. At
09.00 hours, the volunteers were given orally 200 mg 
of sodium oxalate in 250 ml of distilled water or a 
placebo of 250 ml of distilled water. The oxalate load 
is equivalent to 1.77 mmol of sodium oxalate or 159 mg 
of oxalate. Distilled water was given to the 
volunteers throughout the period of sample collection, 
200-400 ml per 2 hours. No other food or drink was 
allowed.
Urine was collected in 2 hour pooled samples from
09.00 hours, for the 6 hours of the study. At 09.00 
hours a zero time blood sample was taken. Subsequent 
samples were taken at 15,30,45,60,90,120,180,240,300, 
and 360 minutes. The cannula was flushed with citrate 
between samples to prevent clotting. Care was taken to 
ensure that the citrate was drawn off before sampling 
took place. All subjects were required to take both 
the oxalate load and the placebo, with a 2 week break 
between each study period.
Preliminary work was performed on two of the subjects. 
Urine samples were collected 2 hourly for 8 hours 
followed by a 16 hour collection. Extra plasma samples 
was taken at 420 and 480 minutes. During the extra 
time periods both subjects tried to avoid oxalate rich
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foods.
4.1.3. Measurement of blood and urine parameters.
All blood and urine samples had oxalate, creatinine, 
and calcium measured. The methods for these analyses 
have been quoted in previous chapters. Plasma samples 
were also analysed for acetoacetate, b-hydroxybutyrate 
and glycerol. These specimens were separated 
immediately on collection and stored frozen. Samples 
were analysed for these parameters within 5 days of 
collection. Acetoacetate and b-hydroxybutyrate were 
measured by the method of Philip et al (1980) , 
glycerol was analysed using an enzymatic kit from 
Randox Laboratories Limited (County Antrim U.K.). 
Additional parameters were derived from the analytes 
measured. These included creatinine clearance, urine 
flow rate, oxalate clearance and the fractional 
excretion of oxalate.
4.1.4. Statistical analysis.
Students two sample t test or paired t test was used 
for comparison of data. Data points on the graphs are 
plotted as mean + or - SEM. Any other statistical 
tests used are quoted in the text. The percentage of 
the oral load absorbed was calculated on the 
assumption that oxalate is not metabolised in vivo and 
its only route of excretion is renal. It is assumed
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that urinary oxalate output reflects intestinal 
absorption in this study. The increment in urinary 
oxalate following oxalate loading was calculated by 
subtracting the urinary oxalate excretion output 
during the placebo period from that during the loading 
period.
4.2. RESULTS.
4.2.1. Urine and plasma oxalate results.
The results of the preliminary study in two subjects 
showed that these subjects absorbed 18.1% and 15.9% of 
the oral sodium oxalate load over a 24 hour collection 
period. Most of the oxalate absorbed had been excreted 
in the first 6 hours of the collection. The 24 hour 
urine output in both subjects was within the normal 
range, 410 and 435 umol/24 hours.
The results of the double blind study involving seven 
subjects can be seen in figures 4.1 and 4.2. All these 
collections were performed over a six hour period. 
Details of the percentage of the load excreted during 
the collection times can be seen in figure 4.3 and 
table 4.1. The peak urine excretion period was the 2-4 
hour after loading. The urinary oxalate output 
increased between 4 times to 20 times the fasting 
level depending on the individual.
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FIGURE 4.1 URINARY OXALATE EXCRETION 
IN SEVEN FASTING SUBJECTS AFTER ORAL 
LOADING WITH OXALATE AND A PLACEBO
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FIGURE 4.2 PLASMA OXALATE LEVELS IN 
SEVEN FASTING SUBJECTS AFTER ORAL 
LOADING WITH OXALATE AND A PLACEBO
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Table 4.1. Data on the excretion of a 1.77 mmol
oxalate load in seven fasting subj ects over different
collection periods.
Urine Collection Period (hour)
0-2 0-4 0—6
Fraction 
of oxalate load 
excreted 
(n=7)
/
Mean (umol) 33.1 123 180.6
SD (umol) 21.3 17.8 19.1
CV (%) 64.3 14.4 10.5
Percentage 
of oxalate load 
excreted 
(n=7)
Mean (%) 1.9 6.9 10.2
SD (%) 1.2 1.2 1.3
CV (%) 63.0 18.2 12.6
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Peak plasma oxalate level after absorption was at 120 
minutes. Individuals varied slightly and one subject 
showed a second absorption peak at 240 minutes.
Paired t tests showed no significant difference in 
flow rate, calcium output or creatinine clearance 
between urine collections when oxalate loaded or on 
placebo. The only exception to this was the 4-6 hour 
urine calcium collection which was significantly lower 
(p<0.05) after the oxalate load. Table 4.2 shows the 
results of paired t tests on plasma and urine data. 
These t tests were performed between the loaded and 
placebo groups and between zero time and post loading 
time points within each group. No significant 
differences were seen in the urine and plasma oxalate 
results between the zero time samples and the 
subsequent collections when the placebo was taken.
4.2.2 Oxalate clearance and fractional excretion.
The results of the oxalate clearance and the 
fractional excretion of the two subjects initially 
investigated were calculated using plasma values at 
the mid point of urine collections. This assumes that 
this plasma value is near to the mean value during the 
urine collection period. Maximal clearance and 
fractional excretion occurred 4-6 hours after loading. 
Data on the oxalate clearance and the fractional 
excretion of the seven fasting subjects before and
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Table 4.2 Results of paired t tests on plasma and 
urine samples between a placebo and an oxalate load in 
seven normal fasting subjects. Data is also compared 
between zero time when oxalate loading and time points 
post loading.
PLASMA
Placebo
V
oxalate loaded
Zero time oxalate 
load sample v 
post load oxalate 
samples.
Time (min)
0 ns -
15 ns ns
30 ns ns
45 p<0.05 p<0.005
60 p<0.005 p<0.005
90 p<0.005 p<0.005
120 p<0.005 p<0.005
180 p<0.05 p<0.01
240 p<0.05 p<0.005
300 p<0.005 p<0.005
360 ns p<0.05
URINE
Placebo Pre load urine
V oxalate sample
oxalate loaded V post load oxalate
samples
Time (hr)
—2—0 ns
0-2 p<0.01 p<0.005
2-4 p<0.005 p<0.005
4—6 p<0.005 p<0.005
ns indicates no significant difference, 
Ï1 “ 7 •
For all data blocks
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after oxalate loading can be seen in figures 4.4 and 
4.5. There was no significant variation in either of 
these derived parameters during the monitoring period 
whilst the placebo was taken. They both showed a 
significant increase (p<0.05) after oxalate loading, 
during some of the collection periods. No significant 
increase was seen -2-0 and 0-2 hour but 2-4 and the 4- 
6 hour periods did show significant increases.
There was a strong positive correlation (r=0.91) 
between the fractional excretion of oxalate and the 
oxalate clearance in the subjects who had been loaded. 
In those who had not been loaded, the same parameters 
showed no significant correlation (r= <0.1). Urine
oxalate output in umol per collection period 
correlated with oxalate clearance (r=0.74) and 
fractional excretion (r=0.72) after loading.
In the placebo group oxalate clearance correlated 
(r=0.86) with urine oxalate output per unit time but 
fractional excretion did not (r=<0.1). Creatinine 
clearance showed no correlation with oxalate
clearance or fractional excretion after oxalate 
loading.
4.2.3 Blood ketones and glycerol.
Measurement of b hydroxybutyrate, acetoacetate and 
glycerol and the calculated total ketones showed no 
significant differences between placebo levels and
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FIGURE 4.4 OXALATE CLEARANCE IN SEVEN 
FASTING SUBJECTS AFTER ORAL LOADING WITH 
OXALATE AND A PLACEBO
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FIGURE 4.5 FRACTIONAL EXCRETION OF 
OXALATE IN SEVEN FASTING SUBJECTS AFTER 
ORAL LOADING WITH OXALATE AND A PLACEBO
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those after oxalate loading.
All subjects showed ketone production at time zero on 
both the placebo and the loaded study period. In the 
fed state ketone levels are undetectable. Glycerol was 
measured to indicate if significant triglyceride
breakdown was occurring as a result of fasting. No
significant difference was seen in glycerol levels 
between the placebo and oxalate loaded results. Data 
comparison was performed which showed that oxalate did 
not enhance ketogenesis in the peripheral circulation 
under the conditions defined. Data on individual 
subjects was compared for the change in ketones when
subjects took the placebo and the oxalate load. The
change was assessed at each time point by comparison 
to zero. The results were also analysed for the 
overall increase in ketone production from time zero 
to 360 minutes and compared with and without oxalate 
loading. Paired t test and t test of this data showed 
no significant difference. Results are shown in table
4.3.
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Table 4.3 Blood ketone production in fasting subjects 
with and without oxalate loading. Data is shown as 
mean (SEM) of seven subjects at each time point.
Time b-hydroxybutyrate Acetoacetate Total ketones
(min) (umol/1) (umol/1) (umol/1)
Pre Post Pre Post Pre Post
0 0.13
(0.07)
0.18
(0.07)
0.26
(0.08)
0.29
(0.05)
0.39
(0.15)
0.47
(0.12)
15 0.12
(0.06)
0.13
(0.05)
0.20
(0.05)
0.27
(0.05)
0.32
(0.10)
0.40
(0.09)
30 0.10
(0.04)
0.10
(0.02)
0.17
(0.04)
0.23
(0.02)
0.26
(0.08)
0.33
(0.04)
45 0.08
(0.03)
0.09
(0.02)
0.17
(0.03)
0.27
(0.04)
0.25
(0.06)
0.36
(0.06)
60 0.08
(0.03)
0.11
(0.03)
0.18
(0.03)
0.27
(0.03)
0.26
(0.06)
0.39
(0.05)
90 0.11
(0.05)
0.15
(0.03)
0.22
(0.05)
0.29
(0.02)
0.33
(0.10)
0.44
(0.05)
120 0.12
(0.04)
0.17
(0.03)
0.20
(0.03)
0.26
(0.04)
0.31
(0.07)
0.43
(0.07)
180 0.14
(0.05)
0.17
(0.03)
0.24
(0.05)
0.37
(0.01)
0.39
(0.10)
0.54
(0.11)
240 0.21
(0.06)
0.22
(0.04
0.33
(0.07)
0.40
(0.05)
0.54
(0.11)
0.62
(0.07
300 0.31
(0.08)
0.35
(0.04)
0.40
(0.09)
0.42
(0.08)
0.70
(0.17)
0.86
(0.14)
360 0.31
(0.07)
0.38
(0.02)
0.45
(0.15)
0.46
(0.08)
0.76
(0.22)
0.83
(0.10)
Overall increase from zero to 3 60 minutes
0.18 0.20 0.19 0.17 0.37 0.36
(0.07) (0.06) (0.05) (0.06) (0.14) (0.12)
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SECTION 2. ORAL INGESTION OF VITAMIN C TABLETS AND 
FOODSTUFFS CONTAINING OXALATE.
4.3. MATERIALS AND METHODS.
4.3.1. Subjects.
Five male and one female subject with normal kidney 
function were investigated. The age range was 3 0 - 38 
years. A separate group of subjects was used for the 3 
month ascorbate loading study. Two female, five male, 
age range 21-50. All subjects conformed to the same 
criteria as stated in section 4.1.1.
4.3.2. Study protocol.
After an overnight fast of 14 hours, all the 
volunteers ingested the load under investigation at
09.00 hours on the morning of the test. On a separate 
occasion the subjects continued fasting for the same 
collection period to establish basal levels. Fluid 
intake was unrestricted. Urine samples were collected 
in two hour periods from 0700 hours until 1500 hours. 
Plasma samples were taken at 0, 60, 180 and 360
minutes after loading.
This study was performed with lOOg of chocolate, 50g 
of chocolate (Bournville Plain, Cadbury Ltd., 
Bournville UK), 3g of coffee (Nescafe instant, Nestlé, 
Croydon UK) and Ig ascorbic acid (Redoxon effervescent
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tablets Roche Products Welwyn Garden City U.K.). The 
oxalate content of the chocolate was 199 mg of oxalic 
acid per lOOg. The oxalate intake for the lOOg was 
2.2mmol and for the 50g, 1.1 mmol. Coffee contained
4.2mg of oxalic acid per gram - the intake was 139 
umol.
An additional long term study was performed on 
ascorbate intake. A 24 hour urine was collected as a 
basal level whilst subjects were on their normal 
diets. Thereafter they took Ig of ascorbic acid a day 
for three months (Redoxon effervescent tablets Roche 
Products Welwyn Garden City U.K.). A twenty four hour 
urine sample and fasting plasma samples were collected 
once a month whilst subjects took the ascorbate. At 
the end of three months, subjects were given a one 
month wash out period when ascorbate tablets were 
discontinued. Then samples of blood and urine were 
collected for the final time. This study was performed 
from October to February.
4.3.3. Blood and urine measurements.
All samples collected had calcium, oxalate and 
creatinine measured by methods previously defined. 
Creatinine clearance and urine flow rate were 
calculated.
Ascorbate was measured in blood and urine where 
appropriate to ensure compliance, using the method of
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Foote, Fry and Starkey (1986).
4.3.4. Statistical analysis.
Statistical analysis was performed as in section 1.
4.4. RESULTS
4.4.1. Study with chocolate
Results of the urine output using lOOg and 50g of 
chocolate as the load can be seen in figure 4.6. There 
was a significant (p <0.005) increase in oxalate 
excretion from basal during the 2-4 hour and the 4-6 
hour urine collection periods after both loads. Plasma 
oxalate showed a significant increase (p<0.005) from 
basal levels at 90 and 180 minutes after loading with
50g (l.lmmol oxalate) and lOOg (2.2mmol oxalate) of
chocolate. Plasma results are expressed as mean +/- 
SEM of the six subjects. Results were as follows :- 
for the l.lmmol oxalate load, at zero time, 1.6 +/- 
0.37; 90 minute sample, 2.0 +/- 0.29; 180 minute
sample, 2.8 +/- 0.3: for the 2.2mmol oxalate load, at 
zero minutes, 1.7 +/- 0.34; at 90 minutes, 2.2 +/-
0.26; at 180 minutes, 2.9 +/- 0.33. Six hours after
loading with l.lmmol and 2.2mmol, 6% and 11.5% of the 
oxalate had been excreted in the urine respectively. 
The l.lmmol load gave oxalate excretion and plasma 
oxalate levels that showed no statistically
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significant difference from the 2.2mmol load. None of 
the subjects showed a significant difference in their 
creatinine clearance or urine flow rate during the 
collection period. Plasma calcium and urine calcium 
levels were measured in all the samples collected and 
no significant changes were observed from the basal 
levels. Calcium content of the chocolate was 64 mg per 
lOOg of chocolate.
Fractional excretion and oxalate clearance increased 
after loading with both 1. Immol and 2.2mmol of 
oxalate. Fractional excretion gave peak levels of 200% 
+/- 27.9 (mean +/-SEM) for the 2.2mmol load and 214% 
+/- 29.5 (mean +/-SEM) for the l.lmmol load. The
equivalent basal level was 47% +/- 9 (mean +/-SEM). 
Oxalate clearance gave peak levels of 188 ml/min +/-
18.2 (mean +/-SEM) for the lOOg load and 184 ml/min 
+/- 19.5 (mean +/-SEM) for the 50g load. The
equivalent basal level was 72.9 ml/min +/- 18.2 (mean 
+/-SEM). Peak fractional excretion and clearance was 
during the 4-6 hour collection period.
4.4.2. Study with coffee and ascorbate.
Results of both plasma oxalate and urine oxalate 
analysis showed no significant difference between 
basal results and during the coffee load. The same was 
found with ascorbate, even in the 3 month study. There
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was no significant difference between basal oxalate 
levels in plasma and urine, and those after ascorbate 
was taken. Compliance was confirmed by increased 
output of urinary ascorbate during the loading period. 
Results of the ascorbate studies are shown in figure 
4.7a and b and figure 4.8a and b. No significant 
difference was seen in the fractional excretion or 
oxalate clearance during the study period.
Inter- and intra- individual variation of plasma and 
urine oxalate during the five months of the long term 
ascorbate load was calculated as in section 3.6.2. 
Variation is expressed as SD. Results were as 
follows;- 24 hour urine collections, intra-individual 
variation 32.4umol, inter-individual variation 
44.6umol; plasma oxalate, intra-individual variation 
0.49umol/l, inter-individual variation not detectable. 
Using the F statistic and paired t test no significant 
variation could be found between collections.
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FIGURE 4.7a URINARY ASCORBATE AND 
OXALATE EXCRETION IN 7 SUBJECTS TAKING 
Ig OF ASCORBATE A DAY FOR 3 MONTHS.
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FIGURE 4.7b PLASMA OXALATE AND ASCORBATE 
LEVELS IN 7 SUBJECTS TAKING Ig OF 
ASCORBATE A DAY FOR 3 MONTHS.
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FIGURE 4.8a URINARY OXALATE AND 
ASCORBATE EXCRETION IN 6 SUBJECTS AFTER 
A Ig ORAL LOAD OF ASCORBIC ACID.
Hr-2-0 Hr 0-2 Hr 2-4
2 hourly urine collection periods
-Q- Oxalate -O- Ascorbate
Load was given at zero time 
All subjects had fasted overnight
Hr 4-6
FIGURE 4.8b PLASMA OXALATE AND ASCORBATE 
LEVELS IN 6 SUBJECTS AFTER A Ig ORAL 
LOAD OF ASCORBIC ACID
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SECTION 3. THE EFFECT OF THE WATER SUPPLY ON THE 
AVAILABILITY OF OXALATE FROM TEA.
4.5. MATERIALS AND METHODS.
The availability of oxalate from the infusion of tea 
bags was tested. Infusion times were varied and the 
water used was taken from different water supply 
areas.
All tea bags used were from the same manufacturer and 
batch and were weighed to ensure the same amount of 
tea was present in each bag. Tea was prepared in the 
same way for each experiment. Boiling water 
(deionised) , 150 ml, was added to a container which
had a tea bag in it. The tea was infused without any 
stirring or agitation of the bag. Timings were 
performed on a stop watch.
The amount of oxalate released after different 
infusion times was assessed. Tea was infused for 
2,4,6,8, and 10 minutes. The water was measured for 
oxalate before the infusion was started.
To assess the effect of the water supply on the 
availability of oxalate, water was collected from 
different areas in the south of England. The water was 
analysed for calcium and magnesium using atomic 
absorption spectroscopy. Samples of tea were prepared 
as above using a 10 minute infusion. The oxalate 
content was measured after extraction as described for
232
urine analysis.
4.6. RESULTS
4.6.1. Tea infusion time.
The results of the infusion experiment can be seen in 
figure 4.9. The data is displayed as mean +/- SD of 
five readings.
4.6.2 The effect of the water supply on oxalate 
availability.
The calcium content and magnesium content of the water 
supply used to infuse the tea, can be seen in table
4.4. Also in this table is the oxalate concentration 
after a 10 minute infusion of tea using each of the 
water samples. There was a negative correlation (r- 
0.85) between the calcium in the water supply and the 
oxalate released from tea leaves after infusion. 
Figure 4.10 shows the results. There was no 
correlation with the magnesium in the water supply.
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FIGURE 4.9 THE EFFECT OF THE INFUSION 
TIME OF A TEABAG ON THE OXALATE 
CONCENTRATION IN THE TEA
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FIGURE 4.10 THE EFFECT OF THE CALCIUM 
CONCENTRATION OF WATER ON THE SOLUBILITY 
OF OXALATE IN TEA
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Table 4.4 Calcium and magnesium concentration in 
different water supplies and the oxalate concentration 
found in tea made with the various waters.
Source Calcium
mmol/1
Magnesium
mmol/1
Oxalate 
concentration 
after 10 minutes 
infusion of tea.
Aldershot 1.80 0.15 371
Ascot 2.84 0.21 426
Alton 3.10 0.10 189
Horsham 1.50 0.16 928
Reading 2.44 0.14 646
Frimley 2.74 0.25 520
Deionised 0.02 0.05 1197
Ripley 3.00 0.23 167
Newport 0.74 0.15 1039
Bognor 2.26 0.60 859
Heatherside 2.36 0.22 726
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DISCUSSION.
The studies in this chapter use both the plasma and 
urine oxalate assays to investigate gut absorption and 
renal handling of oxalate.
During this study the assumption was made that oxalate 
is excreted exclusively by the renal route. There was 
a second assumption, that oxalate is freely 
filtratable at the glomeruli and not significantly 
protein bound. The work described in this thesis tends 
to support this second assumption although this is 
still under investigation (Schwille et al. 1989).
The peak absorption time in plasma, following an 
oxalate load, averaged 120 minutes in the subjects 
studied. This indicates that in normals the small 
intestine is probably the major site of oxalate 
absorption. In the two subjects studied over a 24 
hour time period, absorption did continue at least for 
10 hours. This also implies some degree of absorption 
along the whole length of the gut.
The percentage of the oxalate load absorbed was 
greater than some previous authors have reported 
(Rampton, Kasidas and Rose, 1979, Prenen, Boer and 
Dorhout Mees, 1984) and less than others (Tiselius et 
al. 1981). This probably reflects differences in the 
form in which the oxalate was given, the analytical 
method used and whether the subject was fasted, fed, 
or had taken a test meal.
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The loading of subjects with chocolate produced less 
absorption of the load than with sodium oxalate. The 
chocolate did contain some calcium, which is thought 
to reduce the oxalate available for absorption
(Batille et al. 1983). The chocolate contained 2.2mmol 
(lOOg of chocolate) and l.lmmol (50g of chocolate) of 
oxalate. The percentage absorption over 6 hours
varied, with a mean of 11.5% for the 1.1 mmol load and 
mean of 6.0% for the 2.2 mmol load. However, the 
actual amount of oxalate excreted in the urine was
very similar for both loads. This suggests that a
maximal absorption of oxalate occurs which is 
saturated at the lowest dose of oxalate. These results 
are in agreement with those found by Balcke et al 
(1985), who used an enzymatic method to measure
oxalate. The limited absorption may be due to the
intraluminal calcium concentration (Bataille et al. 
1984), the presence of oxalate degrading bacteria in 
the gut (Allison et al. 1986) or some control via a 
gut transport mechanism (Williams and Wandzilak,
1989).
The very small oxalate load from the coffee, 139umol, 
produced no change in plasma or urine oxalate
suggesting that at very low oxalate intakes little if 
any oxalate is absorbed.
An ascorbate intake of Ig in the short and long term 
studies did not modify oxalate levels in plasma or
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urine. This was an ascorbate intake in excess of the 
recommended daily dose (Levine, 1986) of 60 mg (USA), 
and of a similar intake to that quoted in dietary
studies by Trinchieri et al (1991). The results of
this study indicate that even over an extended period 
(3 months) , Ig of ascorbate a day will not affect 
oxalate levels in blood and urine in vivo. However, 
this may not be true for renal stone formers who may 
have a metabolic defect in handling ascorbate as
suggested by Cowley et al (1987) and by recent studies 
on the influence of diet on renal stone formation 
(Trinchieri et al 1991). Previous studies (Tiselius
and Almgard, 1977) that have demonstrated increased 
urinary oxalate output after subjects have taken Ig of 
ascorbate, may have suffered from in vitro conversion 
of ascorbate to oxalate due to methodological factors. 
The results of the long term ascorbate study also 
suggest that there is no significant biological 
variation of plasma or urine oxalate over a five month 
period. However, the subjects in this study took Ig of 
ascorbate a day, it is conceivable that a seasonal 
variation was disguised by increased urinary oxalate 
output from ascorbate. It could also be argued that 
any seasonal variation would cause problems of 
interpretation with regard to oxalogenesis from 
ascorbate. Although the work of Touitou et al (1983) 
demonstrated no biological variation in the urine
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oxalate output of normals over one year, supporting 
the contention that during this study there was no in 
vivo oxalogenesis of ascorbate. To fully investigate 
these factors studies would have to be performed on a 
group of subjects at the same time of year whilst they 
ate similar diets, first with, then without, ascorbate 
loading. Despite these arguments, the urinary oxalate 
excretion during the long and short term ascorbate 
studies did not enter the hyperoxaluric range. 
Therefore normals are not at increased risk of stone 
formation due to oxalogenesis from ascorbate. The 
ascorbate levels found in the urine and plasma after 
loading further demonstrated that ascorbate does not 
interfere in the current oxalate methodology.
The results of the absorption studies show that it is 
possible to have peaks of urinary oxalate output 
during a 24 hour period that could be a risk factor in 
a renal stone former. To investigate stone patients 
fully the effects of a post prandial oxalate level 
should be considered. The fasting urinary oxalate 
output shows no significant variation in this study, 
but after an oxalate load significant increases can be 
found. The results of this study and those from 
chapter 3 indicate that to identify a variation in 
oxalate output due to diet, urine samples may need to 
be collected 2 hourly. The results here show that very 
high concentrations of oxalate can be found in the
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urine on a transitory basis following meals and that 
24 hour urine analysis or even six hourly urine 
collections may not detect this. However, plasma and 
urine fasting oxalate showed no significant variation 
over the 8 hour period they were measured, indicating 
no inherent biological variation over this time 
period. These factors should be considered when 
collecting samples and interpreting results of oxalate 
analysis. The study of tea, made with water from 
different areas, shows that the calcium content of the 
water correlates inversely with oxalate avail able for 
absorption. This may be an important consideration for 
the bioavailability of oxalate in prepared foods and 
beverages, as the water and its calcium content could 
modify the risk factor to stone formers. This effect 
may also have contributed to the lack of diurnal 
variation found in the subjects studied in chapter 3. 
The renal handling of oxalate has been the subject of 
many studies but results are still limited. This has 
been due to a lack of reproducable and accurate 
methods for plasma oxalate. Much of the data produced 
to date has relied on oxalate infusion studies.
The results presented here on the renal handling of an 
oxalate load has demonstrated an increased clearance 
of oxalate after loading and a change of fractional 
excretion. The increase in the fractional excretion 
after loading to greater than 100%, suggests tubular
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secretion of oxalate. This is in contrast to the net 
tubular absorption before loading or during fasting, 
when fractional excretion is less than 100%. This may 
explain some of the conflicting results on oxalate 
clearance and fractional excretion that have been 
reported. These results would be consistent with the 
work of Knight, Sansom and Senekjian (1981) suggesting 
two transport mechanisms. It is postulated that within 
the proximal tubule, there is a high affinity low 
capacity system operating at low plasma oxalate levels ‘ 
and a high capacity low affinity system at high plasma  ^
oxalate concentrations. These results are consistent 
with the renal handling results found in chapter 3 on 
non fasting and fasting subjects. It suggests in both ' 
cases that subjects have adapted to oxalate loading.
The loading studies indicate an ability to remove 
large quantities of oxalate, which might be expected 
from a useless end product of metabolism. There is 
however some control on oxalate loss at low levels, 
that may indicate a form of homeostasis and a possible 
undefined role for this substance.
The work of Demargue, Cepanec and Leroux (1978) and 
Buc et al (1982, 1983), on isolated hepatocytes from
rats, suggested that oxalate may enhance ketogenesis. 
This was investigated during the loading study. No 
significant effect was was observed on b- 
hydroxybutyrate, acetoacetate or total ketone levels.
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Glycerol was measured as a marker of triglyceride 
breakdown during fasting. None of these showed any 
change between the placebo and the oxalate loaded
group.
All subjects were ketotic after fasting and they were 
assessed for the effects of oxalate on ketogenesis. 
The concentrations of oxalate used by the previous
workers mentioned were 10 to 20 fold higher than those 
produced by loading in this study. The lower oxalate 
concentration here may account for the lack of
response. However, the work on isolated rat
hepatocytes reflects intracellular metabolism and the 
peripheral blood levels in the human subjects may not 
reflect intracellular metabolism directly.
A recent review (Conyers 1990) of endogenous oxalate
production suggests that the role of minor pathways of 
carbohydrate metabolism in oxalate production may be 
of importance in the study of urolithiasis. The
possible effect of oxalate on enzymes involved in 
carbohydrate metabolism may be of importance in
shedding light on the part these pathways play in
oxalate production. Further studies are required to 
investigate these possibilités.
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CHAPTER 5. APPLICATION OF OXALATE METHODS TO THE STUDY 
OF OXALATE METABOLISM IN IDIOPATHIC CALCIUM OXALATE 
STONE FORMERS.
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INTRODUCTION.
Over the last two decades there has been increasing 
interest in oxalate metabolism, particularly in 
patients who suffer from idiopathic calcium oxalate 
nephrolithiasis. Studies in this area have been 
hampered by methodolgical problems. The development of 
reliable methods for the determination of oxalate in 
urine and plasma, and the establishment of normal 
ranges as described in the previous chapters of this 
thesis, enable patient data to be evaluated with 
confidence.
Interest in oxalate and its role in idiopathic calcium 
oxalate nephrolithiasis derives from the following 
observations:- (1) The urine of stone patients tends 
to be more highly saturated with calcium oxalate than 
that of normal subjects (Robertson, Peacock and 
Nordin, 1968). (2) Urine oxalate concentration has a
much greater relative effect on urine supersaturation 
than does calcium concentration (Robertson and 
Peacock, 1980). (3) The more contentious issue of the
urinary oxalate output of stone formers which many 
(Broadus and Thier, 1979, Cohanim and Yendt, 1980 and 
Robertson et al. 1978) but not all (Tiselius, 1977, 
Pak et al. 1980) workers believe to be higher than 
that found in normals. The incidence of hyperoxaluria 
in stone formers is a matter of debate and will be 
investigated in this chapter using a group of
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ambulatory idiopathic calcium oxalate stone formers. 
This group of stone formers was investigated with 
respect to several aspects of oxalate metabolism, 
based on the findings of previous chapters and some of 
the current ideas on oxalate metabolism in renal stone 
formers (Baggio et al. 1986) . All the patients in this 
study have passed at least one stone and have been 
referred from a Urological Outpatients Department to a 
Consultant Chemical Pathologist for metabolic study. 
Much attention has been given to the role of 
hypercalciuria in idiopathic renal stone formation. 
Several classifications have been applied to 
hypercalciuric patients to divide them into groups and 
subgroups (Pak et al. 1975) but little has been done 
to define the origins and control of hyperoxaluria in 
the same way. This deficency has to a large degree 
been due to analytical problems. There is no doubt 
that calcium plays a significant role in the 
bioavailability of oxalate in renal stone formers 
(Bataille et al. 1983, Erickson et al. 1984) but in 
this chapter the emphasis will be on oxalate 
metabolism. During one of the twenty four hour urine 
collections in this study, sodium cellulose phosphate 
was given to the patient. This has been shown to 
modify the bioavailabilty of oxalate in the gut 
(Hayashi, Kaplan and Pak 1975) via its effect on 
calcium.
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Previous chapters have highlighted the effect of diet 
on oxalate output in the urine. The diet can contain 
oxalate or oxalate precursors. Some of the potential 
precursors are present in animal protein (Goldfarb 
1988; Hofmann et al 1983) , though the importance of 
these is contested by a recent study of dietary intake 
in stone formers (Trinchieri et al 1991). In this 
chapter, preliminary investigations are described 
using 24 hour urines and 2 hour fasting urines to try 
and discover whether diet contributes significantly to 
abnormal oxalate excretion in stone formers.
In 1978 Hodgkinson found no significant difference in 
fasting urinary oxalate output between stone formers 
and normals, while others have observed an increased 
output in stone formers on fasting (Drach, Perin and 
Jacobs, 1979). Schwille et al (1989) comments that the 
investigation of fasting urines has been neglected and 
that the data that exists is contradictory. In this 
study, fasting oxalate output in normoxaluric and 
hyperoxaluric stone patients is compared to that of 
controls in order to establish if oxalate is produced 
from a non dietary source.
Work with idiopathic calcium oxalate stone formers has 
rarely included the measurement of plasma oxalate and 
consequently the renal handling of oxalate. More 
recently however, some workers have looked at the 
renal handling of oxalate in calcium oxalate stone
246
formers, in the context of urinary calcium output 
(Schwille et al. 1989) or as an undefined group of 
idiopathic stone formers (Wilson et al. 1988). In the 
study presented here, the renal handling of oxalate is 
examined in the fasting state both in normoxaluric and 
hyperoxaluric patient groups. It was anticipated that 
such studies might provide more information on the 
source of oxalate especially in hyperoxalurics.
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5.1. MATERIALS AND METHODS.
5.1.1. Clinical data on renal stone patients.
This study was performed on 127  ambulatory patients 
who had formed calcium oxalate stones, 34% were single 
stone formers and 64% were recurrent stone formers. 
Control subject data was derived from results reported 
in chapter 2. The stone forming population was 
composed of 27 female subjects and loo  male subjects, 
with a mean age of 4 8 . 8  years and a range of 1 8 - 8 2 .  
The 91  control subjects had a mean age of 3 3 . 2  years 
with a range of 21  to 58 and were composed of 52 males 
and 39 females. Each stone patient had been referred 
to a urological outpatients clinic after he/she had 
passed a stone or had had one removed surgically.
All stone patients had normal renal function as 
defined by plasma creatinine and urea levels within 
the adult reference range. None of the subjects had an 
acute urinary tract infection or a history of 
intestinal ^at malabsorption or of ileal disease. 
Patients with suspected parathyroid disease were 
excluded, which resulted in all the patients in the 
study being normocalcaemic.
5.1.2. Study protocol.
Subjects were assessed by an ambulatory protocol that 
involved the following procedure; Patients were asked
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to collect three 24 hour urines during a 2 week period 
whilst receiving their normal home diet. The samples 
were brought into the laboratory immediately following 
completion and appropriate storage conditions were 
adopted (Ng, Menon and Ladenson, 1984). All samples 
were analysed within seven working days of receipt. 
Following the first twenty four hour collection a 2 
hour urine was collected after an overnight fast (12 
hours) and a venous blood sample was taken.
During the final 24 hour collection and the preceeding 
24 hours, lOg of sodium cellulose phosphate was taken 
to chelate calcium in the gut. This was in preparation 
for a calcium loading test described below. Patients 
were assessed using calcium loading as recommended by 
Pak et al (1975): Subjects fasted from 19.00 hours the 
night before the test, but were allowed to drink 
water. At 07.00 hours on the morning of the test, the 
bladder was emptied and a 2 hour fasting sample was 
collected from 07.00 to 09.00 hours. At 09.00 hours a 
venous blood sample was taken for laboratory 
estimations. The patient was then given a Ig calcium 
load. A four hour urine was collected from 09.00 to
13.00 hours.
5.1.3. Analytical tests.
The three 24 hour urines had their volumes measured 
and were analysed for creatinine, calcium, magnesium.
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oxalate, citrate and urate. Urine flow rate in ml/min 
was calculated from the volume and time of collection. 
The 2 hour fasting urine had its volume measured and 
was analysed for oxalate and creatinine and the blood 
sample for oxalate and creatinine. The urine samples 
from the loading study were analysed for calcium and 
creatinine. The fasting venous blood sample at 09.00 
hours was analysed for calcium, creatinine.
Creatinine was measured by the Jaffe reaction, and 
urate by an enzymatic uricase method (Sigma Chemical 
Company Ltd., Poole, Dorset, UK, catalogue number 
292) . Both were analysed on a routine clinical 
chemistry analyser, the Cobas Bio (Roche Products 
Ltd., Welwyn Garden City, UK) . Calcium and Magnesium 
were measured by atomic absorption spectroscopy. 
Oxalate was analysed by the methods described in this 
thesis and citrate enzymatically using a kit from 
Boehringer Mannheim (Lewes U.K.), catalogue number 
139076.
5.1.4. Statistical analysis and evaluation of data
5.1.4.1. 24 hour urine oxalate output.
Data from the three 24 hour urine oxalate collections 
were examined for the assessment and determination of 
the incidence of hyperoxaluria. (Hyperoxaluria was 
defined as a urine oxalate output greater than 490
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umol/24 hours). This involved examining the incidence 
of hyperoxaluria in each of the three 24 hour 
collections separately, and in all the urines 
collected. Data on the urines was used to examine how 
consistently hyperoxaluria was found within 
individuals. The effect of sodium cellulose phosphate 
on the urinary oxalate output was also investigated. 
This required further evaluation of the data, with and 
without the third twenty four hour collection.
The first two 24 hour urine collections were used to 
investigate urinary oxalate output with respect to its 
distribution, any sex related differences, urine flow 
rate (ml/min), creatinine clearance, calcium 
absorption during calcium loading tests, and the 
patient's age.
The first two urine collections were also used to 
evaluate 24 hour urinary oxalate output in relation to 
magnesium, citrate, urate and calcium. Oxalate output 
was tested for correlation to these parameters 
overall. Then the parameters were subdivided for 
further evaluation.
The subdivisions were as follows
(a) Hypercalciuria (>8.5 mmol/24 hours)
(b) normocalciuria (<5.0 mmol/24 hour)
(c) normouricosuria (<4.0 mmol/24 hour)
(d) hyperuricosuria (>5.5 mmol/24 hour)
(e) hypocitraturia (<1.5 mmol/24 hour)
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(f) normocitraturia (>3.0 mmol/24 hour)
(g) hypomagnesuria (<3.0 mmol/24 hour)
(h) normomagnesuria (>5.0 mmol/24 hour).
The subdivisions were tested to see if there was a 
significant difference between their associated 
urinary oxalate outputs within each parameter and also 
compared to the normal population.
5.1.4.2. Fasting urine oxalate output.
Fasting data is expressed in umol/1, oxalate: 
creatinine ratio (mmol/1:mmol/1) and umol/min output. 
Data is compared and evaluated using the last two 
parameters.
The 2 hour fasting urine oxalate levels in patients 
(n = 107) were compared to the fasting levels in
normal subjects (n = 58) with regard to distribution, 
creatinine clearance and sex related differences. The 
fasting data was tested to see if significant 
differences occurred in the urines of normoxaluric and 
hyperoxaluric patients as defined in the first two 24 
hour collections. Data was also evaluated to see if 
the incidence of hyperoxaluria in 24 hour collections 
related to the fasting urine oxalate output.
Fasting oxalate levels were examined in relation to 
the sub divisions defined in section 5.1.4.1. Fasting 
oxalate results were tested for significant 
differences between sub divisions and for correlation
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with the 24 hour urine output. The fasting output was 
also considered in relation to the calcium loading 
test.
5.1.4.3. Plasma oxalate and renal handling of oxalate.
Two groups of renal stone patients were evaluated. The 
first consisted of twenty six idiopathic calcium 
oxalate stone formers, the second twenty nine and both 
were evaluated for the renal handling of oxalate. The 
first group were sub divided as normocalciuric (n=16) 
and hypercalciuric (n=10). Hypercalciuric subjects had 
a urinary calcium output greater than 7.5 mmol/24 
hours. The second group were divided according to 
their urine oxalate output. The group consisted of 12 
patients who had hyperoxaluria on at least one 
occasion and 17 patients who were normoxaluric. All 
the patients were fasting and normouricosuric. 
Measurement of plasma oxalate, oxalate clearance, 
fractional excretion and creatinine clearance were 
estimated in each group. These results were compared 
to those found in normals and between patient groups.
5.1.4.4. Statistical analysis.
Data was tested for normal distribution by the Chi 
square goodness of fit test. Normally distributed data 
were tested for any significant difference between 
means, by using the standard error of the differences
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between two means or a t test, depending on the size 
of the sample. Variance was tested by the F test. Non 
parametric analysis used the Mann-Whitney test for the 
difference between means and the Kruskal-Wallis test 
for the analysis of variance. The correlations were 
calculated using linear regression analysis, with 
confirmation of the significance of this correlation 
by Spearman's rank correlation coefficient or the 
Fisher Z transformation.
5.2. RESULTS.
5.2.1. Twenty four hour urine collections.
5.2.1.1. Incidence of hyperoxaluria.
It was found that hyperoxaluria did not always occur 
in all three urine samples collected from any one 
individual. Of the 127 patients studied, 6 (4.7%) had
hyperoxaluria on all three occasions, 10 (7.9%) on
two occasions and 27 (21.2%) had hyperoxaluria in only 
one of the three samples. In total, 43 (33.9%)
patients had hyperoxaluria in at least one of their 24 
hour urines (20 (15.7%) patients in collection 1, 17
(13.4%) patients in collection 2 and 26 (20.5%) in
collection 3) .
As sodium cellulose phosphate was taken during the 
third urine collection, re-evaluation of the incidence
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of hyperoxaluria ignoring the third urine was 
appropriate. This re-evaluation showed hyperoxaluria 
occurring in 21 (16.5%) out of 127 patients on only
one occasion, and in 8 (6.2%) patients on more than
one occasion. This gives a total of 29 (22.8%) out of 
127 patients having hyperoxaluria on at least one 
occasion. Five (5.5%) of the 91 normal subjects 
studied in chapter 3 were hyperoxaluric (urinary 
oxalate output above 490 umol/24 hours).
The data were inspected to see if a relationship 
existed between the incidence of hyperoxaluria within 
individuals and the 24 hour urinary oxalate output 
during hyperoxaluric episodes. It was found that there 
was no statistically significant difference between 
patients' urinary oxalate output when data was grouped 
according to incidence. Results can be seen in table
5.1.
5.2.1.2. 24 hour urinary excretion of oxalate in
idiopathic calcium oxalate stone formers.
The 24 hour urine excretion of oxalate from the first 
two 24 hour collections for the entire stone forming 
group was 345 umol +/- 13 6 (mean +/- standard
deviation) and in the normal group of 91 subjects it 
was 303 umol +/- 97. The urinary oxalate excretion was 
significantly higher (p<0.005) in the stone forming 
group.
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Table 5.1 The relationship of the incidence between 
hyperoxaluria found within individuals and the 24 hour 
urinary oxalate output during hyperoxaluric episodes.
n Mean SD
(umol/24 hour)
Data on patients with hyperoxaluria excluding the 
third urine collection.
Patients with hyperoxaluria:
on only one
occasion 21 573 46
on two
occasions 8 581 62
Data on patients with hyperoxaluria including the 
third urine collection.
Patients with hyperoxaluria: 
on only one
occasion 27 582 111
on two
occasions 8 601 68
on all three
occasions 6 593 62
No significant difference was found between any of the data 
blocks» n is the number of patients in each group.
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When the first two 24 hour urinary oxalate collections 
from all the patients were grouped as normoxaluric and 
hyperoxaluric, the results were 3 01 umol +/- 93 and 
588 umol +/- 66 respectively. The normoxaluric group 
showed no significant difference from the normal 
subjects, in either mean value or standard deviation. 
The hyperoxaluric group showed a significant 
difference (p<0.005) from normals as was expected. 
Figure 5.1 shows the distribution of hyperoxaluria and 
normoxaluria seen in the first two 24 hour urine 
collections.
Table 5.2 gives details of data from all three urine 
collections and demonstrates the effect on the overall 
mean and standard deviation of the third urine 
collection. The third urine collection, during which 
sodium cellulose phosphate was taken, had a higher 
mean value than both the previous collections. This 
was however, only a statistically significant 
difference (p<0.05) with respect to the second urine 
collection. The overall mean for all the urines 
measured did rise significantly (p <0.05) if the third 
urine samples were included.
The results of the data from the different urine 
collections are shown when grouped as normoxaluric and 
hyperoxaluric in table 5.3. The mean and standard
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Table 5.2 Data on the 24 hour urine oxalate output in 
127 idiopathic calcium oxalate stone formers. Each 
patient collected three 24 hour urines over a 2 week 
period.
n Mean SD p % of patients
(umol/24h) (versus hyperoxaluric 
normals)
Normal 
Subj ects
91 303 97 5.5
Patient data
1st 24 hour 127 348 143
collection
2nd 24 hour 127 342 130
collection
3rd 24 hour 127 376 148
collection
1st and 2nd 254 345 136
24 hour
collections
1st, 2nd and 381 367 193
3rd 24 hour
collections
<0.005
<0.01
<0.005
<0.005
<0.005
15.7
13.4
20.5
22.8
33.9
n is the number of urines analysed. The percentage of patients 
hyperoxaluric indicates the percentage that were hyperoxaluric in 
at least one of the urines in that data block.
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Table 5.3 Details of data on the normoxaluric and 
hyperoxaluric groups in each of the three 24 hour 
urine collections.
n Mean
(umol/24
SD
hour)
p (versus 
normals)
Normal 
Subj ects
91 303 97 -
Normoxaluric patient data
1st 24 hour 
collection
107 299 96 ns
2nd 24 hour 
collection
110 302 90 ns
3rd 24 hour 
collection
101 316 89 ns
Hyperoxaluric patient data
1st 24 hour 
collection
20 592 74 <0.005
2nd 24 hour 
collection
17 583 56 <0.005
3rd 24 hour 26 597 111 <0.005
collection
There was no statistically significant difference between the 
third 24 hour urine collection and the preceding two, n is the 
number of urines used in each data block.
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deviation of the normoxaluric group does not differ 
significantly from the normal subjects.
5.2.1.3. The effect of gender and age on 24 hour 
urinary oxalate output.
The first two 24 hour urine collections were examined 
for sex related differences in output of oxalate. It 
was found that only 3 out of 54 (5.6%) of the female
u r i n e s  showed hyperoxaluria. A similar percentage 
(5.5%) was found in normal subjects. In male patients, 
34 out of 200 (17%) were found to be hyperoxaluric.
The distribution of male and female 24 hour urinary 
output can be seen in figure 5.2 a and b. Normal 
subjects showed no sex related difference with regard 
to 24 hour urinary oxalate output, as shown in chapter 
3, table 3.0^ Likewise the normoxaluric patients here 
showed no difference. The data on male and female 
patients can be seen in table 5.4. There was no 
correlation between age and the 24 hour urinary 
oxalate output in the patients studied (r<0.1).
5.2.1.4. Relationship of 24 hour urinary oxalate 
output to other urine parameters.
The 24 hour urinary oxalate output in the first two 
urine collections were examined for correlation with 
the 24 hour urinary output of calcium, urate, citrate, 
creatinine and magnesium. Correlation studies between
?
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Table 5.4 Data on the male and female output of 24 
hour urinary oxalate in the first two 24 hour urine 
collections.
n Mean SD 
(umol/24 hour)
p(versus 
normals)
Normal 52 3 03
Urine
Male
100 -
Normal 39 304
Urine
Female
91
Data on urine from male patients 
hour urine collections.
in the first two 24
All urines 200 355 
Male
138 <0.05
Hyperoxaluric 34 583 
Male
60 <0.005
Normoxaluric 166 304 
Male
92 ns
Data on urine from female patients 
hour urine collections.
in the first two 24
All urines 54 3 09 125 ns
Female
Hyperoxaluric 3 571 30 <0.005
Female
Normoxaluric 51 289 95 ns
Female
There was a significant difference between the overall male and 
overall female patient data (p<0,05).
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the 24 urinary oxalate output and the subdivisions of 
these urine parameters, as defined in section
5.1.1.4., were also undertaken. Results can be seen in 
table 5.5.
The mean and standard deviation of the 24 hour urinary 
oxalate output from the samples in the creatinine, 
urate and calcium subdivisions are shown in table 5.6. 
The data was tested to see if there were significant 
differences with respect to normal subjects and
between the sub divisions within each parameter. When 
the significance of urinary oxalate output in the 
calcium sub divisions was tested for, the definition 
of hypercalciuria in section 5.1.4.1. - table 5.5 was 
a urinary calcium output > S'5 nimo/y/^4 A O U  rS which
showed a significant difference from the 
normocalciuric group. However, if the definition of
hypercalciuria is taken as 7.5 mmol/24 hours (the
upper limit of the reference range) then no
significant difference in 24 hour urinary oxalate 
output was found between normocalciuric (343 umol +/- 
13 6) and hypercalciuric (349 umol +/- 140) groups.
Hypomagnesuric and hypocitraturic groups showed no
significant difference from normals in their 24 hour 
urinary oxalate output.
There was a highly significant difference (p<0.005) 
between the 24 hour urine volume of stone formers 
(2196 ml +/- 850) and normals (1525 ml +/- 694). A
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Table 5.5 Correlation of 24 hour urinary oxalate with 
various patient groups.
nParameter
measured
Calcium 254
Urate 254
Creatinine 254
Magnesium 254
Citrate 254
Normo- 7 6
calciuric
(<5.0 mmol/24 hr)
Hyper- 68
calciuric
(>8.5 mmol/24 hr)
Normo- 184
uricosuric
(<4.0 mmol/24hr)
Hyper- 22
uricosuric
(>5.5 mmol/24hr)
Creatinine 39
(>17 mmol/24hr)
Hypomagnesuric 31 
(<3.0 mmol/24hr)
Hypo- 21
citraturic
(<1.5 mmol/24hr)
Correlation with 
24 hour urinary 
oxalate output
0.14
0.38
0.18
0.21 
0.11
0.17
0.32
0.16
0.27
0.32
0.18
0.10
<0.05
<0.005
<0.05
ns
ns
ns
<0.01
<0.05
<0.005
<0.05
ns
ns
Each correlation was tested for significance, n is the number of 
samples per data block.
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Table 5.6 Values for 24 hour urinary oxalate output 
in those patient groups showing a correlation with 
this parameter.
n Mean SD 
(urinary oxalate) 
(umol/24 hour)
p (versus 
normals)
Normal 
Subj ects
91 303 97 -
Normo-
uricosuric
group
184 316 121 ns
Hyper-
uricosuric
group
22 444 153 <0.005
Significance of means between urate groups p<0.005
Normo­
calciuric
group
76 320 133 ns
Hyper­
calciuric
group
68 359 140 <0.01
Significance of means between calcium groups p<0.05
Creatinine 
(<17 mmol/ 
24 hour)
198 334 225 ns
Creatinine 
(>17 mmol/ 
24 hour)
56 432 138 <0.005
Significance 
p<0.005
of means between creatinine groui
n Is the number of urine samples
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weak positive correlation (r=0.15, p<0.05) was found
between urine flow rate (ml/min) and urinary oxalate 
output (umol/min).
A significant positive correlation (r=0.33, p<0.005)
was found between 24 hour urinary oxalate output and 
creatinine clearance. There was also significant 
difference (p<0.005) in the creatinine clearance 
between normocalciurics (155 ml/min +/-82) and 
hypercalciurics (244 ml/min +/-118), normouricosurics 
(164 ml/min +/- 79) and hyperuricosurics (254 ml/min 
+/-135) and finally the normoxalurics (177 ml/min +/- 
84) and the hyperoxalurics (254 ml/min +/-135). Normal 
subjects had a 24 hour creatinine clearance of 97.3 
ml/min +/-27.6.
5.2.1.5. 24 hour urinary oxalate output and the
calcium load test.
Patients defined as absorptive hypercalciuric (n=66) 
by the criteria of Pak et al (1975) had 24 hour 
urinary oxalate outputs (3 65 umol +/-155) 
significantly (p<0.005) higher than 91 normal subjects 
(303 umol +/-97) . Ten patients with renal 
hypercalciuria (325 umol +/-91) showed no significant 
difference from normal.
5.2.2. Fasting urine collections.
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5.2.2.1. Fasting urinary oxalate excretion in
idiopathic calcium oxalate stone formers.
The fasting urine oxalate results are presented as 
concentration (umol/1), oxalate:creatinine ratio and 
umol of oxalate produced per minute. The distribution 
of these results in the stone forming group studied 
can be seen in figures 5.3a and b to 5.5a and b, where 
they are compared to the distribution of normals. The 
oxalate: creatinine ratio approximates to a normal
distribution in stone formers. The fasting urine 
oxalate data on patients was examined in relation to 
their 24 hour urinary oxalate output of the first two 
24 hour urine collections. Four groups were examined:- 
(1) patients with normal 24 hour urinary excretion of 
oxalate, (2) patients with hyperoxaluria in at least 
one 24 hour collection, (3) patients with 
hyperoxaluria in only one 24 hour urine collection, 
(4) patients with hyperoxaluria in both collections. 
The results of groups 1 and 2 can be seen in table 
5.7.
Between groups 1 and 2 there were significant 
differences in oxalate : creatinine ratio (p<0.05) and 
urinary oxalate output umol/min (p<0.05) but no 
significant difference in urinary oxalate 
concentration. Comparison between groups 3 (n=19) and
4 (n=8) showed no statistically significant
differences, but the means of the oxalate :
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FIGURE 5.3a DISTRIBUTION OF FASTING 
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FIGURE 5.4a DISTRIBUTION OF FASTING 
URINE OXALATE CONCENTRATION (UMOL/L) IN 
IDIOPATHIC CALCIUM STONE FORMERS
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FIGURE 5.5a DISTRIBUTION OF FASTING 
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Table 5.7 Results of the fasting urine oxalate 
analysis in patients with normoxaluria and
hyperoxaluria (hyperoxaluric on at least one
occasion).
Ox/Great umol/1
ratio oxalate
umol/min flow rate 
oxalate ml/min
Fasting normals n=58
Mean 0.012 133.6 0.12 1.4
SD 0.007 115.0 0.12 1.0
Normoxaluric stone formers n=80
Mean 0.021 84.2 0.25 3.8
SD 0.009 66.6 0.18 2.1
p (versus <0.005 
normals)
<0.005 <0.005 <0.005
Hyperoxaluric stone formers n=27
Mean 0.031 90.1 0.35 3.8
SD 0.022 53.0 0.28 1.6
p (versus <0.005 
normals)
<0.005 <0.005 <0.005
Normoxalurics versus hyperoxalurics
p <0.05 ns <0.05 ns
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creatinine ratio were higher in group 3 than group 4.
5.2.2.2. The effect of creatinine clearance and urine 
flow rate on fasting urinary oxalate measurements.
Creatinine clearance correlated significantly (r=0.57, 
p<0.005) with oxalate output in umol/min in patients. 
This also occurred in normals (r=0.46, p<0.01).
Creatinine clearance did not correlate significantly 
with oxalate concentration (umol/1) or oxalate : 
creatinine ratio.
There was no significant difference between the
creatinine clearance from the normal subjects (100.2 
ml/min +/-3 0.2) and the normoxaluric stone forming 
groups (95.8 ml/min +/-30.7), but there was a 
significant difference (p<0.005) with the 
hyperoxaluric stone formers (139.8 ml/min +/-51).
Urine flow rate (ml/min) gave a significant positive 
correlation with urine oxalate concentration umol/1 
(r=0.44, p<0.005) and urine oxalate output umol/min
(r=0.47, p<0.005) in the stone formers. This had also 
been seen in normals (r=0.25, p<0.01; r=0.68,
p<0.005). The relationship of urine flow rate to
oxalate concentration and urine flow rate in stone 
formers can be seen in figures 5.6 and 5.7.
There was no significant difference between any of the 
stone forming groups defined with respect to urine 
flow rate, but there was a significant difference
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FIGURE 5.6 RELATIONSHIP BETWEEN URINE 
FLOW RATE (ML/MIN) AND URINARY OXALATE 
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(p<0.005) between normal subjects (1.9 ml/min +/-1.1) 
and stone formers (3.8 ml/min +/-1.6).
Urine creatinine concentration did not differ 
significantly among the stone forming groups, but 
there was a significant difference (p<0.005) between 
normals, 11.9 mmol/1 +/-7.7, and stone formers, 4.1 
mmol/1 +/—3.5.
5.2.2.3. The incidence of abnormal fasting urine 
oxalate results.
The incidence of fasting urines which were outside the 
normal fasting ranges defined in chapter 3 were, 27.1% 
for oxalate : creatinine ratio and 42.0% for oxalate
output in umol/min. In the case of urine oxalate 
concentration, only one sample or 0.8% was outside the 
normal range.
5.2.2.4. Relationship of fasting urine to 24 hour 
urine parameters.
Using the entire data on the first 24 hour urine 
collection, no significant correlation was found 
between any of the fasting oxalate measurements and 24 
hour outputs of calcium, urate, citrate and magnesium. 
The only exception was 24 hour creatinine excretion 
that gave a positive correlation (r=0.21, p<0.01) with 
oxalate ; creatinine ratio.
However, there were some correlations between the
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fasting data and some of the subdivisions of the 24 
hour collections as defined in section 5.1.4.1. There 
was a significant positive correlation (p<0.005) 
between the oxalate:creatinine ratio and the 
normouricosuric (r=0.25), normal 24 hour urinary 
creatinine (r=0.30) and normocalciuric (r=0.39) 
groups.
The fasting urinary oxalate parameters measured in 
each of the sub divisions defined in section 5.1.4.1, 
demonstrated no statistically significant differences 
within any of the urine chemistries measured. Results 
can be seen in table 5.8.
5.2.2.5. Fasting urinary oxalate parameters and the 
calcium loading test.
Patients were assessed by the calcium loading criteria 
of Pak et el (1975) and were catagorised as stated in 
section 5.2.1.5. None of the groups showed any 
correlation with the fasting oxalate parameters.
5.2.3. Plasma oxalate and the renal handling of 
oxalate in idiopathic calcium stone formers.
Results of the patients grouped according to 24 hour 
calcium output were as follows. There was a 
significant (p<0.005) positive correlation (r=0.45) 
between creatinine clearance and oxalate clearance in 
the entire patient group. Fractional excretion of
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Table 5.8 Fasting urinary oxalate results from 
various patient groups.
Group
oxalate
n ®0x/Great ^umol/1 ®umol/min 
ratio oxalate
Normal 59 0.012
(0.007)
133.6
(115.0)
0.12
(0.12)
Normouricosuric 78 0.024 87.1 0.26
(0.013) (67.2) (0.18)
Hyperuricosuric 10 0.022 84.4 0.34
(0.008) (46.3) (0.28)
Normocalciuric 36 0.028 92.6 0.31
(0.014) (47.0) (0.24)
Hypercalciuric 34 0.024 113.9 0.30
(0.017) (94.6) (0.27)
Normocitraturic 79 0.023 87.4 0.26
(0.014) (51.7) (0.18)
Hypocitraturic 18 0.026 112.0 0.35
(0.013) (84.1) (0.27)
Normomagnesuric 51 0.028 91.6 0.45
(0.014) (53.3) (0.36)
Hypomagnesuric 15 0.025 92.1 0.29
(0.015) (72.7) (0.21)
Creatinine 89 0.027 89.9 0.28
(<17 mmol/24hr) (0.024) (66.3) (0.18)
Creatinine 35 0.024 90.6 0.31
(>17 mmol/hr) (0.017) (59.0) (0.26)
n = number of patients» “Results are displayed as mean (+/•
standard deviation)» No significant differences were founi
between sub divisions»
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oxalate correlated highly significantly (p<0.005) with 
oxalate clearance (r=0.83). The results are shown in 
tables 5.9 and 5.10.
Results of patients grouped according to 24 hour 
urinary oxalate output can be seen in table 5.11 and 
5.12. No correlation was found between any of the 
parameters in the patient groups and creatinine 
clearance. In the normoxaluric group, urine flow rate 
correlated with fractional excretion (r=0.44, p<0.05)
and oxalate clearance (r=0.48, p<0.05).
All renal handling data was derived from fasting 
samples.
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Table 5.9 Renal handling of oxalate in normocalciuric 
and hypercalciuric renal stone formers.
Parameter
measured
Normals ®NC 4iC
n 32 16 10
Calcium 4.8 5.2 11.3
mmol/24 hour (1.7) (1.6) (3.0)
Oxalate 303 294 376
umol/24 hour (97) (104) (103)
Urinary oxalate: 0.014 0.025 0.024
creatinine ratio 
mmol:mmol
(0.014) (0.008) (0.017)
Plasma oxalate 1.5 2.1 2.5
umol/1 (0.67) (0.88) (1.5)
Oxalate clearance 88.8 162 173
ml/min (36.2) (81) (127)
Creatinine 107 120 132
clearance ml/min (27.7) (45) (57)
Fractional 81.1 137 130
excretion % (41.2) (60) (100)
Flow rate 1.42 3.5 3.8
ml/min (1.2) (1.4) (1.9)
Data is displayed as mean (+/- standard deviation). “NC =
normocalciuric renal stone formers. ‘’HC = hypercalciuric renal
stone formers. n= number of patients.
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Table 5.10 Tests of significance on the renal 
handling data of oxalate in normocalciuric and 
hypercalciuric stone patients.
Parameter
Measured
Normal v ®NC Normal v ®NC v H^C
Calcium 
mmol/24 hour
Oxalate 
umol/24 hour
ns
ns
Urinary oxalate: p<0.005
creatinine ratio 
mmol:mmol
Plasma oxalate p<0.01
Oxalate clearance p<0.005 
ml/min
Creatinine ns
clearance ml/min
Fractional 
excretion -
Flow rate
p<0.005 
p<0.005
p<0.005 
p<0.05 
p<0.005
p<0.05 
p<0.05
ns
p<0.05 
p<0.005
p<0.005 
p<0.05 
ns
ns
ns
ns
ns
ns
“NC = Normocalciurics (n=16) and ‘’HC = Hypercalciurics (n=10). ns 
= not significant.
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Table 5.11 Data on the renal handling of oxalate in 
normoxaluric and hyperoxaluric stone patients.
Parameter
measured
Normals Normoxaluric Hyperoxaluri
n 32 17 11
Oxalate 303 303 588
umol/24hr (97) (107) (81.9)
Urine 0.014 0.023 0.031
oxalate : (0.014) (0.009) (0.015)
creatinine
ratio
Plasma 1.6 2.5 2.3
oxalate (0.8) (0.63) (0.5)
umol/1
Oxalate 88.8 123.3 192.0
clearance (36.2) (65.8) (117.0)
ml/min
Creatinine 107 130.7 134
clearance (27.7) (55.1) (27.3)
ml/min
Fractional 81.1 95.4 149
excretion % (41.2) (37.0) (94.0)
Urine flow 1.34 3.7 3.9
rate ml/min (1.1) (1.5) (2.2)
Data is presented as mean (+/- standard deviation)
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Table 5.12 Tests of significance on renal handling 
data of normoxaluric and hyperoxaluric renal stone 
patients.
Parameter
measured
Normal v ®N0 Normal v *^ 0 ®N0 v
Oxalate 
(umol/24 hour)
Urine 
oxalate : 
creatinine 
ratio
Plasma
oxalate
umol/1
Oxalate
clearance
ml/min
Creatinine
clearance
ml/min
Fractional
excretion
ns p<0.005 p<0.005
p<0.005
p<0.005
p<0.01
ns
ns
p<0.005
p<0.005
p<0.005
p<0.01
ns
ns
p<0.005 p<0.005
ns
p<0.01
Urine flow 
rate ml/min
p<0.005 p<0.005 ns
“n o = normoxaluric and ‘’HO = hyperoxaluric renal stone patients, 
ns = not significant.
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DISCUSSION
The incidence of hyperoxaluria in idiopathic calcium 
oxalate stone formers has varied in different studies 
from 2 - 3  per cent to as high as 40 - 50 per cent 
(Williams Wandzilak, 1989). The results presented here 
show that the incidence of hyperoxaluria can vary from 
13.4% to 20.5% within the same group of individuals. 
This was due to the fact that hyperoxaluria occurred 
in most of the stone formers intermittently. Only a 
relatively small percentage (7.9%) had persistant 
hyperoxaluria, which may account for the variation in 
the incidence of hyperoxaluria reported in the 
literature. This means that a normal 24 hour urinary 
oxalate on one occasion does not exclude hyperoxaluria 
as a risk factor for stone formation in that same 
individual. Furthermore, it was discovered that the 
degree of hyperoxaluria found in an individual was not 
related to incidence. This means that a patient with 
intermittent hyperoxaluria can have periods of 
increased risk of stone formation equivalent to those 
of patients with persistant hyperoxaluria.
Another factor that may influence the reported 
incidence of hyperoxaluria, is demonstrated by the 
third 24 hour urine collected in this study. Prior to, 
and during the collection of the third urine, sodium 
cellulose phosphate was given. This has been shown to 
increase urinary oxalate output in patients with
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absorptive hypercalciuria, by the binding of calcium 
in the gut, thereby releasing oxalate for absorption 
(Hayashi, Kaplan, Pak, 1975). The results found here 
show that sodium cellulose phosphate increases the 
incidence of hyperoxaluria, overall by 10.2%. It is of 
interest to note, that despite the increase in 
incidence, the urines collected whilst sodium 
cellulose phosphate was taken, did not have 
significantly different means or standard deviations 
in the normoxaluric or hyperoxaluric groups from the 
other two urine collections. This indicates that some 
individuals were susceptible to the action of sodium 
cellulose phosphate while others were not. This may 
reflect the dietary intake of oxalate in some 
patients.
The data presented here, clearly shows that stone 
forming patients have a higher output of urinary 
oxalate than normals. This has been found by most, but 
not all, other workers (Yendt and Cohanim, 1989). The 
results demonstrate the existance of two populations; 
Those who were normoxaluric on all three occasions, 
and the hyperoxalurics (patients who have been 
hyperoxaluric on one or more occasions) . The mean and 
standard deviation of the data on the normoxalurics 
did not differ significantly from normal subjects. 
This suggests that these stone formers do not have an 
altered oxalate metabolism. However, this may not be
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true when one considers the fasting oxalate results 
that are discussed later.
The female stone formers showed an incidence of 
hyperoxaluria no greater than that found in normals, 
whilst male subjects showed an increased incidence. 
This might be expected as four out of five stone 
patients are male and could be consistant with an 
hormonal influence on oxalate metabolism.
The measurement of twenty four hour urine outputs in 
idiopathic calcium oxalate stone formers shows that 
oxalate output correlates to urate, creatinine and 
calcium. The association with calcium is not 
surprising and is well documented (Erickson et al. 
1984, Bataille et al. 1983). The relationship to urate 
and creatinine is more contentious.
In agreement with a recent report (Lindsjo et al. 
1989), 24 hour urinary calcium excretion had a weak
positive correlation with urinary oxalate excretion. 
Examining sub divisions of urinary calcium output, a 
stronger correlation was found with hypercalciuric 
patients, depending on the definition of 
hypercalciuria. Patients with a calcium output greater 
than 8.5 mmol/24 hours gave a significant correlation 
and had a greater urinary output of oxalate than that 
found in normal subjects. However, if samples were 
included with a calcium output above 7.5 mmol/24 hours 
(the upper limit of normal) there was no significant
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correlation. The explanation for this may lie in the 
causes of the hypercalciuria.
The association between absorptive hypercalciuria and 
hyperoxaluria has been well documented (Erickson et 
al. 1984, Yendt and Cohanim, 1989, Lindsjo et el.
1989) and it may be that it is this group of patients 
that predominates with a calcium output above 8.5 
mmol/24 hours. The hypercalciuric group defined as 
greater than 7.5 mmol/24 hour may be too heterogeneous 
with respect to the cause of hypercalciuria to give a 
correlation. Alternatively, a significant number of 
the patients in the 7.5 mmol/24 hour group may have 
had a low oxalate intake which produced only moderate 
urinary oxalate excretion.
The categorisation of hypercalciuria in idiopathic 
calcium stone formers was performed using the criteria 
of Pak et al. (1975) . The results here support the 
idea of a mixed population with regard to the cause of 
hypercalciuria, which have differing urinary oxalate 
outputs. Subjects were identified with absorptive and 
renal hypercalciuria and the urinary oxalate excretion 
was significantly higher in the absorptive group.
The relationship between urinary urate and urinary 
oxalate output is less well defined than that of 
calcium and oxalate. Most investigators agree that the 
hyperuricosuria in idiopathic calcium oxalate renal 
stone formers is due to the dietary intake of protein
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(Smith, 1990) and not because of specific defects in 
urate metabolism. This has been found in studies of 
high dietary protein intake which have increased 
urinary uric acid excretion (Robertson et al. 1979, 
Yendt and Cohanim, 1988)). Dietary protein contains 
glycine, hydroxyproline and hydroxy-beta-ketoadipate 
and 40% of endogenous oxalate production is from 
these precursors of oxalate (Menon and Mahle 1982). 
Therefore dietary protein should increase urinary 
oxalate output. However, two recent studies in Italy 
(Trinchieri et al. 1991, Marangella et al. 1989) state 
that there is no significant correlation between 
urinary oxalate output and dietary animal protein 
intake.
Assuming urinary urate is a good indicator of animal 
protein intake the results of this chapter do not 
support the interpretation of the effect of dietary 
protein intake in renal stone formers quoted above by 
Trinchieri and Marangella. The 24 hour urinary 
excretion of urate had a significant positive 
correlation with the 24 hour urinary oxalate output 
using all the patient data. Positive correlation was 
also found in the sub divisions of normouricosuria and 
hyperuricosuria, the hyperuricosuric group giving a 
more significant correlation. The 24 hour urinary 
oxalate output of the normouricosuric group was not 
significantly different from normal subjects but the
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hyperuricosuric group had an increased output compared 
to normal data. In fact the mean output from the 
hyperuricosuric group was greater (444 umol/24 hour) 
than that from the hypercalciuric group (359 umol/24 
hour) . The findings here are more in agreement with 
Yendt and Cohanim (1988) who suggest that uric acid 
production is associated with endogenous production of 
oxalate, probably from protein. They measured 
glycolate to identify endogenous oxalate production, 
which is an oxalate precursor in an important 
metabolic pathway for endogenous oxalate production. 
They found urinary urate correlated with urinary 
glycolate excretion, suggesting that protein intake 
promotes urinary oxalate output.
The finding of a positive correlation between 24 hour 
urine oxalate output and 24 hour creatinine excretion 
further supports the idea of an increased protein 
intake causing increased urinary oxalate output. The 
24 hour urinary output of oxalate was higher (432 
umol/24 hour) in patients with an elevated creatinine 
excretion than in either those patients with a normal 
creatinine output or normal subjects. The average 
height and weight in the patient populations were 
similar so that differences in muscle mass are not 
likely to cause the increased creatinine output. The 
variation of creatinine output per 24 hours in an 
individual can be between 1.7 to 34%. This variability
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has been attributed to dietary protein intake. 
Chronically the creatinine excretion rate falls when 
dietary protein content is lowered and a protein 
containing meal can acutely raise creatinine 
excretion. Meat protein, specifically cooked meat, has 
the largest effect. Cooking meat can convert two 
thirds of its creatine to creatinine and 50 to 70% of 
dietary creatinine is absorbed (Schuster and Seldin, 
1985). These facts and the findings here further 
support the idea that dietary protein may contribute 
to urinary oxalate production.
Creatinine clearance was higher in stone formers than 
normals. This may reflect a dietary factor as no 
dietary restrictions were put on patients during 24 
hour collections. The differences in creatinine 
clearance in the sub divisions of the measured urine 
parameters may show that glomerular filtration rate 
(GFR) plays a role in the increased output of calcium, 
urate and oxalate but could also further reflect 
dietary excess, as previously discussed. This would 
make the clearance a poor measure of GFR in these 
studies unless subjects were to fast.
When patients fasted their creatinine clearances were 
lower than in the 24 hour studies, though often not as 
low as normals. This further confirms a dietary 
influence on the urine creatinine output of the fed 
subjects.
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As has been reported previously (Galosy et al. 1980), 
there was a weak positive correlation between urine 
flow rate (ml/min) and urinary oxalate excretion 
(umol/min). This did not affect the interpretation of 
urine oxalate output between patient groups as defined 
in the study, because their output did not differ 
significantly. However, this should be borne in mind 
when interpreting results between normals and stone
formers, even though the correlation is a weak one. 
Fasting urines have not been studied in any great 
detail with regard to oxalate metabolism using 
reliable methods (Schwille et al. 1989). This study
examined samples after a minimum 12 hour overnight 
fast. The urine sample collected after this time
should reflect endogenous oxalate production, though 
recent work (Lindsjo et al. 1989) suggests a small 
number of stone formers may still be absorbing some 
oxalate from the gut 24 hours after a load.
The oxalate;creatinine ratio was found to be the most 
reliable indicator of fasting urine oxalate output, as 
it was not affected by urine flow rate or creatinine 
clearance. Urine oxalate concentration has a weak
positive correlation with urine flow rate (ml/min), 
and oxalate output (umol/min) is positively correlated 
with urine flow rate and creatinine clearance.
All the fasting urine indices measured in the patients 
were significantly different from normal subjects. The
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mean oxalate:creatinine ratios were higher in the 
patients than in normals. This included the patients 
who were normoxaluric during 24 hour collections. 
Therefore the results suggest that the stone 
population as a whole has a different oxalate 
metabolism in the fasting state from normals. Although 
there is a population overlap with normals, 27% of the 
stone formers had oxalate:creatinine ratios outside 
the normal range defined in chapter 3.
When the fasting data was grouped according to the 24 
hour urinary oxalate output in individuals, the 
hyperoxaluric group had a significantly higher 
oxalate:creatinine ratio than the normoxalurics. This 
could indicate that these groups have different 
defects or different degrees of the same defect. The 
normoxaluric group though capable of hyperoxaluria, 
may have a lesser degree of the defect. Furthermore 
there was no significant difference in the fasting 
oxalate:creatinine ratio in the patients with 
occasional hyperoxaluria and persistant hyperoxaluria. 
This could mean that the output of oxalate is a 
combination of a metabolic disorder and enviromental 
factors such as diet. The intermittent hyperoxalurics 
may require a dietary factor in order to increase 
their urinary oxalate output. A careful dietary 
history in patients with hyperoxaluria may therefore 
aid in the treatment and management of patients.
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The results presented in fasting patients could be 
explained in three possible ways. Danpure et al (1987) 
have shown that the deficiency of the peroxisomal 
enzyme glyoxylate aminotransferase is responsible for 
type I primary hyperoxaluria and that it is a 
heterogeneous condition. There could be mild variants 
of this disorder which produce increased endogenous 
oxalate, as suggested by the work of Rose (1988) . 
Another possible defect has been identified by the 
work of Baggio et al (1984, 1986, 1990) suggesting an
inherited membrane defect in oxalate transport. The 
defect has been described as an autosomal monogenic 
dominant trait with complete penetrance and variable 
expressivity. A defect of this type could explain the 
fasting results seen in this study.
A simpler explanation for the findings presented, in 
at least some of the patients, may be found in the 
work of Lindsjo et al (1989) mentioned above. Loading 
studies on idiopathic calcium oxalate stone formers 
showed that a small number of patients have delayed 
absorption of oxalate from the gut. Some patients were 
still absorbing oxalate up to 24 hours after loading. 
The work of Lindsjo also suggests that stone patients 
hyperabsorb oxalate as a primary defect, independent 
of the calcium content of the gut. Therefore the 
results found could reflect delayed gut absorption, 
associated with either a primary defect in oxalate
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absorption from the gut or the calcium content of the 
lower gut. The reality may prove to be a combination 
of factors and further studies need to be performed to 
identify the cause or causes of the raised 
oxalate:creatinine ratio.
However, most workers have reported no significant 
difference between fasting urine oxalate:creatinine 
ratio in renal stone formers and normals (Hodgkinson, 
1978; Schwille, Hanisch and Scholz, 1984). Hodgkinson 
(1978) and Schwille (1984) both had mean fasting urine 
oxalate: creatinine ratios that were higher in stone
formers than normals, but they did not achieve 
statistical significance. The present method is more 
specific than the methods used in these previous 
studies. In fact Schwille, Hanisch and Scholz state 
that the method they used lacked specificity. The 
increased specificity of the present method has 
resulted in lower oxalate:creatinine ratios in normals 
than those reported in these early studies and so has 
given better discrimination of patient groups from 
normals. Indeed, the oxalate:creatinine ratio by the 
method reported here is in very good agreement with a 
recently published oxalate:creatinine ratio normal 
range by a reliable enzymatic urine method (Barrett et 
al 1991) .
The fasting samples were examined with respect to the 
subdivisions defined in section 5.1.4.1. Fasting
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oxalate:creatinine ratio correlated with the 
normocalciuric, normouricosuric and normal 24 hour 
creatinine excretion results. These correlations had 
also been seen in the fed state but they were not 
associated with a significant difference in the 
urinary oxalate output of these groups compared to 
normals. None of the sub divisions defined for each 
urine analyte in section 5.1.4.1, showed any
significant difference in fasting urinary 
oxalate:creatinine ratio by comparison to each other. 
This contrasts dramatically with the 24 hour 
collections, where urinary oxalate output was
increased significantly in the hyperuricosuric group, 
hypercalciuric group and the group with elevated
creatinine levels by comparison to patients with 
normal outputs of these analytes.
As has already been discussed the urinary output of 
urate, calcium and creatinine can be associated with
diet and its effect on oxalate metabolism. In the case
of urate (as a measure of dietary protein) and
calcium, it has been shown (Erickson et al. 1984;
Bataille et al. 1983; Yendt and Cohanim, 1988) that
their dietary intake can be involved in promoting 
increased oxalate excretion in the urine. The results 
here demonstrate that these influences of diet on 
urinary oxalate output in hyperoxaluric patients are 
not observable in the fasting state. Therefore the
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fasting data further confirm a dietary role of calcium 
and protein in urinary oxalate production. There was 
still an increased oxalate;creatinine ratio found in 
all the sub divisions defined compared to normal 
subjects. This along with the other data presented on 
fasting and 24 hour urinary oxalate outputs show that 
diet and/or a metabolic defect contribute to a high 
urinary oxalate.
To further investigate the possible cause of 
hyperoxaluria the renal handling of oxalate was 
examined in different patient groups:- normoxaluric, 
hyperoxaluric, hypercalciuric and normocalciuric. The 
data presented allow only preliminary conclusions to 
be drawn.
The patient groups studied show that in agreement with 
previous authors (Schwille et al. 1989; Manoharan et 
al. 1988), there is increased fractional excretion of 
oxalate in some renal stone patients. Evaluation of 
the patients by grouping them according to their 
urinary calcium output indicates that a substantial 
number of patients with both normocalciuria and 
hypercalciuria have a fractional excretion of oxalate 
in excess of 100%. Which indicates net tubular 
secretion of oxalate. However, examination of renal 
handling data in patients grouped according to their 
oxalate output, suggests the normocalciuric and 
hypercalciuric groups contain a mixed population with
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respect to oxalate metabolism. It may therefore be 
better to group patients according to their oxalate 
output.
Investigation of the renal handling of oxalate in 
normoxalurics and hyperoxaluric patients showed that 
the hyperoxaluric group had a fractional excretion of 
oxalate greater than 100% indicating that these 
patients were net secretors of oxalate even in the 
fasting state. On the other hand, the normoxaluric 
group had a fractional excretion of less than 100% and 
so are net absorbers of oxalate. These patients showed 
no significant difference from normals, although the 
mean value for fractional excretion was higher. As 
discussed before this group may display a mild form of 
a defect seen in the hyperoxaluric group.
All the patient groups had significantly higher plasma 
oxalates than normal, although most of the results 
were within the normal range. Other workers have found 
lower or similar plasma oxalates to normals in 
patients with idiopathic hypercalciuria and 
normocalciuria respectively (Schwille et al. 1989, 
Manoharan et al. 1988). In both these studies net 
tubular secretion was found in the patient groups, as 
described here. Wilson et al. (1988) found no 
difference between plasma oxalate in normals and stone 
formers and the plasma levels in patients were the 
same as those found in this study (Stone formers
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2.5umol/l +/- 3.6). These were higher than Schwille 
et al (1989) who had a mean result on male 
normocalciuric stone formers of 1.78 umol/1. These 
differences, at such low concentration may be due to 
methodological factors. They are however critical to 
the interpretation of the data.
The method of Schwille et al (1989) indicated that 11- 
16% of oxalate is protein bound in vivo. The present 
method finds little or no protein binding, in 
agreement with the equilibrium dialysis results of 
Wilson et al (1988). The plasma oxalate fractions 
measured here and by Schwille et al (1989) , could 
therefore be different. In addition, Wilson et al
(1988) acidified samples before ultrafiltration which 
could have resulted in poor recovery (Costello and 
Landwher 1988). Other factors which may influence 
plasma levels include age and sex related differences 
in the subjects used in the different studies.
It is not clear from the data presented whether the 
increased net secretion of oxalate from the kidney 
tubules is due to an increased load from endogenous 
production or delayed gut absorption, or a renally 
mediated loss of oxalate. The increased plasma levels 
compared to normals suggests an increased load. 
However, the normoxaluric and hyperoxaluric groups 
have similar plasma oxalate levels with differing 
urine outputs. The hyperoxalurics have a higher urine
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oxalate output, which could be explained by an 
increased loss which is renally mediated. Further 
studies with stricter control on collection criteria 
are needed to clarify these possibilités.
The fractional excretion results obtained for fasting 
urine, could also be consistent with a metabolic 
defect or membrane defect of variable expression. The 
idea of a delayed gut absorption was only seen in a 
small number of patients in a study by Linds jo et al
(1989) and so would probably not explain all the 
results seen here. ;
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CHAPTER 6 FINAL DISCUSSION
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Much of the work performed in this thesis has been 
fully discussed in each of the chapters. The final 
discussion will therefore concentrate on future 
developments and studies in the light of the work 
performed.
The work described in this thesis is based on the 
development of reliable and sensitive methods for the 
analysis of oxalate in plasma and urine. (Fry and 
Starkey, 1991). The investigation of oxalate 
metabolism has until recently been limited, due to the 
problem of measuring oxalate in biological fluids, 
particularly plasma. The methods developed here use 
relatively small sample volumes and have a sample 
preparation and analysis time that is suitable for 
routine clinical use.
At the time this work was started, there were no 
plasma methods which could easily be applied to large 
numbers of samples in a busy District General 
Hospital. The Sigma Chemical Company had produced a 
kit for urine analysis (1985) but this was criticised 
for poor recovery and interference from ascorbate 
(Glick, 1987) . At this time, no one urine method was 
clearly better than any of the others (Zerwekh et al.
1983).
The first objective of the thesis was achieved in 
developing a reliable and robust method for oxalate 
analysis which could be applied in a routine
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laboratory (Fry and Starkey, 1991). There are however 
areas of further development which could be considered 
with regard to the methodology;
6.1. Methodology and sample collection and storage.
The use of dithiothreitol for stabilising plasma 
samples against oxalogenesis is a novel approach. Most 
previous authors have stabilised by acidifying the 
plasma (Kasidas, 1988, Wilson et al. 1988, Schwille et 
al. 1988). Acidification can cause poor recovery of 
oxalate if samples are subsequently ultrafiltered at 
low pH (Costello and Landwehr, 1988) . The use of acid 
to stabilise samples in the present method, affected 
the quality of the chromatograms, and a number of 
other procedures used to prevent oxalogenesis in ion 
chromatographic methods have not effectively 
eliminated the overestimation of oxalate (Petrarulo et 
al. 1990). Stabilisation with dithiothreitol was
inexpensive and effective, and may offer an
alternative to acidification in other methodologies. 
The success of the reducing agents dithiothreitol and 
dl homocysteine to protect against oxalogenesis was 
not unexpected, as Okamura (1980) has demonstrated 
the ability of dithiothreitiol to act as a reducing 
agent on dehydroascorbic acid to produce ascorbate.
The use of dithiothreitol was tested on the enzymatic 
method of Kasidas and Rose (1986) with no
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interference. Further evaluation is necessary to 
assess whether this form of stabilisation could be 
applied to enzyme methods.
Initial concentration of dithiothreitol (2.5mmol/l) 
used to stabilise samples was adequate for ascorbate 
concentrations found in the plasma of normal subjects 
(40 - 108umol/l). However, the results from the
studies in Chapter 2 show that at room temperature
with 3 00umol/l of ascorbate added to plasma, even 
after stabilisation, some oxalogenesis can occur over 
a 24 hour period (Figure 2.11). This is not surprising 
if one assumes that dithiothreitol reduces 
dehydroascorbate quantitatively, to fully protect a 
sample at high ascorbate concentration (300umol/l) may 
require the stabiliser concentration to increase eg. 
to 5.0mmol/l. When considering an increase it should 
be noted that dithiothreitol is electroactive and that 
the concentration used should be kept to a minimum to 
avoid interference on the chromatogram. The
stabilisation of samples was only complete over
extended periods when the stabiliser and the 
temperature of -70°C. were used together, which 
suggests both factors are important, confirming the
findings of Margolis and Davis (1988). The 
concentration of ascorbic acid in plasma samples did 
not exceed 200umol/l even after supplementation with 
Ig a day, the maximum value found after such loading
302
was 125umol/l. Therefore, 2.5mmol/l dithiothreitol is 
adequate for stabilising clinical samples. Further 
stability studies may be of value on subjects taking 
large doses of Vitamin C (greater than 4g a day).
The investigations performed on sample stability, 
involved the addition of the reducing agent after the 
plasma had been separated from the red cells. Sample 
collection and stability may be further improved by 
adding the dithiothreitol to the tube into which the 
blood is collected - further evaluation will be 
required. This would also have advantages if samples 
were being collected for red cell oxalate analysis, 
which is a potential area of interest following the 
work of Baggio et al (1984) on transmembrane oxalate 
flux in red cells.
Urine samples were stabilised by collection into acid 
and were shown to be stable during the analysis. Urine 
samples analysed under the conditions described here, 
were more stable at higher ascorbate concentrations 
than recent ion chromatographic (Petrarulo et al.
1990) and enzymatic methods (Inamdar et al. 1991). The 
urine method described in the thesis could be improved 
by the addition of dithiothreitol to extracted urine 
samples. This would extend the period of stability of 
these extracts, and may have advantages if samples 
were analysed overnight on an autosampler.
The extraction procedure for plasma has been
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successfully applied to urine using small number of 
samples. The use of a strong anion exchange cartridge 
is by far superior to the CIS cartridge used for the 
extraction of oxalate from urine, as the chromatogram 
contains fewer peaks. The disadvantage is that strong 
anion exchange cartridges cannot be reused, and are 
therefore expensive. In addition, the use of strong 
anion exchange does not significantly alter the 
quality of the urine results, but it may be useful for 
individual samples if an unusual interfèrent were to 
be found.
Future developments of the method applied to other 
body fluids may be of value. A preliminary examination 
of the measurement of oxalate in red cells has been 
performed. Initial results were encouraging but the 
preparation of an haemolysate and its extraction 
requires further evaluation. The work of Baggio et al 
(1984, 1986), suggesting an abnormal transmembrane
oxalate flux in idiopathic calcium oxalate stone 
formers, offers the possibility that an investigation 
of red cell oxalate levels in stone formers and 
normals may reveal significant differences. These 
could be useful in further characterising patients 
with hyperoxaluria and may in the long term, prove 
useful in the diagnosis and management of these 
patients.
In a preliminary experiment I have been able to
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confirm the presence in bile of oxalate. Although an 
enterohepatic circulation of oxalate has not been 
previously reported, the main site of oxalate 
biosynthesis is believed to be the liver. Therefore 
the finding of oxalate in the bile is to be expected. 
The concentration of the oxalate in the three samples 
investigated was remarkably consistent, which may 
indicate some metabolic control by the liver. It has 
been shown that oxalate can be actively exchanged for 
chloride and hydroxyl ions in the gut (Williams and 
Wandzilack, 1988). This process may occur in the bile 
ducts and is worthy of further investigation.
6.2. Reference ranges.
Following development and evaluation of the oxalate 
method, reference ranges were established for its
application to clinical situations and metabolic 
studies. There was no sex related difference
observable in 24 hour urinary oxalate output in
agreement with previous workers (Berckmans and Boer, 
1988) , but the mean plasma oxalate was found to be 
lower in females than males. This has been reported 
before (Costello and Landwehr, 1988) but has not been 
a consistent finding (Costello and Landwehr, 1988). 
The explanation for this is not clear. It could be due 
to a difference in diet, age, menstural cycle and
drugs (eg. oral contraceptive) . There may of course be
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a true sex related difference, possibly associated 
with hormonal factors.
To further investigate the effect of gender, a larger 
sample of the population must be examined. If the 
difference between males and females is confirmed, 
then studies on female subjects pre and post menopause 
may be of value in identifying any oestrogen effect on 
oxalate metabolism.
The fact that some urinary oxalate is derived from 
diet has been known for a long time (Hodgkinson, 
1970). However, the study of fasting urines has not 
been pursued (Schwille et al. 1989) and the methods 
used to obtain fasting urinary oxalate outputs in 
normals have often been unreliable and prone to 
interference (Hodgkinson, 1978, Schwille, Hanisch and 
Scholz, 1984). These ranges were re-evaluated using 
the current method and the effect of diet on plasma 
samples was investigated. Fasting reduced the output 
of urinary oxalate and reduced plasma oxalate levels. 
Reference ranges in the literature do not normally 
quote whether plasma samples are collected fasting or 
non fasting. This study shows that different ranges 
will apply to fasting and non-fasting samples and 
therefore for accurate interpretation the appropriate 
reference range should be applied. The investigation 
of the effect of diet and gender on oxalate levels and 
the establishment of reference ranges for this method
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should enable further studies to be performed in 
patient groups, and allow the method to be used in
clinical situations.
6.3. Renal handling and gastrointestinal absorption of 
oxalate.
The accurate measurement of urine and plasma oxalate 
enabled the study of renal handling of oxalate in
normal subjects. Many previous studies have been 
inconclusive because of indirect measurements of 
plasma oxalate, or non physiological conditions being 
used (Constable et al. 1979; Boer et al. 1984;
Williams and Wandzilak, 1989). The investigation of 
the renal handling of oxalate with respect to fasting 
and non-fasting normal subjects has revealed 
differences that might explain the variation in data 
quoted in the literature on the renal handling of 
oxalate (Williams and Wilson, 1990). Oxalate
clearance was significantly lower in the fasting state 
and the fractional excretion indicated a net tubular 
reabsorption of oxalate. The data in the fed state, 
which was based on twenty four hour urine collections 
with a plasma sample during the collection period, 
appeared to have two populations. Based on the 
fractional excretion, some subjects were net 
reabsorbers and others net secretors of oxalate. 
Similar results have been reported recently (Kasidas,
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Nemat and Rose, 1990). However, as the plasma oxalate 
level is influenced by diet, it may therefore vary 
during the day and thus estimates of renal oxalate 
handling based on one level may not give a wholly 
accurate picture. Nevertheless it was thought that 
these results might represent a renal response to 
different oxalate loads in different diets. This 
interpretation was further supported by the studies on 
the biological variation of oxalate where individuals 
could change from net reabsorbers to net secretors in 
a twenty four hour period.
Investigation of renal handling in normals following a 
sodium oxalate load, revealed that individuals can 
also change from net reabsorbers of oxalate to net 
secretors when handling an oxalate load. Investigation 
of the renal handling of calcium oxalate stone 
patients in the fasting state and after a load, would 
aid the understanding of altered oxalate excretion in 
these patients. Further studies with calcium oxalate 
stone formers, not only with regard to the renal 
handling of oxalate but also its intestinal 
absorption, would be of value. Lindsjo et al (1989) 
have demonstrated in a small number of these patients 
that enhanced intestinal uptake of oxalate occurs. 
This is independent of calcium absorption and suggests 
a primary disorder of oxalate absorption in the gut. 
The study by Lunds jo measured uptake and did not
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measure plasma oxalate.
It should be noted that the results of the loading 
studies here may show an exaggerated effect on renal 
handling compared to subjects on a normal diet. Giving 
oxalate in a non physiological load or to a patient in 
a fasting state can result in increased absorption and 
excretion. In addition, two other factors should be 
mentioned. The plasma value used to calculate the 
fractional excretion after loading, was a mid point 
value and it was assumed that this reflected the mean 
plasma oxalate during the 2 hour urine collection. 
Secondly, the creatinine clearance used in this study 
was measured after the subjects had fasted for 12 
hours and therefore should be free of the influence of 
dietary protein which could alter its value. Therefore 
the creatinine clearance values may be lower (but more 
accurate as a measure of glomerular filtration rate) 
than those derived on non fasting subjects. These 
comments do not alter the fact that the kidney 
modified its handling of oxalate when loading 
occurred, but they may be relevant when comparing 
these results to subjects on a normal diet (Kasidas, 
Nemet and Rose, 1990) and when designing future 
studies. If studies are performed in the fed state and 
creatinine clearance is used as a measure of 
glomerular filtration, then it should be remembered, 
following the work of Bosch et al (1986) , that an
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acute oral protein load can increase the true 
glomerular filtration rate.
The results of the sodium oxalate loading study were 
compared both with and without the subtraction of the 
endogenous oxalate, measured when the subjects were on 
a placebo. The results were more precise with regard 
to the percentage of oxalate absorbed, when the 
endogenous level was subtracted. This loading study 
needs further evaluation to ascertain whether it would 
be a reliable test in the assessment of patients with 
malabsorption. Previous attempts (Andersson and 
Gillberg, 1977, Rampton et al. 1979) to use oxalate 
loading as a test for malabsorption, have been 
critisised for their high percentage of false 
negatives (Foster et al. 1984). The methods used for 
some of these evaluations were suspect (Foster et al.
1984) and a further appraisal using this methodology 
and loading test would be appropriate. Tests of 
absorptive function deserve further study.
The ingestion of oxalate from the diet has been shown
in this thesis to affect the urinary output of
oxalate, the intake can be of oxalate contained in 
food (Andersson and Gillberg, 1977) or . as a
precursor - ascorbate for example (Cowley et al. 1987,
Brown et al. 1987).
Loading studies were therefore also performed using 
two different amounts of chocolate. The intake of
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chocolate caused an increase in urinary oxalate as 
well as an increase in plasma oxalate levels, 
confirming results of Balcke et al (1985). The 1.1 
mmol/1 and 2.2 mmol/1 oxalate loads ingested as 
chocolate gave similar amounts of oxalate excretion, 
suggesting a limit to the amount of oxalate that can 
be obsorbed from the gut. Additional studies of 
oxalate loading at different concentrations of 
oxalate, to identify maximal absorption in normals and 
patient groups, may be useful in identifying disorders 
in the gastrointestinal absorption of oxalate. Lindsjo 
et al (1989) suggest from their results that a primary 
defect in the control of oxalate absorption from the 
gut may exist. If this is a membrane defect of the
type suggested by Baggio et al (1986) then it may
present in the population in a variable manner and
maximal absorption data may help identify patients 
with this problem.
6.4. Ascorbate and oxalate metabolism.
The intake of Ig of ascorbate, an oxalate precursor, 
both as a single dose and daily over a 3 month period, 
did not significantly alter oxalate levels in the 
urine or plasma. This suggests that normal subjects 
are not at increased risk of stone formation when 
taking Ig of ascorbate a day. This finding is contrary 
to the results of an earlier study by Tiselius and
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Almgard (1977) using the same dose. However, in vitro 
oxalogenesis may have occurred in this previous study. 
The results here suggest a protective mechanism in 
vivo, as the conditions in the plasma are ideal for 
oxalate production from ascorbate. The pH and 
temperature are suited to oxalogenesis and the ratio 
of plasma ascorbate to oxalate is high (40:1). The 
investigation of renal stone formers may reveal 
differences. It has been suggested by Cowley et al 
(1987) that these patients have altered 
gastrointestinal handling of ascorbate. Further 
investigation of ascorbate metabolism in stone formers 
with regard to oxalate, would be worthwhile.
6.5. Idiopathic calcium oxalate stone formers.
Further studies into the cause of hyperoxaluria would 
be worth pursuing, with particular emphasis on fasting 
data, renal handling and 24 hour urinary oxalate 
output. The results on fasting samples and renal 
handling in the fasting state, suggest a defect in 
calcium oxalate renal stone formers. It was shown that 
the fractional excretion of oxalate exceeded 100% in 
hyperoxaluric patients on fasting, suggesting net 
tubular secretion. The plasma levels were higher than 
those of normals. In addition, normoxaluric and 
hyperoxaluric stone patients had higher fasting 
urinary oxalate outputs than normals, the
312
hyperoxaluric output being higher than that of the 
normoxaluric group. These results suggest either a 
metabolic defect or a renal loss of oxalate. There is 
also the possibility of delayed gut absorption but 
that will be discussed later. The work of Baggio et al 
(1986) on a membrane defect in oxalate transport or 
the work of Danpure et al (1987) on a metabolic 
defect, could explain these results.
A defect in oxalate metabolism does seem to be present 
in some stone formers. The present information 
indicates that a possible metabolic defect and/or a 
membrane defect may be common among the stone formers 
studied. Glycolate, a metabolic precursor of oxalate, 
would be elevated during fasting if the source of 
oxalate is endogenous overproduction due to a defect 
in a metabolic pathway. If a membrane defect is 
present, endogenously derived glycolate would not 
necessarily be raised. Therefore, a study of glycolate 
excretion in normoxaluric and hyperoxaluric patients 
may help to elucidate the cause of the increased 
oxalate excretion. This work is being pursued at 
present. A method for glycolate analysis has been 
adapted to a centrifugal analyser and normal fasting 
glycolate:creatinine ratio is being assessed as a 
metabolic marker. If oxalate is produced from an 
endogenous source through this precursor, one might 
expect to find that urinary levels of glycolate are
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elevated in fasting patients.
The renal handling of oxalate by patients presented 
here, agrees with some recent studies, in so far as 
the fractional excretion of oxalate exceeds 100% 
(Schwille et al. 1989, Wilson et al. 1988), especially 
in hyperoxaluric patients. However, the plasma results 
are not in complete agreement with these previous 
reports and the cause of the increased oxalate 
excretion therefore remains to be explained. Further 
studies of renal handling using stricter collection 
criteria may help to identify whether a renal loss of 
oxalate is occurring. Both or either of the defects 
mentioned above could be present, and the methods 
developed here should help investigate these 
possibilités.
Another explanation for the results observed is that 
patients in this study may have had delayed gut 
absorption (Lundsjo et al. 1989) which was modified by 
dietary calcium levels. Non absorbed dietary calcium 
in the intestinal tract combines with intestinal 
oxalate, thereby making an insoluble complex which is 
unsuitable for absorption. Conversely intestinal 
oxalate absorption increases when dietary calcium is 
reduced (Bataille et al. 1983). Some renal stone 
formers are known to hyperabsorb calcium from the gut 
(Pak et al 1975) . Therefore less calcium is available 
in the gut to complex oxalate so that more oxalate is
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absorbed. If this is the case some residual oxalate 
may continue to be excreted after a 12 hour fast due 
to absorption occurring in the colon. The results of 
the normoxaluric and hyperoxaluric groups may then 
reflect dietary intake of calcium and oxalate in the 
previous 24-48 hours. However, the fact that the 
patients had increased plasma oxalate and fractional 
excretion in both the normoxaluric and hyperoxaluric 
groups compared to normals, could also be explained in 
terms of a primary hyperabsorption of oxalate in the 
patient groups to varying degrees.
Limited conclusions only can be drawn from these 
results and as stated earlier, stricter control 
studies are required. These would involve calcium and 
oxalate intake being standardised over several days 
before fasting or the use of labelled oxalate with 
a very low calcium intake as Linds jo et al (1989) did, 
but investigating normoxaluric and hyperoxaluric 
groups of patients.
6.6. Concluding remarks.
Future studies using the methods developed in this 
thesis may help to categorise oxalate defects in a 
similar manner to calcium (Pak et al. 1975) and 
prepare a logical sequence of investigations, using 
the derived normal data.
A reliable method for oxalate analysis in urine and
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plasma has been established with its own reference 
ranges. This will allow further metabolic studies to 
be performed with confidence.
The methods developed have been applied in routine 
clinical use as well as in research. They have been 
used in the management of two cases of primary 
hyperoxaluria and in the investigation and management 
of numerous renal stone patients. A Regional Renal 
Unit has also made use of these assays in the 
management of some of their patients with end stagé 
renal failure. The methods defined here have therefore 
been shown to be clinically useful in the diagnosis, 
treatment and management of patients.
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APPENDIX 1
Chromatographic parameters:
Retention time - t^ . The retention time of a substance 
is from the time of sample injection to the peak 
maximum of that substance.
Adjusted retention time - t^ . The adjusted retention 
time is the retention time of a substance from the 
solvent front to the peak maximum of that substance.
Phase capacity ratio - Adjusted retention time:time 
from sample injection to solvent front.
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APPENDIX 2
Oxalate clearance =
(ml/itiin)
Urine oxalate fumol/1^  x Volume (ml) 
Plasma oxalate (umol/1) x Time (min)
Fractional excretion of oxalate (%) =
Oxalate clearance x 100
Creatinine clearance
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APPENDIX 3
Phosphate buffers used in chapter 2, section 1, sub
section 2.1.1. are described below. These buffers were 
used to optimise the conditions of the mobile phase.
Potassium dihydrogen phosphate and disodium hydrogen
phosphate were used to produce a range of buffers as
described below. All buffers were made up in double
deionised water.
(a) 0.1 M Phosphate buffers with the following pH
values:-
5.5 
6.0
6.5
7.0
7.5
8.0
(b) pH 7.0 phosphate buffers with the following molarity 
values:-
0.025M
0.05M
O.IM
0.2M
All final buffer solutions contained 10% methanol.
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APPENDIX
Sample collection protocol for the 2 00 mg sodium 
oxalate loading study in chapter 4, section 1.
DAY 1 ^
(Fasting
DAY 2 /
(Fasting;
Urine
1
Urine
2
Urine
3
Urine
4
19.00 hrs. (Start fast-subjects can drink 
distilled water only.
Vigorous exercise taken)
07.00 hrs. (Empty bladder)
-09.00 hrs 
'09.15 hrs 
09.30 hrs 
09.45 hrs 
10.00 hrs
10.3 0 hrs
V 11.00 hrs
f
12.00 hrs
^ 13.00 hrs 
(
14.00 hrs
15.00 hrs
(Load given) .Blood
Blood
Blood
Blood
Blood
Blood 6 
Blood 7
■Blood 8
f Blood 9
 ^ Blood 10
f Blood 11
■s 01 C/i,
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T h e  d e te r m in a t io n  o f  o x a la te  in  u r in e  a n d  p la sm a  b y  
h ig h  p e r fo r m a n c e  liq u id  c h r o m a to g r a p h y
Ian D R Fry and Bryan J Starkey*
From the Chemical Pathology Department, Frimley Park Hospital, Portsmouth Road, Frimley, and 
'^Department o f  Clinical Biochemistry and Clinical Nutrition, St Luke’s Hospital, Warren Road, 
Guildford, Surrey, UK
SUMMARY. We describe a simple, sensitive assay for oxalate in urine or plasma. 
Acidified urine is pretreated by dilution with neutral phosphate buffer and passage 
through a C,g cartridge. Stabilized plasma is diluted with neutral acetate buffer and 
oxalate extracted using a strong anion exchange cartridge. Treated samples are applied 
to an ion-paired chromatographic system and oxalate detected electrochemically. 
Recovery of oxalate from augmented samples exceeded 97% from both urine and 
plasma. Within- and between-assay coefficients of variation assessed at three 
concentrations were, respectively, better than 4-1% and 8-4% for urine and 3-9%  
and 5-2% for plasma. The reference range for urinary oxalate excretion is 
109-497 /im oi/24h. The range for plasma oxalate concentration is 0 -6 -2 -8  /zmol/L 
or 0-7-3  -9 ^tmol/L after an overnight fast or without dietary restriction, respectively. 
Urine and plasma oxalate concentrations from this method, gave correlation 
coefficients (r) of 0-97 and 0-98, respectively, when compared with those from 
established oxalate oxidase based assays.
Additional key phrases: urolithiasis; electrochemical detection; solid phase extraction; 
reference ranges
Measurement of oxalate concentration in blood 
and urine is important in the investigation of 
urolithiasis, chronic renal failure, primary hyper­
oxaluria and intestinal malabsorption.'”* Many 
methods for the determination of oxalate in 
plasma or urine have been reported. Earlier 
methods,^ involving precipitation, solvent 
extraction, isotope dilution or enzymic reactions 
were often laborious, insensitive, expensive and 
inaccurate. Subsequent methods'^* including gas 
and liquid chromatographic procedures and 
improved enzymic techniques, have greater preci­
sion and accuracy, but are often complex,’ 
require large sample volumes,' are prone to 
interference*® or cannot be applied to both plasma 
and urine."
High performance liquid chromatography 
(HPLC) offers specificity and sensitivity. Published 
HPLC methods for oxalate have, to date, been 
largely limited to urine and have required extensive 
sample preparation and derivatization’-*- or
Correspondence: p r I D R Fry.
C<^ rL.\L Tkk.
AvTV'i/q)
specialized ion chromatographic equipment."""* 
The method presented here combines the specificity 
of HPLC with the sensitivity of electrochemical 
detection and requires minimal sample preparation 
and no derii^ization. It is applicable to both urine 
and plasma samples, and is therefore ideal for use 
in metabolic studies.
MATERIALS AND METHODS
Equipment and reagents
Equipment comprised a single piston HPLC 
pump (Gilson Model 302; Anachem Ltd, Luton, 
UK) an autosampler (WISP 71GB, Millipore Ltd, 
Watford, UK), an electrochemical detector 
(EG and G; Princeton Applied Research 
Model 400; Jones Chromatography Ltd, Cardiff, 
UK) and a chart recorder (Gould Scientific 
Ltd, Harrow, UK). Analytical colum ns 
(Spherisorb ODS 2; 5 n, 2 5 0x4-6  mm) and 
preparative columns (1 mL Bond Elut C.  ^ and 
SAX) were supplied by Jones Chromatography 
Ltd.
91/33/1 /JC
ACB91/33/2 Frv and Siarkev
Reagents (analytical grade) were obtained from 
BDH Ltd (Poole, UK) with the exception of 
hexadecyltrimethylammonium bromide (cetri- 
mide) from Fisons Ltd (Loughborough, UK); 
HPLC grade methanol (Rathbum Chemicals Ltd, 
Peebleshire, UK); dl-dithiothreitol and oxalic acid 
dihydrate (Sigma Chemical Co., Poole, UK) and 
helium (BOC, Crawley, UK). Commercial kits for 
comparative determination of oxalate in urine 
were a gift from Sigma Chemical Co. (product 
number 591). Results for plasma oxalate were 
compared with those from a previously published 
enzymic method.-
The HPLC mobile phase comprising 
100 mmol/L phosphate buffer, pH 7*0: methanol 
(90:10 v/v) was helium-degassed prior to use. The 
column conditioning solution consisted of 
methanol: water (25:75 v/v) containing 2 mmol/L 
cetrimide.
Aqueous standards typically in the concentration 
range 0-40/im ol/L  for plasma oxalate and 
0-600 umol/L for urinary oxalate analysis were 
prepared from stock (10 mmol/L) oxalic acid 
solution immediately prior to use. Stock oxalic 
acid solution was stored at 4°C and prepared at 
3-monthly intervals.
Preliminary studies
Optimum conditions for sample pretreatment 
were developed by assessing recovery of added 
oxalate from plasma and urine samples subjected 
to different extraction procedures. Extraction of 
oxalate from plasma using SAX cartridges was 
optimized with respect to the pH, volume and 
molarity of diluent buffer, wash solution composi­
tion, and eluent buffer pH and ionic strength. 
Conditions were chosen to give maximum recovery 
and optimum resolution of oxalate on the chromat­
ographic system. The effects o f different pH and 
different initial dilution upon the Bond Elut^ ‘^ 
C|g pretreatment of urine samples were also 
assessed and conditions optimized for maximum 
recovery.
Chromatographic conditions were chosen to 
give the shortest retention time compatible with 
complete resolution of oxalate from other extraaed 
moieties. Possible interference from other 
compounds was investigated by addition of these 
substances to urine and plasma at concentrations 
of twice that expected to occur either physio­
logically or pathologically.
Final procedure
Sample collection: Heparinized blood samples 
were centrifuged within 30 min of collection.
Plasma ( I mL) was stabilized by addition of 20 nL 
dl-dithiothreitol (12-5 mmol/L), stored at -  70°C 
and analysed within 4 weeks. Twenty-four hour 
urine specimens were colleaed into bottles contain­
ing 20 mL 6M-HC1 as preservative and the pH 
checked on receipt at the laboratory to ensure it 
^ b e lo w  pH 1*5.
WAS
Plasma extraction
Two millilitres acetate buffer (50 mmol/L, pH 7-0) 
was added to 1 mL stabilized plasma or standard. 
The solution was mixed and passed through a 
Bond Elut™ SAX column preconditioned with 
I mL methanol and 1 mL acetate buffer 
(50 mmol/L, pH 7-0). The column was then 
washed with 2 mL acetate buffer (50 mmol/L, 
pH 7-0) and oxalic acid was eluted with two 
400 fiL aliquots of 600 mmol/L potassium di­
hydrogen orthophosphate, pH 3 - 0 (adjusted with 
600 mmol/L orthophosphoric acid). Eluents were 
mixed and 100/tL taken for chromatography.
Urine extraction
Eight hundred microlitres phosphate buffer 
(100 m mol/L, pH 7-0) was added to 200/zL 
acidified urine. The solution was passed through 
a Bond Elut™ C,g column preconditioned with 
1 mL methanol and 1 mL phosphate buffer 
(100 m mol/L, pH 7-0). A sample (20^L) of 
eluent was taken for chromatography.
Chromatography
The analytical column was preconditioned by 
pumping to waste, at 1 mL per min, 200 mL 
cetrimide preconditioning solution followed by 
200 mL mobile phase. After connecting the 
electrochemical detector, the mobile phase was 
recirculated and replaced every 2-4  weeks 
depending upon workload. The ion-pair system 
generated gave reproducible retention times for 
2-6  months (approximately 800 injections) after 
which shortened retention time or unacceptable 
peak broadening necessitated column recondition­
ing or replacement. Samples were assayed at 
ambient temperature using a flow rate of 1-2 m L/ 
min, 1250 mV applied potential, DC mode and 
a time constant o f 5 s. The sensitivity setting 
required depended upon the condition of the 
electrode but was typically 1 - 0 /lA full scale for 
urine and 0 ‘5 nA  full scale for plasma analysis.
RESULTS
Figure 1 shows typical chromatograms for plasma 
and urine samples. W ithi^and between^^assay H
Oxalate determination bv H P LC ACB91/33/
co
&0)q:
0 25-
T
4 6 8 10
<
3.
10-
0
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Figure 1. T y p i c a l  c h r o m a t o g r a m s  o f  ( a )  p l a s m a  o x a l a t e  f t )  u r i n e  o x a l a t e ;  ]  d e n o t e s  o x a l a t e .  P l a s m a  o x a l a t e  
c o n c e n t r a t i o n  1 2  \ u n o l / L ;  u r i n e  o . x a l a t e  c o n c e n t r a t i o n  2 2 0  i i m o l / L .
T a b l e  1. W i t h i n -  a n d  b e t w e e n - a s s a y  c o e f f i c i e n t s  o f  
v a r i a t i o n  f o r  d e t e r m i n a t i o n  o f  o x a l a t e  i n  p l a s m a  a n d  
u r i n e
Plasm a
mean
n  (ftm ol/L)
CV
(% ) n
Urine
m ean
(#tmol/L)
CV
(% )
W ithin-assav
12 3-9 3 -0 15 76-6 3-2
12 21-2 3-5 15 271-0 4-1
12 37-8 3 -9 15 467-3 2-6
Betw een-assay
18 3-8 5-2 15 79-2 3-4
18 20-3 4 -2 15 276-5 3-2
18 39-3 4-7 15 481-4 2-8
precision data are summarized in Table 1. 
Recovery studies, assessed by analysis of urine 
and plasma samples before and after addition of 
known amounts of oxalate^gave the results in 
Table 2. The limit o f linearity was shown to 
exceed I(XX)/imol/L for urinary oxalate analysis 
and 50 fzmol/L for plasma oxalate analysis. The 
limit o f detection, defined as the lowest oxalate 
concentration distinguishable from baseline noise
with 95% confidence, was 35 ^mol/L for urine 
and 0-5 ;tmol/L for plasma oxalate using the 
analytical conditions described.
Investigation of optimum urine dilution showed 
that even the most concentrated urine gave 
maximum oxalate recovery provided a fivefold 
dilution was used. Dilution in phosphate buffer 
at a molarity of 100 mmol/L and pH 7-0 resulted 
in a final pH above pH 6-2 (i.e., two pH units 
above the highest pK, o f oxalic acid) ensuring 
almost complete ionization of oxalate and its non­
retention on the C|g preparative column.
T a b l e  2 . 
u r i n e
R e c o v e r y  o f  o x a l a t e  a d d e d  t o  p l a s m a  a n d
Plasm a U rine
A ddition
(/zmoi/L)
R ecover\ *
(To)
A ddition
(/im ol/L )
Recovery*
(% )
10\0 1
3 0 /0 //
99 1 (5-5) 
98-5 (4 -0) 
98-1 (4-5)
200
400
600
97-0  (4-1) 
101-4 (3 -4) 
101-0 (2 -3)
^ M e a n  ( ± S D )  o f  10 estim ations.
Endogenous oxalate concentrations: plasma (3-9 ;unol/L ); 
urine (1 7 0 /im o l/L ).
No
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Table 3. I n t e r f e r e n c e  s t u d i e s
C om pound C o ncen tra tion  i/im ol/L ) R R T ‘
A scorbate 5000 0-32
U rate 1000 0 44
Lactate 5000 0-38
Succinate 200 ND
P yruvate 200 0-81
G lycollate 4000 0-35
Glyoxylate 400 0-38
Fum arate 100 ND
M alaie 100 ND
C itrate 4000 2-20
G lucose 20000 ND
•R elative retention tim e =  retention tim e/reten tion  time 
oxaiapeT^^
ND/no/MQ McT T)é:T£CTO>
Studies of sample stability demonstrated that 
urine samples collected as described had pH 
values less than pH 1 • 5 and were stable with 
respect to oxalate concentration for at least 4 
months at -2 0 °C . The pH of urine diluted for 
analysis was in this range of pH 6-2-pH  6 6. We 
demonstrated that no detectable oxalogenesis 
occurred in urine samples augmented with up to 
20 mmol/L ascorbic acid, provided the assay was 
completed within 4 h o f urine dilution. Likewise, 
addition of dl-dithiothreitol to plasma prevented 
conversion of ascorbic acid to oxalic acid up 
to a plasma ascorbate concentration exceeding 
400 ixmo\/L. Plasma samples prepared as described 
were stable with respect to oxalate concentration 
for at least 7 days at -  20°C or 4 weeks at -  70°C.
Interference studies (Table 3) showed that there 
was no analytical interference from any of the 
compounds tested. These substances were added to 
urine and plasma in concentrations in at least a
twofold excess o f those expected to occur and 
samples were subjected to the complete analytical 
procedure. Of the substances tested only pyruvic 
acid had a retention time similar to that of oxalic 
acid and even this showed baseline resolution. 
Incubation of urine and plasma samples with 
oxalate oxidase (EC 1.2.3.4.) resulted in the 
complete loss o f the oxalate peak on chromat­
ography. This indicated that the chromatographic 
peak identified from standard material as oxalic 
acid contained no other co-chromatographing 
component.
Correlation data are shown in Fig. 2. Compar­
ison of the method presented with a commercial 
kit using oxalate oxidase for urine oxalate 
determination gave for 78 samples (range 
45-970 /xmol/L by HPLC) a regression equation 
of y  = Q-91x-y 14; r=0-97 (y = HPLC; %= enzymic 
kit). Comparison of results for plasma oxalate by 
the present method and by an enzymic assay- 
gave for 19 samples (range 0 5-39-3 /imol/L by 
HPLC) a regression equation of_y= 1 -02x+0-04; 
r = 0-98 (7 = HPLC; .v= enzymic assay).
Reference ranges for oxalate in urine and 
plasma determined in healthy subjects (age range; 
20-56 years) on an unrestricted diet are shown 
in Table 4. The range o f oxalate concentration 
in plasma samples collected after an overnight 
(12 h) fast is also shown.
DISCUSSION
The method described facilitates analysis of 
oxalate both in plasma and in urine by the same 
chromatographic system. The system is similar to 
that previously described,'^ but has been adapted 
for use with the more conventional glassy carbon
( a  ) (b)
1000-40-
800-
3  30-
I 600-
y
a.
0 -
200-
0 3020 40 0 200 1000400 600 800
Enzymic m e thod  ( ^ m o l /L ) Enzymic kit (ymol/L)
Figure 2 .  C o r r e l a t i o n  o f  r e s u l t s  f r o m  H P L C  o x a l a t e  m e t h o d :  ( a t  p l a s m a  m e t h o d  v e r s u s  e n z y m i c  p l a s m a  o x a l a t e  
m e t h o d  ( 2 } ;  ( b )  u r i n e  m e t h o d  v e r s u s  e n z y m i c  u r i n e  o x a l a t e  k i t  ( S i g m a  C h e m i c a l  C o . ,  p r o d u c t  n o .  5 9 1 ) .
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T a b le  4. Reference values fo r  plasm a oxalate  
concentration and urine oxalate output
n M ean Range
P lasm a (unrestricted) 48 2 01 
P lasm a (fasting) 32 1*47 
U rine (unrestricted) 91 303
0 * 7 -3 -9  fim ol/L  
0-6-2-8 ffmol/L 
109-497 /im o i/24  h
electrode. Inclusion o f the ion pair reagent in the 
mobile phase is not possible since the bromide 
counter-ion oxidizes at 1 • 1 V, a voltage less than 
the optimum oxidation potential (1*25V) of 
oxalate. Preconditioning the column with cetri­
mide has not proved a disadvantage since it is only 
necessary to repeat the procedure after several 
hundred injections when the retention time of 
oxalate decreases or unacceptable peak broadening 
occurs. Derivatization of oxalate, essential in 
some HPLC methods,^ is unnecessary and
this obviates the need to analyse an underivatized 
or enzyme-treated sample blank. In contrast to a 
recently reported ion chromatographic method*"* 
only a short equilibration time is necessary, 
sample throughput is relatively rapid and dedicated 
instrumentation is not required.
Sample pretreatment differs for plasma and 
urine specimens. Dilution o f stabilized acidified 
urine with neutral phosphate buffer results in a 
pH of 6'2 to pH 6-6. Oxalogenesis from ascorbic 
acid occurs in this pH range (unpublished results) 
but investigation showed that samples were stable 
with respect to oxalate concentration even in urine 
augmented with 20 mmol/L ascorbic acid, 
provided the assay was completed within 4 h of 
sample dilution. Plasma samples were shown to 
be stable with respect to oxalogenesis from 
ascorbate provided the strong reducing agent dl- 
dithiothreitol was added at the time of collection. 
Close attention tc detail in sample collection and 
storage to avoid spurious elevation o f oxalate 
concentration is vital, and poorly designed sample 
collection protocols may contribute to the large 
variation in reference range reported for plasma^ 
and urine** oxalate concentration.
A  recent report' has suggested that oxalate in 
plasma may be protein-bound at low pH. Dilution 
of plasma in acetate buffer at neutral pH not only 
ensures that oxalate is ionized and therefore binds 
to the anion exchanger, but also prevents any 
potential losses by protein binding. The method 
described therefore results in quantitative recovery 
of oxalate from plasma (Table 2). Thus preliminary 
ultrafiltration o f plasma samples to prevent 
oxalate loss through protein binding, as suggested 
by some authors*' is unnecessarv. The use of the
anion exchange procedure produced a very clean 
extract for chromatography. Since no suitable 
internal standard could be identified for the assay 
reproducible extraction efficiency, as demonstrated 
in the method described, is essential.
Pretreatment of urine samples with C;g 
cartridges has been used by other authors under 
a variety o f conditions.'*-*’ Using the method 
described these cartridges could be re-used several 
times provided they are pretreated with methanol 
and phosphate buffer and close attention is paid 
to oxalate recovery. The pretreatment procedure 
for urine is unsuitable for plasma analysis since 
the clean-up achieved is insufficient and the 
dilution required results in unacceptably low 
sensitivity at the much lower oxalate concentra­
tions found in plasma.
In agreement with a previous report*  ^we found 
no sex-related differences in the reference ranges 
for urinary oxalate output. The reference range 
found for urinary oxalate excretion is in agreement 
with other reports'^ using physical methods but 
is lower than that reported for an enzymic 
procedure," possibly reflecting the higher 
selectivity o f the method currently described 
(Table 5). The range found for urinary oxalate 
output showed a normal distribution with an 
upper limit approximating to 500 /zmol/24 h. In 
our view, however, patients in whom oxalate 
output exceeds 450 ptnol/24  h warrant funher 
investigation in view of the importance of oxalate 
as a risk factor in renal stone formation.
The range for plasma oxalate concentration 
(Table 5) agrees with that from in-vivo isotope 
dilution studies*’ 3-* and recent enzymic methods--^ 
indicating that the method is substantially 
interference free, as confirmed by the interference 
studies performed (Table 3). The effect of diet 
shown in our study may be a contributory factor 
in some o f the higher reference ranges previously 
reported for non-fasting subjects.' Diet has been 
shown previously-* to affect urinary oxalate 
output and would therefore be expected to affect 
plasma oxalate concentration. Dietary intake of 
oxalate or its precursors must therefore be 
considered when interpreting results. .Another 
factor which may contribute to differences between 
reference ranges reported for both urine and 
plasma is oxalogenesis from ascorbic acid or other 
precursors during sample collection, storage or 
analysis.
Comparative studies (Fig. 2) demonstrated 
excellent agreement between plasma oxalate 
results from this method and those from a 
previously reported procedure.- This correlation
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T a b le  5. R e p o r t e d  r e f e r e n c e  r a n g e s  f o r  u r i n e  a n d  p l a s m a  o x a l a t e
li
Year (Ref.) Range M ean n M ethod
Urine
1983'^
1984"
1985-'
1986'"
1988"
1989-*^
This paper
l l f 3  —^ ^ 4 -
—5?>6?-jkW um ol/24  h 
160-670 um ol/24  h 
60-420  ^imol/24 h 
170-420 Atmol/24h 
100-560 u m o l/2 4 h  
150-450 «m ol/24  h 
109-497 «m ol/24  h
282 « m ol/24  h 
370 «m ol/24  h 
240 « m ol/24  h 
300 « m ol/24  h 
280 « m ol/24  h 
NG
303 « m ol/24  h
25
17
61
11
27
35
91
Ion chrom atography  
O xalate decarboxylase 
O xalate oxidase 
D eriv a tiza tio n /H P L C  
O xalate oxidase 
O xalate decarboxylase 
H P L C
P lasm a
1979^*
1984-“
1986-
1989'*
1989"
This paper
0 -7 -1  -4 «m o l/L  
1 -2 -6 -4  « m o l/L
1 -3 -3 -1  « m o l/L
0 7 -2 -9  «m ol/L *  
< 0 - 8 -2 - 0 « m o l /L  
0 -7 -3 -9  « m o l/L  
0 -6 -2 -8  « m ol/L *
1 -0 « m o l/L  
3-3 « m o l/L  
2 -0  « m o l/L
1 - 9 « m o l/L  
NG
2 -0  « m o l/L  
1-5 « m o l/L
5
24
21
23
14
48
32
j n  v i v o  Isotope dilution 
O xalate oxidase 
Im m obilized oxalate 
oxidase 
Ion  chrom atography  
O xalate decarboxylase 
H P L C
•F astin g  range. 
N G , N ot given.
probably results in part from the fact that the 
samples for comparison were collected simultan­
eously and stored identically prior to analysis 
thereby reducing pre-analytical variables to a 
minimum. Comparison of urine oxalate values 
with those from the commercially available kit also 
showed acceptable correlation suggesting that the 
modifications made by the manufacturer to mini­
mize the reported ascorbate interference'® in this 
methodology have been successful.
In summary, the method described is simple 
enough for routine use and possesses the sensitivity 
and selectivity of HPLC with electrochemical 
detection. A strict sample collection and storage 
procedure prevents oxalogenesis, and oxalate 
losses during sample pretreatment are minimal. 
The accuracy and precision of the method, 
coupled to the fact that it is applicable to both 
plasma and urine, make it ideal for use in 
metabolic studies.
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